publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
algorithm
diagnosi
acut
chronic
trichinellosi
taken
account
order
initi
appropri
treatment
prevent
sever
complic
laboratori
diagnosi
simpl
relev
acut
stage
chronic
stage
peopl
receiv
corticosteroid
elisa
neg
confirm
test
imunoblot
multiplex
pcr
muscl
biopsi
determin
diagnosi
epidemiolog
evalu
geograph
region
differ
trichinella
speci
clinic
evolut
diseas
close
relat
parasit
burden
parasit
speci
host
immun
respons
cope
wormi
world
treatment
helminth
helminth
infect
among
common
infect
men
differ
helminth
infect
current
may
import
european
countri
return
travel
expatri
immigr
refuge
come
endem
countri
succinctli
present
follow
way
nematod
roundworm
intestin
nematod
ancylostomiasi
hookworm
infect
emerg
issu
blactamasemedi
resist
symposium
jointli
arrang
fem
class
carbapenemas
origin
activ
express
epidemiolog
produc
l
poirel
le
kremlin
bicetr
fr
oxacillinas
class
blactamas
group
divers
enzym
usual
sensit
blactamas
inhibitor
oxacillinas
hydrolys
narrowspectrum
blactam
other
expandedspectrum
cephalosporin
worri
oxacillinas
hydrolys
carbapenem
latter
oxacillinas
name
chdl
carbapenemhydrolys
class
blactamas
identifi
varieti
gramneg
bacteri
speci
hydrolys
penicillin
carbapenem
low
level
hydrolysi
spectrum
includ
expandedspectrum
cephalosporin
inhibit
clavulan
acid
inhibit
nacl
vitro
chdl
correspond
naturallyoccur
blactamas
encod
chromosom
varieti
speci
acinetobact
baumannii
pseudomona
aeruginosa
ralstonia
pickettii
correspond
gene
often
poorli
express
impact
carbapenemas
carbapenem
suscept
correspond
speci
seem
margin
howev
demonstr
overexpress
naturallyoccur
gene
baumannii
link
insert
element
upstream
gene
lead
decreas
suscept
imipenem
contrast
chdl
consid
acquir
lead
esist
carbapenem
acquir
chdl
identifi
baumannii
three
type
acquir
enzym
may
either
plasmidor
cchromosomeencod
oxacillinas
identifi
worldwid
alway
identifi
carbapenemresist
isol
latter
often
origin
nosocomi
outbreak
interestingli
sourc
gene
recent
identifi
chromosom
carbapenemsuscept
acinetobact
radioresisten
speci
poorli
express
anoth
acquir
chdl
identifi
firstli
carbapenemresist
klebsiella
pneumonia
isol
turkey
wide
dissemin
istanbul
respons
larg
outbreak
gene
plasmidencod
recent
evidenc
enterobacteri
speci
countri
interestingli
sourc
acquir
chdl
shown
gramneg
environment
waterborn
speci
shewanella
oneidensi
conclus
besid
acquisit
metalloblactamas
even
class
carbapenemas
suck
kpctype
enzym
confer
carbapenem
resist
gram
neg
current
emerg
spread
chdl
repres
worri
threat
dissemin
mechan
difficult
trace
thu
control
consid
current
avail
test
allow
detect
chdl
metalloblactamaseproduc
enterobacteriacea
phenotyp
genet
preval
clinic
signific
product
serin
blactamas
molecular
class
c
remain
clinic
signific
blactam
resist
mechan
among
enterobacteria
increas
concern
dissemin
strain
zincdepend
class
b
metalloblactamas
mbl
acquir
enzym
display
extrem
wide
spectrum
hydrolysi
includ
also
carbapenem
mblencod
gene
commonli
occur
cassett
integron
carri
varieti
transfer
plasmid
enterobacteri
chromosom
underscor
spread
potenti
inde
physic
linkag
mbl
integron
transpos
element
instanc
document
vim
imp
blactamas
main
mbl
type
found
enterobacteria
alreadi
achiev
global
spread
southern
europ
far
east
affect
region
quit
epidemiolog
studi
unveil
mode
spread
mblproduc
enterobacteria
nevertheless
understand
mbl
product
entail
term
clinic
impact
still
limit
yet
clear
mic
mbl
produc
must
consid
face
valu
isol
must
report
potenti
resist
carbapenem
moreov
perform
routin
detect
method
base
edtablactam
synergi
optim
yet
standardis
aim
present
discuss
recent
advanc
genet
epidemiolog
clinic
signific
mblproduc
enterobacteria
trichinellosi
parasit
diseas
due
presenc
trichinella
spp
larva
muscl
tissu
emerg
diseas
seem
becom
reemerg
diseas
mani
endem
countri
human
clinic
case
relat
consequ
breakdown
local
legisl
central
eastern
europ
trichinella
infect
still
repres
import
health
problem
accord
statist
data
regist
ict
mani
speci
trichinella
larva
encapsul
respons
human
case
accord
data
collect
refer
laboratori
rome
one
typic
clinic
appear
geograph
distribut
spirali
pseudospirali
britovi
nativa
nelsoni
murelli
papua
endem
countri
medic
attent
paid
acut
chronic
trichinellosi
acut
trichinellosi
familiar
medic
doctor
short
incub
period
follow
gastrointestin
phase
day
acut
stage
weak
chill
fever
headach
sweat
tachycardia
eyelidperioculargeneralis
oedema
muscl
pain
sometim
complic
cardiovascular
ocular
neurolog
respiratori
etc
differenti
convalesc
stage
residu
myalgia
sequel
chronic
trichinellosi
still
remain
well
defin
chronic
trichinellosi
either
symptomat
gener
discomfort
chronic
muscl
pain
tingl
neuropsychiatr
sign
persist
sweat
patient
histori
trichinellosi
asymptomat
accident
discov
muscl
biopsi
examin
reason
ie
laryng
tongu
neoplasm
residu
igg
antibodi
level
prove
persist
residu
viabl
larva
chronic
hypereosinophilia
bioelectr
muscl
disturb
persist
role
chronic
trichinellosi
larva
cofactor
develop
cancer
debat
studi
necessari
conduct
order
confirm
direct
relationship
trichinella
larva
neoplasm
chronic
inflamm
direct
carcinogenet
role
cofactor
carcinogenesi
european
harmonis
least
seven
differ
mic
breakpoint
committe
guidelin
antimicrobi
suscept
test
use
europ
consequ
europ
sever
differ
set
antimicrobi
breakpoint
rang
variat
technic
method
becam
increasingli
evid
harmonis
breakpoint
necessari
therapi
resist
surveil
escmid
set
eucast
repres
european
countri
repres
industri
eucast
restructur
major
respons
work
eucast
taken
activ
nation
breakpoint
committe
europ
steer
committe
form
current
compris
repres
activ
nation
breakpoint
committe
eucast
gener
committe
repres
european
countri
chairperson
scientif
secretari
clinic
data
coordin
decis
make
process
establish
wherebi
propos
made
steer
committe
distribut
eucast
gener
committe
relev
expert
group
industri
consult
final
decis
made
consensu
steer
committe
take
account
comment
made
consult
process
expertis
nation
breakpoint
committe
utilis
wide
consult
propos
nation
committe
take
respons
implement
decis
subcommitte
set
deal
specif
topic
includ
suscept
test
fungi
anaerob
expert
rule
suscept
test
websit
establish
http
wwweucastorg
give
detail
eucast
activ
eucast
breakpoint
public
anoth
websit
develop
collect
mic
data
present
speciesspecif
wild
type
mic
distribut
eucast
fund
escmid
nation
breakpoint
committe
grant
eu
ecdc
industri
contribut
financi
ask
contribut
data
requir
determin
breakpoint
comment
propos
breakpoint
eucast
achiev
harmonis
exist
breakpoint
europ
formal
relationship
emea
regard
set
breakpoint
new
agent
revis
breakpoint
exist
agent
process
appli
sever
new
drug
document
variou
aspect
suscept
test
also
publish
eucast
soon
harmonis
european
breakpoint
exist
antimicrobi
also
part
emea
process
approv
new
drug
eucast
determin
breakpoint
sever
antimicrobi
work
committe
enter
wider
implement
phase
exist
class
drug
end
complet
set
eucast
clinic
breakpoint
epidemiolog
cutoff
valu
earli
clinic
breakpoint
implement
ast
system
bsac
uk
casfm
franc
crg
netherland
din
germani
nwga
norway
srga
sweden
new
antimicrobi
eucast
determin
breakpoint
part
emea
approv
process
new
antimicrobi
eucast
breakpoint
breakpoint
includ
summari
product
characterist
spc
daptomycin
tigecyclin
alreadi
approv
anoth
drug
handl
antimicrobi
suscept
test
devic
work
ongo
implement
eucast
clinic
breakpoint
phoenix
bd
vitek
biomerieux
expect
eucast
breakpoint
avail
earli
fact
eucast
breakpoint
nation
breakpoint
simplifi
develop
test
panel
well
benefit
user
eucast
disk
diffus
method
preliminari
result
questionnair
determin
expect
clinic
microbiologist
europ
indic
eucast
take
lead
develop
disk
diffus
test
base
muellerhinton
agar
futur
eucast
eucast
financ
escmid
nation
breakpoint
committe
franc
germani
norway
sweden
netherland
uk
mani
year
last
year
eu
ecdc
contribut
financi
hope
continu
ecdc
need
sustain
european
committe
antimicrobi
suscept
test
beyond
breakpoint
harmonis
process
new
antimicrobi
need
breakpoint
compani
approv
antimicrobi
seek
approv
extens
clinic
microbiolog
indic
modifi
dosag
new
resist
mechan
occasion
necessit
review
exist
breakpoint
establish
european
disk
diffus
test
major
undertak
need
continu
develop
accommod
new
antimicrobi
new
resist
mechan
effort
best
serv
common
european
committe
eucast
urinari
tract
infect
uti
common
bacteri
infect
women
spectrum
includ
umpteenth
patientfamiliar
episod
recurr
cystiti
fatal
utilink
gramneg
sepsi
primari
healthcar
phc
three
major
clinic
pictur
import
acut
cystiti
uncompl
lower
uti
recurr
cystiti
acut
pyelonephr
discuss
treatment
cystiti
phc
regard
essenti
grow
resist
uropathogen
familiar
drug
use
cystiti
place
newer
drug
oral
chinolon
durat
therapi
therapeut
dilemma
commun
acquir
acut
pyelonephr
patient
treat
ambulatori
drug
acut
recurr
cystiti
treatment
choic
mostli
empir
impli
bacteri
speci
resist
anticip
reliabl
recent
year
alarm
resist
data
uropathogen
persuad
physician
choos
broadspectrum
antimicrobi
agent
data
come
surveil
studi
uropathogen
region
bacteriolog
laboratori
import
select
urin
sampl
occur
set
sampl
sent
bacteriolog
laboratori
came
complic
infect
immuneincompet
patient
peopl
urolog
problem
pyelum
stone
contrast
major
cystiti
encount
healthi
women
extrapol
resist
data
specul
perform
surveil
healthi
popul
cystiti
found
alarm
resist
moreov
new
surveil
year
later
show
increas
resist
uropathogen
encount
women
mean
nitrofurantoin
remain
first
choic
belgian
gpguidelin
appli
dutch
french
guidelin
trimethoprim
still
use
gb
netherland
resist
observ
chinolon
effici
superior
high
resist
amoxicillin
given
empir
major
problem
pregnant
women
safest
drug
ideal
durat
treatment
remain
controversi
recent
cochran
review
show
equival
success
treatment
day
compar
day
studi
drug
case
uncertain
use
nitrofuran
frequent
prescrib
five
day
lack
data
day
physician
awar
short
treatment
patient
still
symptom
moment
drug
intak
stop
field
recurr
cystiti
unpopular
studi
data
scars
nitrofuran
seem
activ
cours
renal
impair
taken
account
result
less
drug
intak
equal
efficac
selftreat
attract
chronic
use
acut
pylonephr
common
former
infect
cours
potenti
lifethreaten
situat
hospitalis
rule
recent
chinolon
proven
safe
ambulatori
oral
treatment
otherwis
healthi
individu
reserv
chinolon
seriou
infect
induc
chinoloneresist
gramneg
bacteria
spoil
lifesav
drug
uncompl
infect
uti
interest
field
develop
studi
ration
antbiotherapi
singl
sinus
patient
benefit
antibiot
treatment
lindbaek
oslo
background
respiratori
tract
infect
rti
common
gener
practic
compris
approxim
daili
practic
consult
often
result
antibiot
prescript
make
antibiot
prescript
gener
practic
thu
play
import
part
develop
antimicrobi
resist
differ
proport
penicillin
resist
pneumococci
demonstr
highest
lowest
prescrib
countri
europ
need
antibiot
prescript
common
rti
acut
otiti
media
sore
throat
acut
bronchiti
acut
sinus
highli
debat
mani
year
mani
studi
demonstr
limit
benefit
antibiot
patient
gener
practic
studi
fail
demonstr
clinic
signific
differ
antibiot
treatment
placebo
us
uk
receiv
antibiot
acut
sinus
holland
scandinavia
proport
lower
condit
situat
particular
sinc
two
differ
guidelin
treatment
acut
sinus
publish
clinic
evid
one
patient
confirm
sinus
state
antibiot
moder
effect
one
patient
clinic
sinus
antibiot
recommend
diagnost
problem
acut
bacteri
sinus
gener
practic
set
difficult
distinguish
bacteri
viral
sinus
number
studi
use
variou
refer
standard
demonstr
find
may
valu
howev
proven
prognost
valu
durat
diseas
nonselect
popul
furthermor
even
studi
refer
standard
half
patient
less
none
symptom
day
also
patient
high
predict
valu
bacteri
infect
spontan
rate
recoveri
high
treatment
challeng
high
proport
spontan
recoveri
demonstr
patient
bacteri
sinus
studi
risk
factor
long
durat
symptom
among
patient
acut
sinus
show
signific
differ
affect
older
patient
howev
newer
relev
studi
demonstr
predictor
longshort
durat
danish
studi
demonstr
high
crpvalu
predict
higher
cure
rate
antibiot
patient
much
pain
compar
placebo
still
small
proport
patient
acut
sinus
high
fever
much
pain
deterior
gener
condit
benefit
antibiot
treatment
otherwis
waitandse
approach
reason
studi
delay
prescript
strategi
demonstr
reduc
antibiot
treatment
less
prescript
dispens
pharmaci
demonstr
consider
proport
antibiot
prescrib
acut
sinus
gener
practic
avoid
role
topic
steroid
also
debat
result
variou
studi
given
conflict
result
exacerb
chronic
obstruct
pulmonari
diseas
copd
frequent
clinic
problem
primari
care
hospit
microorgan
associ
exacerb
well
recognis
includ
virus
chlamydia
bacteria
pneumonia
h
influenza
p
aeruginosa
sever
copd
exacerb
associ
differ
pathogen
primari
care
set
usual
exacerb
mild
need
hospitalis
routin
care
patient
administ
antibiot
accord
investig
great
part
mild
exacerb
would
requir
antibiot
treatment
viral
origin
infecti
howev
clinic
practic
difficult
distinguish
two
situat
recent
studi
group
copd
exacerb
patient
confirm
exist
sputum
purul
refer
patient
sensit
specif
variabl
associ
posit
bacteri
cultur
bronchoscop
sampl
know
inform
extrapol
ambulatori
patient
probabl
ye
cours
patient
expector
may
bacteri
infect
eccmid
oral
present
case
perhap
biolog
marker
could
help
differenti
viral
bacteri
infect
procalcitonin
pct
studi
copd
exacerb
one
randomis
trial
use
continu
discontinu
antibiot
without
recurr
problem
limit
method
need
blood
sampl
avail
method
abl
detect
small
amount
pct
term
pathogen
one
controversi
issu
role
pseudomona
aeruginosa
studi
countri
confirm
pseudomona
aeruginosa
isol
around
exacerb
howev
pathogen
mechan
pseudomona
aeruginosa
copd
exacerb
unclear
current
recommend
advis
treat
patient
antipseudomon
antibiot
risk
factor
known
individu
studi
er
guidelin
includ
among
follow
prior
antibiot
treatment
longterm
treatment
steroid
prior
colonis
isol
p
aeruginosa
two
four
variabl
present
antipseudomon
treatment
recommend
meticillinresist
aureu
isol
caus
communityacquir
infect
camrsa
major
problem
around
world
commun
camrsa
account
commun
aureu
isol
isol
typic
uniqu
staphylococc
chromosom
cassett
sccmec
iv
carri
antibiot
resist
gene
lower
molecular
weight
cassett
carri
typic
nosocomi
mrsa
isol
camrsa
isol
gener
suscept
clindamycin
trimethoprimsulfamethoxazol
doxycyclin
camrsa
aureu
isol
also
typic
carri
gene
code
pantonvalentin
leukocidin
pvl
although
role
pvl
pathogenesi
infect
remain
unclear
unit
state
one
particular
clone
identifi
puls
field
gel
electrophoresi
pfge
account
vast
major
camrsa
isol
clone
predomin
differ
area
world
genom
two
camrsa
isol
fulli
sequenc
may
eventu
provid
clue
success
spread
caus
infect
far
common
infect
associ
camrsa
isol
skin
soft
tissu
infect
includ
abscess
cellul
camrsa
common
aetiolog
abscess
much
better
document
eas
cultur
purul
drainag
children
common
site
infect
buttock
perineum
extrem
camrsa
isol
also
associ
seriou
invas
infect
especi
osteomyel
pneumonia
recurr
soft
tissu
infect
infect
within
famili
caus
camrsa
isol
common
import
aspect
manag
superfici
skin
soft
tissu
infect
appropri
surgic
drainag
clinician
also
administ
effect
oral
agent
tmpsmx
clindamycin
although
contribut
antibiot
therapi
surgic
incis
drainag
investig
empir
vancomycin
clindamycin
typic
administ
seriou
invas
infect
osteomyel
septic
arthriti
suspect
staphylococc
pneumonia
region
camrsa
common
commun
aureu
isol
clindamycin
efficaci
treat
camrsa
infect
caus
suscept
organ
effect
measur
prevent
camrsa
infect
remain
unclear
van
belkum
rotterdam
nl
staphylococcu
aureu
essenti
clonal
bacteri
speci
impli
variou
lineag
exist
appear
ecolog
highli
succesful
meticillin
suscept
resist
strain
demonstr
mani
belong
pandem
clone
base
observ
well
compar
analysi
mani
avail
staphylococc
genom
sequenc
suggest
genom
complex
aureu
pictur
simpl
model
genom
aureu
consist
core
element
approxim
entir
genom
core
variabl
element
call
variabl
accessori
genom
model
attract
simplic
would
suggest
core
genom
would
encod
overal
aureuscharacterist
trait
wherea
core
variabl
variabl
moieti
encod
factor
provid
aureu
strain
clone
specif
trait
talk
describ
genom
tool
avail
defin
aureu
popul
structur
stucutr
use
defin
emergenc
novel
lineag
addit
factor
present
accessori
genom
defin
trait
host
specif
invas
epidem
discuss
final
recent
research
suggest
human
individu
share
genotyp
would
permit
aureu
colonis
nasopharyng
would
also
suggest
interact
aurteu
human
requir
intric
match
bacteri
human
featur
relev
aureu
genom
flexibl
establish
hostmicrob
ointeract
discuss
past
decad
meticillinresist
staphylococcu
aureu
mrsa
emerg
caus
commun
acquir
ca
infect
among
patient
without
establish
risk
factor
mrsa
differenti
camrsa
hospitalassoci
ha
mrsa
becom
difficult
sinc
camrsa
could
spread
hospit
camrsa
caus
skin
softtissu
infect
also
caus
necrotis
tissu
infect
fulmin
pneumonia
camrsa
strain
produc
pantonvalentin
leucocidin
pvl
leukocyt
poreform
toxin
strongli
associ
invas
diseas
virul
transmiss
camrsa
person
person
well
document
ascrib
close
contact
eg
sport
practic
prison
stay
also
transmiss
occur
among
famili
member
unit
state
camrsa
report
frequent
caus
softtissu
infect
predomin
camrsa
clone
belong
clonal
complex
cc
characteris
particular
puls
field
gel
electrophoresi
pattern
sccmec
type
iv
encod
pvl
product
camrsa
preval
europ
divers
although
rate
hamrsa
high
england
south
mediterranean
countri
camrsa
frequent
report
northern
central
european
countri
isol
predomin
genotyp
mani
european
countri
sinc
late
denmark
sweden
norway
netherland
germani
england
franc
switzerland
howev
anoth
domin
genotyp
relat
clone
usa
emerg
spread
mani
countri
netherland
franc
spain
switzerland
greec
norway
spain
high
endem
rate
hamrsa
isol
pvlposit
camrsa
increas
last
year
predomin
clone
camrsa
spain
affect
famili
group
patient
recent
travel
famili
relat
countri
south
america
worrisom
featur
isol
pandem
genotyp
paediatr
clone
highli
preval
among
hamrsa
mani
european
countri
found
carri
pvl
toxin
camrsa
prevent
control
camrsa
infect
outsid
healthcar
set
repres
real
challeng
health
system
may
seriou
problem
contain
spread
camrsa
within
hospit
popul
mrsa
emerg
signific
communityassoci
ca
pathogen
perhap
surpris
mrsa
identifi
variou
anim
speci
mrsa
prime
exampl
oftenoverlook
close
relationship
human
anim
potenti
transmiss
pathogen
direct
anim
could
play
role
human
mrsa
direct
contact
environment
contamin
food
howev
direct
contact
rout
clearli
demonstr
anim
popul
could
also
reservoir
mrsa
epidemiolog
clinic
aspect
human
risk
mrsa
anim
vari
greatli
speci
direct
transmiss
mrsa
household
pet
human
contact
demonstr
pet
may
particularli
import
recurr
mrsa
household
mrsa
strain
found
pet
tend
predomin
strain
found
human
geograph
area
like
human
sourc
mrsa
household
pet
epidemiolog
differ
hors
uncommon
human
epidem
clone
predomin
suggest
rel
horseadapt
zoonot
infect
hors
owner
veterinari
personnel
identifi
group
also
high
rate
mrsa
colonis
tend
colonis
clone
commonli
found
hors
suggest
frequent
zoonot
transmiss
contrast
recent
report
involv
food
anim
particularli
pig
describ
predomin
strain
histor
import
caus
human
diseas
clone
import
caus
camrsa
infect
first
person
pig
contact
gener
popul
region
signific
concern
reservoir
mrsa
may
complic
aggress
mrsa
control
programm
identif
mrsa
food
anim
logic
lead
concern
potenti
foodborn
transmiss
mrsa
risk
current
unclear
investig
overal
role
anim
human
mrsa
infect
still
unclear
like
anim
play
direct
indirect
role
least
case
appar
spread
pig
broader
commun
europ
potenti
role
pet
household
reservoir
perhap
greatest
concern
failur
properli
investig
role
anim
human
mrsa
infect
chang
epidemiolog
camrsa
could
compromis
control
measur
conclus
observ
studi
incid
cap
legionella
rose
notabl
doctor
consid
entiti
ongo
investig
hospit
polici
consid
use
lua
pneumonia
diagnos
contrari
legionella
infect
consid
rare
entiti
period
investig
clinic
data
suggest
ld
incid
declin
significantli
period
iii
extrapol
data
case
cap
figur
would
increas
consider
probabl
thousand
patient
would
diagnos
ld
worldwid
ip
n
lee
rainer
g
antonio
g
lui
chau
f
ng
e
leung
hui
p
chan
hong
kong
hk
object
communityacquir
pneumonia
cap
lead
infecti
caus
death
throughout
world
pandem
avian
influenza
impend
concern
prevent
remain
one
highest
prioriti
hong
kong
previou
influenza
case
occur
diagnost
exclus
remain
one
import
exclus
new
pathogen
multiplex
pcr
examin
virus
includ
influenza
h
type
appli
nasopharyng
aspir
adult
hospitalis
commun
acquir
pneumonia
method
prospect
observ
studi
consecut
inpati
cap
perform
univers
hospit
new
territori
conclus
septifast
pcr
clinic
use
neutropen
cancer
patient
persist
fever
despit
antibacteri
therapi
postop
risk
factor
caus
infect
heart
transplant
cardiovascular
clinic
medellin
colombia
p
bedoya
mf
gomez
mejia
g
franco
rl
fernandez
jc
gonzalez
medellin
co
object
tri
identifi
possibl
risk
factor
acquir
infect
heart
transplant
procedur
perform
cardiovascular
clinic
medellin
colombia
januari
juli
clinic
leader
institut
heart
lung
transplant
colombia
south
america
first
time
tri
find
scope
transplantrel
infect
method
cross
section
studi
case
control
analysi
made
case
defin
episod
postop
infect
heart
transplant
receptor
control
patient
develop
infect
similar
surgeri
review
medic
chart
patient
infect
infect
done
presum
preoper
sex
age
diabet
copd
renal
failur
previou
hospitalis
surgic
durat
ischemi
perfus
time
postop
cardiac
tamponad
bleed
diabet
ventricular
failur
graft
reject
etc
risk
factor
assess
result
patient
includ
studi
appear
least
one
episod
infect
defin
cdc
criteria
associ
found
p
follow
post
transplant
event
acut
renal
failur
diabet
delay
start
cyclosporin
therapi
hour
mechan
ventil
prolong
stay
icu
among
surgic
event
durat
ischemi
procedur
statist
relev
conclus
studi
main
risk
factor
acquir
heart
transplant
relat
infect
postop
import
attempt
control
factor
depend
medic
intervent
like
stay
icu
day
mechan
ventil
onset
cyclosporin
therapi
measur
prevent
presenc
infect
type
speci
clone
symposium
arrang
esgem
tetanu
varicella
zoster
viru
patient
immunosuppress
diseas
treatment
aim
assess
vaccin
histori
exposur
vaccin
prevent
diseas
ibd
patient
immunosuppress
prior
establish
chronic
inflammatori
diseas
assess
clinic
method
conduct
prospect
survey
consecut
ibd
patient
immunosuppress
medic
thorough
vaccin
histori
obtain
blood
sampl
taken
assess
past
exposur
vaccin
statu
result
total
ibd
patient
assess
crohn
diseas
ulcer
coliti
indetermin
histori
immunosuppress
use
includ
azathioprin
prednisolon
methotrex
antitnf
patient
receiv
annual
influenza
vaccin
never
vaccin
patient
adequ
vaccin
pneumococcu
never
vaccin
varicella
zoster
viru
igg
detect
patient
previou
histori
chickenpox
previou
histori
shingl
patient
vaccin
hepat
b
chronic
hepat
b
infect
vaccin
conclus
studi
indic
vaccin
uptak
amongst
ibd
patient
immunosuppress
regimen
extrem
poor
current
irish
guidelin
recommend
vaccin
patient
ignor
guidelin
put
patient
risk
prevent
diseas
establish
design
infecti
diseas
assess
clinic
commenc
address
vaccin
requir
provid
healthcar
advic
pertain
infecti
complic
immunosuppress
therapi
particular
biolog
agent
intend
expand
servic
medic
specialti
utilis
immunosuppress
regimen
lazzarotto
chiereghin
l
gabrielli
ad
pinna
lauro
dazzi
c
zanfi
cescon
l
potena
c
magelli
e
petrisli
p
monari
pop
mp
landini
bologna
object
studi
carri
assess
diagnost
prognost
valu
cytomegaloviru
cmv
determin
whole
blood
heart
intestin
recipi
biopsi
tissu
sampl
intestin
recipi
transplant
patient
virolog
surveil
analys
cmv
cell
respons
transplant
method
monitor
heart
transplant
recipi
htr
compris
three
intestinalmultiviscer
transplant
sbmtr
compris
three
cmv
antigenaemia
real
time
pcr
monitor
twice
weekli
first
month
everi
week
next
two
month
everi
two
week
sixth
month
monthli
onward
addit
blood
biopsi
sampl
taken
clinic
indic
immunolog
surveil
done
htr
sbmtr
studi
cmvspecif
tcell
respons
consist
two
stage
collect
blood
sampl
per
patient
time
transplant
ii
collect
sampl
per
patient
month
posttranspl
followup
lymphocyt
suspens
obtain
use
ficol
gradient
process
elispot
immunoenzymeassay
base
search
cell
viral
specif
antigen
one
protein
marker
cell
activ
ifngamma
around
blood
sampl
intestin
biopsi
specimen
process
virolog
test
analys
elispot
result
htr
sbmtr
develop
activ
cmv
infect
respect
htr
infect
four
mildmoder
symptomat
infect
leucopenia
fever
sbmtr
infect
patient
two
sever
symptomat
cmv
infect
pneumonia
enter
reject
led
patient
death
three
mild
infect
fever
conclus
quantit
determin
cmv
blood
organ
biopsi
molecular
test
elect
assay
monitor
viral
load
sinc
directli
correl
viral
replic
clinic
symptom
preliminari
outcom
immunolog
monitor
show
cmv
tcell
immun
respons
first
month
transplant
associ
reduct
mean
peak
cmv
viral
load
ii
good
earli
reconstitut
develop
cmvspecif
tcell
respons
shorten
durat
cmv
infect
control
risk
incur
repeat
episod
link
recurr
infect
listeria
monocytogen
outbreak
comprehens
cancer
transplant
centr
e
lingaa
bo
johnsen
torfoss
dh
dorenberg
ct
andersen
f
ingebretsen
p
gaustad
tm
leegaard
nordoey
oslo
object
listeria
monocytogen
infect
rare
man
known
occur
immunocompromis
host
high
fatal
rate
l
monocytogen
wide
distribut
environ
abil
multipli
even
low
temperatur
fear
foodborn
pathogen
describ
outbreak
univers
hospit
oslo
norway
hospit
primarili
cancer
transplant
centr
method
identif
l
monocytogen
base
gram
stain
betahaemolysi
catalas
vitek
identif
camptest
resist
pattern
serotyp
mlva
perform
confirm
outbreak
result
octob
l
monocytogen
isol
blood
cultur
n
pu
n
faec
n
women
men
median
age
year
rang
fourteen
patient
predispos
underli
diseas
receiv
immunomodul
therapi
receiv
antacid
thirteen
patient
fever
patient
diarrhoea
none
classic
symptom
mening
somnol
andor
headach
three
patient
die
diagnosi
confirm
remain
patient
receiv
appropri
treatment
l
monocytogen
isol
recov
eight
patient
receiv
empir
monotherapi
cephalosporin
onset
fever
patient
die
blood
cultur
posit
within
day
identif
confirm
isol
patient
serotyp
ident
mlva
profil
pattern
resist
pasteuris
camembert
chees
sourc
outbreak
report
l
monocytogen
outbreak
mortal
set
predomin
immunocompromis
patient
use
empir
cephalosporin
monotherapi
set
immunocompromis
patient
may
hazard
l
monocytogen
resist
antibiot
foodregul
hospit
seem
warrant
mlst
propos
portabl
approach
identif
bacteri
clone
base
three
develop
increas
avail
decreas
cost
highthroughput
sequenc
ii
improv
understand
bacteri
popul
biolog
implic
epidemiolog
iii
increas
avail
power
internet
mean
data
share
sinc
time
mlst
becom
gold
standard
method
characteris
mani
bacteri
pathogen
number
nonpathogen
mlst
made
possibl
compar
bacteri
isol
obtain
differ
part
world
differ
time
simpli
accur
use
gener
techniqu
without
necess
share
reagent
isol
addit
solv
mani
problem
inher
characteris
isol
divers
recombinogen
bacteria
mlst
also
provid
data
enabl
extens
studi
bacteri
popul
genet
speciat
evolut
provid
substanti
ad
valu
epidemiolog
studi
mlst
approach
also
provid
indic
effici
mean
exploit
next
gener
dna
sequenc
machin
j
lindsay
london
uk
microarray
solid
support
spot
thousand
tini
dna
probe
use
quickli
determin
gene
present
bacterium
sampl
caus
revolut
understand
bacteri
popul
structur
vari
evolv
also
help
identifi
marker
virul
epidemiolog
microarray
also
extrem
valueabl
develop
valid
improv
routin
type
method
type
laboratori
method
need
cheap
rapid
accur
reproduc
microarray
technolog
expens
experiment
chang
print
appropri
probe
valid
use
endless
limit
abil
interpret
data
gener
g
vergnaud
p
bouchon
grissa
c
pourcel
orsay
fr
multipl
loci
variabl
number
tandem
repeat
vntr
analysi
mlva
type
techniqu
base
polymorph
certain
tandemli
repeat
dna
sequenc
although
biolog
function
evolut
mechan
fulli
understood
divers
practic
applic
includ
strain
identif
bacteri
epidemiolog
typic
mlva
assay
twenti
vntr
distribut
entir
bacteri
genom
analys
code
correspond
number
repeat
locu
determin
code
easili
store
databas
use
strain
cluster
epidemiolog
studi
show
list
current
propos
mlva
assay
briefli
describ
repres
exampl
includ
open
question
compar
mlva
approach
discuss
issu
relat
standardis
possibl
offer
internet
term
share
databas
mlva
mlva
web
servic
cluster
regularli
interspac
short
palindrom
repeat
crispr
loci
part
recent
discov
mechan
use
bacteria
archaea
defenc
genet
element
particular
phage
structur
consist
repeat
sequenc
long
call
direct
repeat
dr
separ
uniqu
sequenc
similar
size
call
spacer
polymorph
use
differenti
strain
insid
speci
due
either
acquisit
new
motif
dr
spacer
polaris
fashion
interstiti
delet
one
sever
consecut
motif
spoligotyp
method
wide
appli
genotyp
mycobacterium
tuberculosi
base
analysi
crispr
locu
assess
interest
crispr
analysi
genotyp
method
import
first
identifi
structur
genom
interest
extract
classifi
constitut
element
crispr
identifi
sequenc
strain
silico
analysi
phase
polymorph
investig
speci
pcr
amplif
sequenc
phase
last
phase
consist
classif
number
spacer
order
compar
strain
produc
tent
phylogenet
tree
present
web
servic
tool
develop
purpos
discuss
effici
inform
crispr
analysi
genotyp
tool
depend
speci
divers
sinc
earli
netherland
adopt
search
destroy
polici
respect
meticillinresist
staphylococcu
aureu
mrsa
polici
impli
nation
guidelin
control
search
carrier
among
defin
group
patient
healthcar
worker
strict
isol
carrier
treatment
carrier
guidelin
enforc
health
inspector
addit
nation
surveil
system
implement
surveil
know
mrsa
detect
approxim
person
patient
healthcar
worker
number
compris
carrier
infect
person
low
number
confirm
earss
data
netherland
one
countri
europ
lowest
burden
mrsa
stringent
dutch
polici
applic
mani
year
number
carrier
low
realiz
screen
strict
isol
dutch
way
imposs
number
mrsa
carrier
becom
high
dutch
experi
howev
lesson
learn
might
provid
basi
copi
past
part
dutch
approach
countri
higher
burden
mrsa
among
nation
approach
nation
surveil
provid
support
healthcar
worker
involv
motiv
keep
effort
success
strategi
prevent
healthcareassoci
infect
requir
multifacet
evidencebas
approach
includ
provid
practition
best
evid
clinic
effect
practic
support
understand
use
evid
minimis
infect
risk
increas
patient
safeti
present
describ
nation
evidencebas
guidelin
depart
health
nation
institut
health
clinic
excel
england
form
foundat
ensur
avail
best
evid
practition
nation
health
servic
nh
develop
associ
elearningblend
learn
programm
support
practition
effect
use
evid
protect
patient
risk
prevent
infect
care
incorpor
nation
guidelin
local
polici
protocol
routin
daili
clinic
practic
patient
safeti
enhanc
risk
patient
acquir
infect
episod
healthcar
nh
facil
england
minimis
homeless
peopl
particularli
expos
ectoparasit
live
condit
crowd
shelter
provid
ideal
condit
spread
lice
flea
tick
mite
bodi
lice
long
recognis
human
parasit
although
typic
preval
rural
commun
upland
area
countri
close
equat
increasingli
encount
develop
countri
especi
homeless
peopl
inner
citi
econom
depriv
popul
flea
widespread
adapt
specif
host
may
occasion
bite
human
common
flea
parasit
human
cat
rat
human
flea
ctenocephalid
feli
xenopsylla
cheopi
pulex
irritan
respect
tick
belong
famili
ixodida
particular
genera
dermacentor
rhipicephalu
ixod
frequent
parasit
human
sarcopt
scabiei
var
homini
mite
arachnida
class
respons
scabi
oblig
parasit
human
skin
hematophag
bite
mite
liponyssoid
sanguineu
mite
rat
mous
domest
rodent
also
bite
human
threat
pose
ectoparasit
homeless
ectoparasit
associ
infecti
diseas
may
transmit
human
except
scabi
ectoparasit
potenti
vector
infecti
agent
three
lous
born
diseas
known
time
trench
fever
caus
bartonella
quintana
epidem
typhu
caus
rickettsia
prowazekii
relaps
fever
caus
spirochet
borrelia
recurrenti
flea
transmit
plagu
xenopsylla
cheopi
pulex
irritan
murin
typhu
xenopsylla
cheopi
fleaborn
spot
rickettsiosi
due
recent
describ
speci
rickettsia
feli
ctenocephalid
feli
occasion
catscratch
diseas
due
bartonella
hensela
ctenocephalid
feli
role
flea
potenti
vector
b
quintana
recent
suggest
among
hematophag
bite
mite
liponyssoid
sanguineu
respons
transmiss
rickettsia
akari
aetiolog
agent
rickettsialpox
virtual
data
avail
tickborn
diseas
popul
review
deal
epidemiolog
diagnosi
prevent
treatment
ectoparasit
infecti
diseas
transmit
homeless
peopl
avsiczupanc
ljubljana
si
hantavirus
belong
emerg
pathogen
gain
attent
last
decad
virus
member
famili
bunyavirida
group
separ
genu
known
hantaviru
unlik
bunyavirida
hantavirus
arthropodborn
arbovirus
rodentborn
robovirus
hantaviru
primarili
carri
distinct
rodentinsectivor
speci
although
host
switch
seem
occur
ten
million
year
coevolut
carrier
anim
hantavirus
maintain
cyclic
transmiss
persist
infect
rodent
incident
infect
human
transmiss
occur
primarili
inhal
aerosol
infect
rodent
urin
faec
saliva
hantavirus
found
worldwid
known
caus
two
seriou
often
fatal
human
diseas
haemorrhag
fever
renal
syndrom
hfr
hantaviru
cardiopulmonari
syndrom
hcp
hantavirus
identifi
approxim
half
known
caus
hfr
hp
serotyp
hantaan
htn
seoul
seo
puumala
puu
dobrava
dob
viru
predominantli
caus
haemorrhag
fever
renal
syndrom
hfr
diseas
characteris
renal
failur
haemorrhag
shock
wherea
hantaviru
cardiopulmonari
syndrom
hcp
sever
cardiopulmonari
ill
often
caus
sin
nombr
viru
ill
begin
nonspecif
febril
prodrom
patient
quickli
develop
noncardiogen
pulmonari
edema
respiratori
failur
shock
overal
case
fatal
rate
hcp
approxim
percent
pathogenesi
hfr
poorli
understood
howev
known
integrin
mediat
entri
pathogen
hantavirus
hantavirus
regul
apoptosi
also
evid
increas
capillari
permeabl
essenti
compon
pathogenesi
hfr
hcp
although
differ
target
tissu
kidney
lung
affect
two
diseas
hfr
patient
show
local
increas
level
tnfa
plasma
kidney
high
level
urinari
secret
proinflammatori
cytokin
diagnosi
acut
hantaviru
infect
primarili
base
serolog
sinc
viral
rna
regularli
detect
blood
urin
patient
immunofluoresc
test
enzym
immunoassay
wide
use
detect
specif
igm
lowavid
igg
antibodi
characterist
acut
infect
vaccin
hantaviru
infect
use
year
china
korea
europ
america
specif
therapi
use
europ
although
ribavirin
interferona
success
use
trial
china
high
rate
mortal
could
reduc
effect
therapeut
could
discov
treatment
ill
improv
inflammatori
respons
outcom
streptococcu
pneumonia
infect
reduc
level
neg
regul
lung
h
lagler
sharif
hasling
u
matt
k
stich
furtner
k
schmidt
knapp
vienna
background
trigger
receptor
express
myeloid
cell
cell
surfac
receptor
present
monocytesmacrophag
neutrophil
shown
amplifi
cytokin
chemokin
product
respons
bacteri
toll
like
receptor
tlr
ligand
block
studi
reveal
valuabl
target
prevent
overwhelm
inflamm
sepsi
time
highli
express
within
pulmonari
compart
solubl
valuabl
marker
indic
presenc
pneumonia
human
biolog
role
commun
acquir
pneumonia
pneumococc
pneumonia
known
aim
present
studi
determin
function
inflammatori
respons
streptococcu
pneumonia
infect
vivo
mechan
occur
outcom
infect
method
mice
intranas
infect
pneumonia
follow
ip
treatment
pb
isotyp
ab
agonist
mab
bacteri
count
lung
histolog
neutrophil
influx
chemokinecytokin
respons
signal
mediat
well
surviv
evalu
vivo
time
depend
manner
vitro
immortalis
lung
alveolar
macrophag
mh
respiratori
epitheli
cell
utilis
studi
respons
pneumonia
treatment
result
mice
pretreat
agonist
display
significantli
amplifi
cytokin
chemokin
respons
tnf
well
neutrophil
influx
lung
induct
pneumonia
enhanc
earli
inflamm
associ
lower
number
bacteria
lung
reduc
pulmonari
inflamm
result
improv
surviv
vitro
studi
corrobor
result
earli
time
point
reduct
neg
regul
tlr
signal
lung
observ
mice
pretreat
vivo
conclus
boost
earli
inflammatori
respons
pneumonia
infect
vivo
lower
level
neg
regul
lung
result
acceler
bacteri
clearanc
ultim
improv
surviv
sepsi
clinic
syndrom
result
system
respons
host
infect
outcom
sepsi
poor
even
develop
world
mortal
rate
remain
high
western
world
sepsi
frequent
caus
bacteria
commonli
isol
pathogen
gramposit
sepsi
staphylococcu
aureu
streptococcu
pneumonia
common
gramneg
caus
bacteria
escherichia
coli
klebsiella
sp
pseudomona
aeruginosa
although
bacteria
also
isol
patient
sepsi
tropic
area
sever
caus
must
consid
potenti
lethal
caus
sepsi
tropic
includ
malaria
viral
haemorrhag
fever
leptospirosi
typhoid
fever
melioidosi
mani
aspect
host
respons
tropic
eccmid
oral
present
infect
resembl
host
respons
sepsi
seen
western
world
includ
activ
inflammatori
procoagul
pathway
studi
compar
host
respons
western
sepsi
tropic
sepsi
discuss
calandra
lausann
ch
innat
immun
system
assum
essenti
role
natur
host
defenc
microb
sens
microbi
pathogen
either
tissu
contact
host
environ
system
circul
invas
bloodstream
carri
macrophag
dendrit
cell
natur
killer
cell
granulocyt
monocyt
act
sentinel
innat
immun
system
recognit
invas
pathogen
immun
cell
reli
capac
detect
microbi
molecular
motif
endotoxin
peptidoglycan
subcompon
lipopeptid
glucan
mannan
flagellin
nucleic
acid
via
microbialrecognit
receptor
microbeassoci
molecular
motif
bind
famili
microbi
recognit
molecul
express
immun
nonimmun
cell
includ
tolllik
receptor
peptidoglycanrecognit
protein
nucleotidebind
oligomeris
domainlik
receptor
helicasedomaincontain
like
receptor
retino
acidinduc
gene
rigi
melanomadifferentiationassoci
gene
ctype
lectin
receptor
trigger
receptor
express
myeloid
cell
trem
receptor
famili
ligandactiv
receptor
turn
signal
transduct
pathway
transcript
immun
gene
result
express
costimulatori
molecul
cell
surfac
releas
immunoregulatori
effector
molecul
extracellular
compart
recent
increas
knowledg
pathophysiolog
basi
sepsi
translat
clinic
benefit
late
howev
sever
treatment
approach
first
time
yield
encourag
albeit
still
arguabl
result
ie
earlygo
direct
therapi
activ
protein
c
hydrocortison
therapi
intens
insulin
therapi
new
immunomodul
therapi
target
compon
innat
immun
system
current
underway
guchev
ratchina
r
kozlov
smolensk
ru
object
compar
toler
clinic
efficaci
novel
formul
amoxicillinclavulan
acid
aca
dispers
tabletswith
origin
filmcoat
tablet
hospitalis
adult
bacteri
lower
respiratori
tract
infect
lrti
primari
efficaci
analysi
studi
noninferior
tlv
compar
van
clinic
cure
rate
clinic
evalu
ce
patient
addit
pool
analys
two
studi
specifi
prospect
result
total
patient
randomis
treat
patient
ce
studi
demograph
baselin
characterist
similar
two
treatment
group
noninferior
achiev
alltreat
ce
popul
studi
well
pool
analysi
pool
clinic
cure
rate
display
tabl
clinic
cure
rate
ce
patient
vap
numer
higher
tlv
group
tabl
comparison
antibiot
placebo
treatment
presum
acut
bacteri
sinus
metaanalysi
randomis
control
trial
falaga
k
giannopoul
k
vardaka
g
dimopoulo
karageorgopoulo
athen
gr
object
controversi
regard
benefit
antibiot
treatment
patient
presum
acut
bacteri
sinus
method
perform
metaanalysi
randomis
placebocontrol
trial
rct
evalu
effect
safeti
antibiot
indic
result
sixteen
rct
includ
among
perform
exclus
children
involv
antibiot
arm
amoxicillin
penicillin
v
amoxicillinclavulan
antibiot
compar
placebo
use
antibiot
associ
higher
proport
cure
improv
patient
random
effect
model
rem
odd
ratio
confid
interv
ci
data
rct
speedier
resolut
symptom
trend
toward
fewer
complic
patient
rem
rct
howev
also
associ
higher
proport
advers
event
patient
rem
rct
although
associ
significantli
withdraw
due
advers
event
patient
rem
rct
conclus
antibiot
treatment
presum
acut
bacteri
sinus
compar
placebo
associ
round
ad
benefit
clinic
outcom
cost
approxim
equal
increas
rate
advers
event
consid
observ
advers
event
gener
seriou
use
antibiot
may
carri
appreci
risk
diseas
complic
believ
clinic
benefit
obtain
antibiot
use
justifi
risk
associ
treatment
conclus
fluoroquinolon
effect
blactam
treatment
osteomyel
consid
use
altern
physician
armamentarium
valu
fluoroquinolon
treatment
osteomyel
lie
fact
administ
outpati
set
howev
use
caution
preserv
activ
increasingli
resist
bacteria
g
cachovan
giersdorf
hallier
streichert
haddad
u
platzer
rh
k
wegscheid
sobottka
hamburg
berlin
rotenburg
de
object
odontogen
infect
bacteri
origin
penetr
primarili
soft
boni
oromaxillofaci
tissu
produc
submucos
infiltr
abscess
infect
typic
mix
infect
anaerob
bacteria
thought
central
aetiolog
role
often
take
mild
cours
infect
may
depend
patient
immunocompet
site
inflammatori
process
also
produc
lifethreaten
complic
avail
effect
effici
antibiot
treatment
odontogen
infect
therefor
essenti
preclin
studi
shown
good
oromaxillari
tissu
penetr
moxifloxacin
mxf
earli
clinic
report
suggest
mxf
may
effect
treatment
odontogen
infect
object
studi
systemat
evalu
efficaci
mxf
larger
compar
clinic
trial
method
prospect
randomis
doubleblind
multicentr
phase
ii
trial
compar
efficaci
toler
mxf
clindamycin
cli
treatment
inflammatori
infiltr
odontogen
abscess
patient
receiv
either
mxf
mg
daili
cli
mg
four
time
daili
day
primari
efficaci
endpoint
percent
reduct
patient
perceiv
pain
visual
analog
scale
va
day
day
associ
plasmidmedi
quinolon
resist
gene
blactamas
extendedspectrum
blactamas
enterobact
cloaca
isol
moroccco
bouchakour
timinouni
k
zerouali
jd
perriergrosclaud
mc
ploy
n
el
mdaghri
p
courvalin
casablanca
limog
fr
pari
fr
object
determin
genet
environ
qnr
gene
among
enterobacteriacea
isol
univers
hospit
ibn
rochd
casablanca
morocco
method
third
gener
cephalosporin
resist
unrel
e
cloaca
strain
n
isol
ibn
rochd
hospit
casablanca
survey
conduct
octob
march
antibiot
suscept
disc
diffus
method
mic
screen
extend
spectrum
betalactamas
esbl
perform
accord
french
societi
microbiolog
guidelin
characteris
quinolon
resist
gene
qnra
qnrb
qnr
aac
ibcr
investig
pcr
identif
esbl
tem
shv
group
perform
pcr
identif
plasmid
ampc
blactamas
perform
multiplex
pcr
pcr
product
sequenc
strand
conjug
experi
perform
use
azideresist
escherichia
coli
recipi
strain
result
among
esblproduc
strain
resist
third
gener
cephalosporin
test
except
cefepim
mic
mgl
aac
ibcr
except
strain
aac
ib
identifi
strain
transfer
plasmid
dna
success
obtain
strain
transconjug
confirm
e
coli
use
biochem
test
transconjug
express
resist
third
gener
cephalosporin
except
cefepim
specif
primer
aac
ibcr
prove
cotransf
transconjug
cotranf
two
transconjug
conclus
studi
demonstr
associ
aac
ibcr
determin
e
cloaca
strain
isol
casablanca
moreov
first
report
e
cloaca
isol
contain
transmiss
plasmidmedi
h
wang
h
yang
q
yang
l
peng
h
sun
xu
chen
beij
shenzhen
cn
object
investig
preval
plasmidmedi
quinolon
resist
qnr
aac
object
extendedspectrum
cephalosporin
quinolon
use
primari
treatment
sever
salmonellosi
therefor
emerg
simultan
resist
drug
clinic
isol
salmonella
great
therapeut
concern
studi
perform
investig
molecular
epidemiolog
resist
cefotaxim
ctx
nalidix
acid
et
al
includ
studi
comparison
suscept
test
perform
agar
dilut
method
accord
clsi
guidelin
molecular
type
done
use
fluoresc
multiplelocu
variablenumb
tandemrepeat
analysi
mlva
pcr
sequenc
use
identifi
ctxm
blactamas
gene
characteris
genet
context
well
determin
gyra
qrdr
sequenc
ctxmcode
plasmid
compar
use
rflp
analysi
psti
pvuii
endonucleas
result
isol
studi
share
common
phenotyp
ctx
resist
revers
clavulan
acid
resist
due
product
esbl
whose
gene
associ
element
locat
small
kb
plasmid
exhibit
ident
rflp
pattern
isol
eighteen
isol
resist
na
none
resist
ciprofloxacin
mlva
group
isol
type
link
vntr
loci
distinguish
type
quinoloneresist
isol
distribut
among
mlva
type
also
includ
nasuscept
isol
resist
na
strongli
correl
presenc
known
mutat
tyr
gli
gyra
qrdr
sequenc
otherwis
ident
isol
notabl
isol
differ
mlva
type
differ
gyra
mutat
conclus
studi
support
clonal
origin
sti
isol
continu
spread
russia
belaru
kazakhstan
provid
evid
frequent
independ
acquisit
quinolon
resist
among
isol
samuelsen
l
b
aasna
k
fuurst
b
haldorsen
leegaard
rajendra
j
rydberg
gs
simonsen
toleman
walder
yong
tr
walsh
sundsfjord
cg
gisk
aarhu
dk
oslo
stockholm
lund
se
cardiff
uk
se
object
scandinavian
countri
histori
low
level
antibiot
resist
due
effect
infect
control
measur
restrict
use
antibiot
new
resist
mechan
therefor
less
like
emerg
endogen
sourc
studi
assess
epidemiolog
characteris
mbl
produc
clinic
isol
detect
denmark
norway
sweden
object
acquir
metallobetalactamas
mbl
produc
isol
uncommonli
describ
spain
mostli
confin
p
aeruginosa
describ
emerg
produc
p
aeruginosa
isol
hospit
epidem
involv
differ
produc
enterobacteri
speci
tato
et
al
cid
identifi
genet
context
method
two
mbl
produc
p
aeruginosa
isol
recov
respect
mbl
product
detect
doubledisc
synergi
test
mcl
versu
imipenem
ceftazidim
clonal
analysi
determin
speipfg
pcr
blavim
class
integron
sequenc
perform
sequenc
transfer
antibiot
resist
determin
filterm
use
p
aeruginosa
strain
result
pfge
reveal
differ
restrict
pattern
p
aeruginosa
isol
gene
locat
within
class
integron
case
mbl
gene
carri
deriv
lack
cs
contain
differ
class
integron
detect
integron
also
differ
found
contemporari
mblenterobacteri
isol
hospit
gene
transfer
frequenc
rang
conclus
firstli
report
produc
p
aeruginosa
countri
integron
platform
contain
gene
isol
differ
found
enterobacteri
speci
contemporarili
recov
epidem
hospit
dissemin
gene
associ
differ
genet
structur
bacteri
host
depict
complex
scenario
emerg
threat
hospit
see
tabl
case
also
like
receiv
inact
antibiot
first
treatment
vs
p
even
document
resist
vs
p
also
experienc
frequent
relaps
vs
p
higher
mortal
control
vs
p
conclus
incid
cigrec
caus
urinari
tract
infect
increas
hospit
impact
outcom
patient
ciprofloxacin
gentamicin
longer
use
empir
treatment
uti
among
patient
receiv
quinolon
previou
year
risk
factor
associ
isol
colistinresist
gramneg
bacteria
match
casecontrol
studi
matthaiou
michalopoulo
p
rafailidi
karageorgopoulo
v
papaioann
g
ntani
g
samoni
falaga
athen
gr
object
emerg
multidrug
resist
gramneg
bacteria
led
reus
colistin
resist
agent
alreadi
report
aim
investig
potenti
risk
factor
isol
colistin
interest
case
suscept
resist
antibiot
revers
meticillin
resist
staphylococcu
aureu
thioridazin
jk
christiansen
mn
skov
bh
kallipol
hj
kolmo
odens
dk
object
thioridazin
phenothiazin
agent
shown
revers
oxacillin
meticillin
resist
meticillinresist
staphylococcu
aureu
mrsa
vitro
mechan
behind
observ
effect
yet
clarifi
aim
studi
determin
thioridazin
alon
combin
oxacillin
affect
transcript
meticillin
resist
gene
meca
protein
level
code
protein
penicillin
bind
protein
method
growth
mrsa
atcc
examin
liquid
media
presenc
meticillin
analogu
oxacillin
nonantibiot
thioridazin
alon
combin
furthermor
transcript
meca
analys
northern
blot
primer
extens
protein
level
analys
western
blot
condit
observ
increas
suscept
mrsa
toward
oxacillin
presenc
oxacillin
thioridazin
compar
bacteria
grown
oxacillin
thioridazin
alon
transcript
meca
reduc
increas
concentr
thioridazin
presenc
oxacillin
compar
bacteria
grown
oxacillin
thioridazin
alon
addit
protein
level
reduc
bacteria
treat
combin
oxacillin
thioridazin
thioridazin
affect
growth
mrsa
meca
conclus
result
present
studi
indic
revers
meticillin
resist
thioridazin
mrsa
may
explain
reduc
transcript
meticillin
resist
gene
meca
protein
level
code
protein
conclus
iclaprim
bactericid
human
clot
wild
type
tkdefici
strain
equipot
sxt
vancomycin
iclaprim
bacteriostat
parent
rat
clot
kill
tkdefici
mutant
media
bactericid
activ
iclaprim
mrsa
human
clot
set
mimick
intravascular
milieu
show
potenti
drug
treatment
mrsa
infect
human
tkdefici
mutant
could
also
prove
use
studi
diaminopyrimidin
rodent
object
iclaprim
icl
novel
diaminopyrimidin
within
class
trimethoprim
potent
broadspectrum
bactericid
activ
vitro
intraven
formul
icl
success
complet
phase
iii
trial
complic
skin
skin
structur
infect
phase
ii
trial
hospitaland
ventilatorassoci
pneumonia
underway
oral
form
icl
also
evalu
phase
trial
current
studi
ascertain
vitro
activ
icl
compar
pyogen
ga
agalactia
gb
method
mic
determin
clsi
broth
microdilut
methodolog
recent
ga
primarili
respiratori
infect
recent
gb
predominantli
wound
swab
origin
icl
activ
isol
slightli
activ
ga
gb
includ
isol
resist
cla
cli
trail
endpoint
observ
sxt
ga
produc
falseresist
unless
read
strictli
growth
reduct
accord
clsi
method
potenti
subject
read
procedur
necessari
icl
conclus
icl
show
excel
activ
vitro
ga
gb
support
use
iclaprim
treatment
infect
caus
bacteria
efflux
pump
inhibitor
may
overcom
antibiot
resist
multiresist
bacteria
increas
intracellular
drug
concentr
leitner
j
nemeth
abrahim
h
lagler
erker
zeitling
vienna
introduct
multi
drug
resist
mdr
bacteria
increas
problem
clinic
practic
antimicrobi
therapi
inhibit
bacteri
efflux
mechan
appear
promis
target
order
restor
antimicrobi
suscept
mdr
bacteria
previou
invitro
studi
shown
inhibitor
bacteri
efflux
pump
may
improv
antimicrobi
effect
fluoroquinolon
howev
substanc
concentr
necessari
restor
antimicrobi
suscept
high
clinic
use
might
ascrib
insuffici
increas
intracellular
concentr
antimicrobi
present
studi
set
investig
potenc
variou
efflux
pump
inhibitor
epi
overcom
mdr
explor
chang
intracellular
concentr
ciprofloxacin
potent
substanc
method
two
previous
describ
epi
piperazin
nmp
phenylargininebetanaphthylamid
pabn
two
novel
specif
pglycoprotein
pgp
inhibitor
tariquidar
elacridar
investig
term
effect
vitro
antibacteri
activ
antimicrobi
suscept
ciprofloxacin
absenc
presenc
epi
test
follow
strain
staphylococcu
aureu
atcc
sa
ciprofloxacin
resist
aureu
rsa
pseudomona
aeruginosa
atcc
ps
mdr
stenotrophomona
maltophilia
atcc
sm
chang
intracellular
concentr
ciprofloxacin
determin
use
ciprofloxacin
result
inhibit
pgp
mediat
drug
efflux
tariquidar
elacridar
reduc
mic
ciprofloxacin
rsa
mgl
mgl
dose
depend
manner
wherea
minor
effect
observ
sa
gramneg
strain
addit
mnp
pabn
high
concentr
increas
suscept
toward
ciprofloxacin
resist
strain
test
addit
tariquidar
elacridar
dose
depend
increas
intracellular
ciprofloxacin
detect
conclus
find
suggest
tariquidar
elacridar
potent
inhibitor
pgp
mediat
bacteri
efflux
substanc
may
restor
suscept
pgp
express
pathogen
dose
depend
increas
intracellular
ciprofloxacin
mdr
stenotrophomona
maltophilia
could
overcom
specif
pgp
inhibitor
suscept
could
increas
addit
high
dose
mnp
pabn
r
arnitz
nagl
w
gottardi
innsbruck
object
chloramin
cat
monochloramin
activ
chlorin
compound
wellknown
antisept
broadspectrum
microbicid
activ
cat
stronger
oxid
activ
latter
one
smaller
molecul
lipophil
genet
host
suscept
infecti
diseas
mannosebind
lectin
genet
exampl
singl
gene
influenc
host
suscept
toward
infect
report
appear
literatur
patient
suffer
recurr
upper
respiratori
tract
infect
first
year
life
whose
defect
appear
failur
phagocytos
saccharomyc
cerevisia
baker
yeast
effici
defect
revers
serum
donor
use
assay
opson
defect
could
found
high
proport
appar
healthi
popul
found
frequent
children
recurr
unexplain
infect
known
common
opson
defect
due
defici
protein
term
mannan
mannosebind
lectin
mbl
member
collectin
subfamili
ctype
lectin
initi
lectin
pathway
complement
activ
follow
bind
mannos
nacetylglucosamin
fucos
glucos
residu
present
orient
densiti
commonli
found
microorgan
bound
mbl
activ
complement
system
antibodi
manner
predominantli
mediat
serin
proteas
cleav
gener
convertas
human
collectin
gene
locat
cluster
chromosom
gene
compris
four
exon
known
three
singl
point
mutat
exon
lead
function
defici
mbl
protein
sever
polymorph
also
identifi
promot
region
mbl
gene
larg
combin
structur
gene
promot
polymorph
mbl
concentr
vari
thousandfold
appar
healthi
individu
approxim
third
caucasian
popul
genotyp
confer
concentr
deem
insuffici
numer
studi
perform
determin
role
mbl
clinic
set
would
appear
individu
defici
protein
prone
get
rang
infect
particularli
context
anoth
immun
defect
howev
also
situat
diseas
mbl
defici
may
protect
talk
outlin
current
think
role
mbl
suscept
infect
updat
peril
gramneg
bacteria
symposium
jointli
arrang
icaac
program
committe
extendedspectrum
blactamas
spread
commun
sinc
first
descript
eighti
nineti
detect
extendedspectrum
blactamas
esbl
shv
tem
type
mainli
describ
klebsiella
pneumonia
associ
nosocomi
outbreak
situat
dramat
chang
last
year
worldwid
esblproduc
isol
esherichia
coli
express
ctxm
enzym
major
recov
commun
patient
mainli
urinari
tract
infect
uti
new
risk
factor
identifi
moreov
increas
esblproduc
isol
detect
nurs
home
healthcar
associ
facil
commun
potenti
influx
esbl
commun
hospit
also
increas
preval
faecal
carriag
esblproduc
isol
outpati
healthi
volunt
describ
esbl
produc
also
recognis
nonhospit
compart
includ
farm
companion
anim
environ
popul
structur
ctxmproduc
isol
complex
initi
associ
polyclon
spread
esblproduc
describ
allodemia
andor
specif
plasmid
mobil
platform
genet
element
nevertheless
applic
mlst
type
scheme
esblproduc
e
coli
isol
addit
pfge
base
scheme
show
new
situat
descript
success
intern
dissemin
multiresist
clone
harbour
specif
epidem
plasmid
case
illustr
situat
e
coli
clone
belong
phylogroup
associ
multidrugresist
incfii
plasmid
harbour
gene
found
differ
countri
world
mostli
isol
patient
uti
commun
exampl
well
dispers
esbl
commun
former
frequent
report
west
europ
north
america
potenti
dispers
epidem
plasmid
differ
clone
preval
europ
south
america
asia
moreov
esbl
belong
classic
group
seem
also
well
dispers
commun
compart
widespread
europ
associ
salmonella
isol
recent
e
coli
isol
uti
although
associ
blaesbl
gene
success
mobil
genet
platform
magnifi
import
factor
increas
preval
esbl
presenc
specif
virul
determin
esbl
produc
might
also
facilit
persist
subsequ
dispers
esbl
addit
coresist
nonblactam
antibiot
decreas
therapeut
treatment
option
commun
patient
also
might
facilit
coselect
process
mainten
esbl
produc
remark
new
plasmid
mediat
resist
gene
includ
qnr
aac
ibcr
qepa
affect
fluoroquinolon
methylas
gene
affect
aminoglycosid
arma
rmtb
found
esblproduc
organ
sever
commun
compart
landscap
revers
current
pandem
situat
esbl
commun
seem
difficult
new
strategi
design
local
intern
level
curtail
spread
enzym
emerg
resist
broad
spectrum
blactam
increasingli
observ
main
gramneg
speci
involv
human
infect
ie
enterobacteriacea
pseudomona
aeruginosa
acinetobact
baumannii
besid
clavulanicacid
inhibit
extendedspectrum
blactamas
plasmidmedi
clavulanicacid
resist
cephalosporinas
increasingli
report
enterobacteri
speci
express
natur
ampc
escherichia
coli
proteu
mirabili
salmonella
sp
klebsiella
pneumonia
confer
resist
expandedspectrum
cephalosporin
chromosomeencod
cephalosporinas
extend
spectrum
activ
toward
ceftazidim
cefepim
also
report
e
coli
serratia
marcescen
enterobact
sp
carbapenemas
hydrolys
least
imipenem
ertapenem
orand
meropenem
ambler
molecular
class
b
enterobacteriacea
emerg
carbapenemas
mostli
plasmidmedi
kpc
vimimp
enzym
enterobacteriacea
carbapenemas
confer
reduc
suscept
carbapenem
may
remain
underestim
consequ
lack
detect
p
aeruginosa
baumannii
blactamas
mediat
resist
carbapenem
also
emerg
p
aeruginosa
metalloblactamas
imp
vim
spm
gim
report
worldwid
sourc
nosocomi
outbreak
baumannii
although
metallo
blactamas
known
acquir
oxacillinas
quit
specif
acinetobact
sp
main
sourc
carbapenem
resist
natur
reservoir
carbapenemas
unknown
notic
except
gene
identifi
acinetobact
radioresisten
shewanella
sp
respect
final
resist
carbapenem
may
result
gramneg
speci
impair
permeabl
overexpress
efflux
togeth
overexpresss
blactamas
weak
carbapenemas
activ
lower
rate
mrsa
cdad
relat
strateg
plan
intervent
inclus
infect
control
ic
staff
develop
programm
howev
certain
intervent
exampl
increas
level
train
relat
higher
infect
rate
mani
aspect
outcom
data
describ
possibl
confound
factor
studi
england
associ
found
lower
rate
mrsa
cdad
face
valu
support
evid
infect
control
literatur
howev
found
relationship
intervent
higher
infect
rate
counterintuit
may
repres
exampl
call
reactiv
practic
higher
rate
infect
whilst
interest
hypothesis
intervent
may
swift
simpl
introduc
may
sustain
compar
strateg
plan
intervent
link
lower
infect
rate
confirm
studi
time
barrio
ruiz
j
e
bouza
madrid
es
background
vad
mechan
pump
take
function
damag
ventricl
patient
heart
failur
recoveri
myocardi
function
effect
bridg
heart
transplant
ht
criticallyil
patient
prone
nosocomi
devicerel
infect
noninfecti
complic
bleed
thromboembol
report
come
countri
long
waitinglist
heart
transplant
ht
averag
support
may
exceed
spain
averag
wait
time
ht
shorter
vadrel
infect
set
suffici
analys
method
period
jan
patient
requir
vad
institut
clinic
microbiolog
record
review
determin
incid
risk
factor
outcom
nosocomi
infect
patient
standard
cdc
center
diseas
control
criteria
use
syndrom
definit
result
mean
age
year
male
median
vad
support
length
day
common
reason
vad
postcardiotomi
ventricular
failur
follow
allograft
failur
ht
medic
cardiogen
shock
infect
episod
diagnos
patient
pneumonia
urinari
tract
vad
infect
wound
infect
cathet
relat
other
aureu
follow
enterobacteriacea
cn
p
aeruginosa
common
pathogen
nontranspl
patient
die
due
noninfecti
caus
reach
transplant
despit
suffer
infect
end
vad
support
patient
aliv
die
due
cardiogen
failur
neurolog
complic
infect
account
earli
death
late
demis
conclus
infect
complic
cours
patient
requir
shortterm
vad
studi
preclud
heart
transplant
studi
report
mortal
rate
patient
without
vap
includ
data
extract
use
standardis
form
qualiti
studi
determin
valid
score
system
result
studi
total
patient
met
inclus
criteria
mortal
rate
patient
vap
rang
pool
studi
result
statist
indic
consider
heterogen
therefor
preclud
estim
overal
effect
signific
associ
vap
mortal
univari
analys
observ
studi
yet
nine
studi
also
perform
multivari
analys
signific
independ
associ
persist
four
studi
origin
heterogen
could
explain
differ
studi
design
studi
qualiti
diagnost
approach
howev
heterogen
limit
studi
investig
trauma
patient
acut
respiratori
distress
syndrom
ard
patient
estim
rel
risk
mortal
patient
vap
patient
group
ci
among
trauma
patient
ci
among
ard
patient
wide
held
belief
vap
associ
attribut
mortal
base
avail
evid
observ
studi
fact
two
specif
patient
group
trauma
ard
evid
absenc
associ
analys
includ
patient
specif
data
therebi
allow
adjust
possibl
confound
might
confirm
reject
presum
associ
patient
group
effect
year
surveil
incid
surgic
site
infect
netherland
j
van
den
hof
jc
will
b
van
benthem
bilthoven
hagu
utrecht
nl
object
surgic
site
infect
ssi
continu
present
major
proport
advers
event
surgic
patient
mani
countri
establish
nation
surveil
system
aim
reduc
patient
risk
infect
studi
evalu
timetrend
ssi
rate
five
frequentlyperform
surgic
procedur
netherland
method
hospit
particip
least
three
consecut
year
dutch
prezi
surveil
network
includ
cdc
definit
ssi
use
hospit
receiv
feedback
report
per
surgic
procedur
includ
crude
expect
ssi
rate
usual
spread
discuss
hospit
involv
personnel
per
surgic
procedur
associ
ssi
rate
surveil
year
estim
odd
ratio
obtain
logist
regress
adjust
confound
method
postdischarg
surveil
random
coeffici
model
multilevel
logist
model
use
adjust
risk
estim
random
variat
among
hospit
result
among
five
surgic
procedur
number
includ
surveil
year
vari
year
number
hospit
number
procedur
number
ssi
overal
ssi
rate
result
multilevel
logist
model
present
tabl
nonsignific
increas
ssi
rate
found
mastectomi
signific
decreas
ssi
rate
per
surveil
year
occur
total
hip
prosthesi
indic
decreas
year
decreas
trend
ssi
rate
per
increas
surveil
time
appear
replac
head
femur
colectomi
knee
prosthesi
although
statist
signific
conclus
one
five
surgic
procedur
decreas
trend
ssi
rate
statist
signific
three
procedur
show
nonsignific
decreas
trend
encourag
result
like
result
improv
qualiti
care
caus
chang
infect
control
hospit
studi
show
activ
surveil
system
feedback
infect
rate
hospit
staff
might
effect
strategi
reduc
ssi
incid
addit
intervent
might
decreas
ssi
rate
sustain
control
effort
necessari
maintain
low
ssi
level
object
cost
catheterrel
bloodstream
infect
crbsi
substanti
term
morbid
mortal
financi
resourc
guidelin
recommend
dedic
multidisciplinari
team
reduc
incid
infect
total
parenter
nutrit
tpn
wellrecognis
risk
factor
crbsi
hospit
dedic
tpn
surveil
nurs
promot
staff
grade
quarterli
multidisciplinari
meet
introduc
studi
show
reduct
crbsi
annual
cost
save
conclus
studi
show
decreas
crbsi
rate
introduct
dedic
tpn
nurs
quarterli
multidisciplinari
meet
calcul
save
made
reduct
crbsi
conclud
clinic
econom
viabl
employ
dedic
tpn
nurs
figur
take
account
save
cost
antimicrobi
treatment
medic
laboratori
investig
medicin
public
health
siti
implement
ensur
standardis
definit
data
collect
report
procedur
coher
helicsicu
benchmark
method
hospit
invit
join
spinuti
project
gisio
member
start
surveil
particip
icu
gather
order
involv
key
stakehold
project
particip
plan
first
phase
consist
train
session
share
refin
protocol
data
collect
tool
four
electron
data
form
design
use
spss
data
entri
enterpris
server
spss
inc
webbas
data
collect
present
discuss
monitor
phase
final
spinuti
protocol
tool
produc
integr
much
possibl
conclus
debat
discuss
analysi
method
use
exist
nation
surveil
protocol
sixmonth
patientbas
prospect
survey
perform
novemb
may
preced
onemonth
surveil
pilot
studi
assess
overal
feasibl
programm
determin
need
time
resourc
particip
hospit
result
spinuti
project
includ
icu
patient
length
stay
longer
two
day
patientday
total
infect
report
account
incid
rate
per
patient
incid
densiti
per
patientday
frequent
encount
infect
site
pneumonia
pseudomona
aeruginosa
frequent
infectionassoci
microorgan
follow
staphylococcu
aureu
acinetobact
baumannii
sitespecif
infect
rate
pneumonia
bloodstream
infect
central
venou
catheterrel
bloodstream
infect
urinari
tract
infect
stratifi
accord
patient
risk
factor
percentil
report
helic
network
benchmark
conclus
spinuti
project
show
introduct
ongo
surveil
seem
possibl
mani
italian
hospit
studi
provid
opportun
particip
helic
project
use
benchmark
data
comparison
better
understand
factor
impact
associ
risk
e
faecali
p
aeruginosa
use
epidemiolog
marker
analysi
transmiss
event
intens
care
unit
kola
f
schwab
eckmann
k
weist
e
dinger
klare
w
witt
h
p
gastmeier
hannov
berlin
wernigerod
de
object
least
nosocomi
infect
intens
care
unit
due
crosstransmiss
caus
organ
patient
contrast
endogen
infect
exogen
infect
like
prevent
infect
control
measur
therefor
knowledg
surrog
organ
analysi
patienttopati
transmiss
would
use
method
known
kiss
german
hospit
infect
surveil
system
baumannii
e
faecium
e
faecali
k
pneumonia
p
aeruginosa
aureu
amongst
common
pathogen
respons
nosomi
infect
icu
two
year
period
primari
isol
six
indic
organ
cultur
clinic
sampl
patient
stay
icu
two
univers
hospit
genotyp
pfge
puls
field
gel
electrophoresi
genet
indistinguish
isol
differ
patient
consid
crosstransmiss
patient
hospitalis
icu
tempor
proxim
least
day
associ
isol
six
pathogen
cross
transmiss
transmiss
event
per
patient
day
per
cultur
organ
analys
result
patient
day
microbiolog
specimen
patient
sampl
averag
investig
densiti
sampl
per
patient
day
indic
organ
cultur
aureu
e
faecali
p
aeruginosa
e
faecium
k
pneumonia
baumannii
altogeth
crosstransmiss
incid
densiti
transmiss
per
patient
day
rang
per
patient
day
depend
respect
icu
discern
due
e
faecali
e
faecium
p
aeruginosa
resp
aureu
baumannii
signific
correl
isol
e
faecali
p
aeruginosa
transmiss
per
patient
day
resp
per
cultur
organ
spearman
correl
coeffici
p
conclus
e
faecali
p
aeruginosa
use
epidemiolog
marker
analysi
patienttopati
transmiss
icu
nonoutbreak
set
crosstransmiss
indic
poor
clinic
care
transmiss
analysi
e
faecali
p
aeruginosa
may
use
monitor
adher
standard
infect
control
precaut
blactamas
produc
klebsiella
pneumonia
intens
care
unit
necessari
absenc
outbreak
g
metan
c
ozkuyumcu
koseoglu
eser
tope
iskit
g
hascelik
unal
kayseri
ankara
tr
object
extendedspectrum
blactamas
produc
klebiella
pnemonia
esblkp
concern
import
nosocomi
infect
respons
outbreak
particularli
intens
care
unit
icu
pharmacolog
paramet
similar
cell
type
drug
except
rifampicin
show
higher
emax
lower
static
concentr
keratinocyt
data
extend
keratinocyt
poor
activ
oxacillin
vancomycin
linezolid
seen
intracellular
aureu
macrophag
also
suggest
assess
potenti
advantag
offer
context
daptomycin
moxifloxacin
quinupristindalfopristin
rifampicin
louie
c
fregeau
w
liu
k
bush
g
noel
gl
drusano
albani
us
object
pharmacodynam
interact
ceftobiprol
cefto
plu
levofloxacin
levo
examin
mous
thigh
infect
model
judg
greco
interact
model
mous
thigh
infect
model
describ
craig
employ
mice
made
neutropen
cyclophosphamid
mgkg
day
mgkg
day
p
aeruginosa
atcc
inject
posterior
thigh
mice
burden
cfu
preliminari
studi
perform
dose
rang
cefto
alon
levo
alon
sigmoid
emax
analysi
employ
identifi
area
greatest
fisher
inform
model
paramet
preliminari
experi
allow
identif
dose
inform
link
exposur
respons
allow
second
experi
perform
cohort
notreat
control
cefto
alon
levo
alon
combin
therapi
cohort
h
mice
sacrif
posterior
thigh
dissect
homogenis
plate
serial
dilut
plate
without
drug
estim
total
bacteri
load
plate
contain
x
baselin
mic
either
cefto
levo
isol
resist
one
drug
greco
ursa
model
fit
data
use
adapt
ii
weight
invers
observ
varianc
result
cefto
singl
drug
emax
cell
kill
log
cfug
mgkg
levo
singl
drug
emax
log
cfug
mgkg
combin
therapi
statist
significantli
synergist
interact
paramet
ci
cell
kill
demonstr
figur
perhap
importantli
combin
effici
suppress
resist
emerg
either
two
drug
dose
levo
greater
mgkg
combin
cefto
dose
greater
mgkg
gener
suppress
resist
bacteria
ceftobiprolelevofloxacin
combin
therapi
p
aeruginosa
combin
two
agent
may
prefer
empir
therapi
patient
seriou
infect
suspect
caus
p
aeruginosa
vivo
model
ceftolevo
combin
therapi
synergist
p
aeruginosa
isol
suppress
emerg
resist
import
find
warrant
evalu
isol
p
aeruginosa
includ
derepress
ampc
blactamas
object
previous
develop
mathemat
model
predict
respons
p
aeruginosa
meropenem
j
antimicrob
chemoth
levofloxacin
ann
biom
eng
howev
applic
model
pathogen
unknown
extend
model
predict
effect
variou
fluctuat
amikacin
amk
exposur
baumannii
ab
emerg
bacterium
associ
multidrug
resist
method
timekil
studi
tk
cfuml
ab
atcc
baa
baselin
perform
amk
mic
use
mic
mgl
experiment
data
use
deriv
estim
bestfit
model
paramet
ab
respons
variou
amk
exposur
predict
via
respons
surfac
comput
model
predict
subsequ
valid
use
invitro
hollow
fiber
infect
model
hfim
amk
profil
correspond
mgkg
everi
mgkg
everi
investig
hour
result
tk
data
satisfactorili
captur
mathemat
model
r
signific
initi
reduct
bacteri
burden
predict
amk
exposur
examin
regrowth
time
due
resist
emerg
predict
mgkg
everi
erad
bacteri
popul
predict
mgkg
everi
predict
correl
well
experiment
data
hfim
mathemat
model
reason
predict
extend
ab
respons
variou
fluctuat
amk
exposur
qualit
base
limit
input
data
tk
view
robust
effici
mathemat
model
approach
hold
great
promis
high
throughput
screen
tool
dose
regimen
select
antimicrobi
pre
clinic
develop
temocillin
protein
bind
concentrationdepend
restrict
albumin
carryn
jw
mouton
n
couwenbergh
pm
tulken
brussel
nijmegen
nl
object
temocillin
tmo
penicillin
highli
protein
bound
healthi
volunt
howev
recent
observ
level
protein
bind
pb
lower
critic
ill
patient
receiv
tmo
continu
infus
less
individu
patient
variat
could
major
therapeut
impact
gener
presum
free
form
blactam
activ
therefor
studi
bind
properti
temocillin
whole
human
serum
purifi
human
serum
albumin
hsa
method
solut
hsa
water
whole
serum
pbsdilut
serum
solut
spike
known
concentr
tmo
mgl
free
fraction
tmo
measur
hplc
separ
protein
ultracentrifug
kda
cutoff
membran
centrifre
millipor
result
pb
tmo
hsa
serum
concentrationdepend
decreas
increas
concentr
tmo
sigmoid
function
hill
equat
could
fit
pbbind
data
see
paramet
estim
tabl
hsa
valu
proport
hsa
concentr
residu
bind
increas
concentr
serum
maxim
pb
observ
consist
observ
made
healthi
volunt
hill
slope
much
less
steep
hsa
serum
pb
decreas
gradual
mgml
interestingli
pb
remain
unchang
serum
spike
high
tmo
concentr
mgl
dilut
pb
except
high
dilut
max
bind
object
treatment
shuntassoci
ventricul
sav
requir
administr
effect
antibiot
regimen
avoid
lifethreaten
sequela
due
antimicrobi
spectrum
penetr
properti
fosfomycin
cefepim
rifampicin
frequent
consid
treatment
sav
present
studi
aim
describ
kill
kinet
fosfomycin
cefepim
rifampicin
cerebrospin
fluid
csf
compar
convent
growth
medium
addit
gener
applic
human
csf
growth
medium
bacteriolog
experi
explor
method
csf
collect
patient
receiv
antibiot
timekil
curv
hour
perform
use
drug
concentr
mic
staphylococcu
aureu
test
strain
timekil
curv
preform
mullerhintonbroth
mhb
csf
csf
incub
ambient
serv
adjust
ph
csf
physiolog
valu
result
expect
drug
concentr
mic
led
effect
bacteri
kill
mhb
addit
fosfomycin
csf
induc
inhibit
bacteri
growth
incub
ambient
air
experi
perform
csf
physiolog
ph
achiev
incub
show
sustain
growth
inhibit
fosfomycin
concentr
mic
regrowth
observ
lower
fosfomycin
concentr
rifampicin
kill
pattern
similar
fosfomycin
observ
contrast
cefepim
exert
higher
kill
csf
incub
mhb
less
effect
csf
ambient
air
mhb
conclus
csf
elig
perform
bacteriolog
experi
csf
mhb
differ
substanti
regard
bacteri
growth
kill
csf
incub
bacteri
regrowth
occur
fosfomycin
rifampicin
level
mic
cefepim
concentr
mic
exert
inhibitori
effect
conclud
depend
investig
antibiot
use
mhb
might
overestim
underestim
efficaci
antibiot
csf
thu
csf
consid
medium
evalu
efficaci
antimicrobi
drug
intracerebr
infect
order
better
reflect
clinic
set
temocillin
daili
critic
ill
patient
continu
infus
vs
convent
administr
pf
laterr
dugerni
x
wittebol
n
couwenbergh
pm
tulken
carryn
brussel
ottigni
object
temocillin
tmo
current
use
critic
patient
pk
data
popul
scarc
tmo
recent
proven
suitabl
continu
infus
de
jongh
et
al
jac
press
howev
serum
free
concentr
sfc
achiev
convent
posolog
may
close
mic
critic
ill
due
increas
volum
distribut
alter
pkpd
order
achiev
accept
sfc
therefor
administ
tmo
daili
either
tid
continu
infus
ci
method
icu
patient
document
gramneg
infect
suscept
tmo
includ
randomis
group
patient
renal
replac
therapi
exclud
blood
sampl
collect
dose
tid
group
daili
day
ci
group
assess
hplc
sfc
tmo
measur
separ
protein
ultracentrifug
kda
cutoff
membran
centrifre
millipor
safeti
assess
advers
event
monitor
result
patient
includ
group
intraabdomin
infect
lrti
uti
patient
posit
bloodcultur
signific
differ
observ
group
age
sem
tid
ci
tmo
total
free
concentr
dose
regimen
shown
figur
valu
repres
tid
time
belgian
suscept
breakpoint
ie
mgl
sfc
reach
averag
ci
sfc
remain
time
breakpoint
even
reach
concentr
time
lowest
mean
free
concentr
mgl
expect
critic
ill
patient
alpha
halflif
tid
group
highli
decreas
first
inject
less
termin
halflif
remain
close
final
despit
high
serum
concentr
reach
advers
event
relat
tmo
observ
conclus
tmo
safe
posolog
per
day
tid
seem
suffici
achiev
pkpd
goal
blactam
efficaci
ci
allow
better
margin
secur
compar
breakpoint
data
suggest
optim
dose
tmo
critic
ill
without
renal
replac
therapi
increas
daili
object
explor
possibl
relationship
voriconazol
concentr
plasma
efficaci
phase
iiiii
clinic
studi
method
plasma
sampl
taken
randomli
voriconazol
therapi
itt
patient
phase
iiiii
clinic
studi
fungal
infect
analys
use
valid
hplc
assay
data
summaris
weekli
mean
concentr
oneweekli
window
relationship
plasma
concentr
efficaci
investig
logist
regress
use
one
overal
mean
plasma
concentrationpati
upon
binari
outcom
variabl
success
failur
determin
investig
end
therapi
success
defin
complet
partial
respons
failur
polynomi
model
use
investig
linear
curvatur
impact
covari
assess
mic
determin
use
clsi
methodolog
yeast
mould
result
yeast
success
mould
success
infect
identifi
clinic
baselin
mean
voriconazol
plasma
concentr
divid
band
relationship
respons
mean
plasma
level
nonlinear
best
fit
quadrat
polynomi
model
p
mean
plasma
level
associ
clinic
respons
individu
signific
covari
studi
p
protocol
p
primarysalvag
therapi
p
region
p
yeastmould
p
durat
therapi
p
site
infect
p
underli
diseas
p
mean
level
p
combin
quadrat
model
none
covari
alter
nonlinear
patient
baselin
pathogen
mic
avail
linear
relationship
mean
voriconazol
free
drug
levelm
ratio
clinic
respons
p
conclus
signific
nonlinear
relationship
voriconazol
mean
plasma
concentr
efficaci
covari
signific
impact
combin
chang
curvilinear
relationship
signific
linear
relationship
mean
voriconazol
free
drugmic
ratio
clinic
respons
object
optim
dose
select
phase
clinic
trial
critic
success
drug
develop
applic
pharmacokineticpharmacodynam
pkpd
principl
provid
scientif
basi
optimis
dose
durat
therapi
dose
regimen
shortcours
therapi
evalu
oritavancin
ori
novel
glycopeptid
current
develop
complic
skin
skin
structur
infect
csssi
method
use
pk
data
intensivelysampl
subject
receiv
ori
mg
iv
x
day
popul
pk
model
develop
pk
paramet
estim
base
model
use
conduct
simul
evalu
daili
cumul
freedrug
plasma
auc
valu
follow
frontload
ori
regimen
ie
major
auc
deliv
day
mg
singleand
multipledos
regimen
evalu
multipledos
regimen
involv
load
dose
follow
booster
dose
mg
day
popul
pk
analysi
simul
perform
use
sadapt
freedrug
auc
valu
regimen
assess
rel
associ
cfu
decreas
aureu
use
data
neutropen
murinethigh
infect
model
craig
wa
andr
dr
icaac
abstr
singledos
freedrug
auc
valu
mice
correspond
cfu
decreas
respect
freedrug
auc
valu
also
assess
rel
success
studi
previou
csssi
studi
mg
x
day
aureu
mic
popul
statist
result
model
zeroord
input
linear
clearanc
best
describ
pk
data
plasma
concentr
well
fit
model
ori
mg
x
dose
mg
day
follow
mg
day
provid
mean
cumul
freedrug
auc
valu
exceed
nonclin
freedrug
auc
target
similar
valu
previous
studi
day
mg
regimen
see
tabl
discussionconclus
approach
support
select
shortcours
dose
regimen
describ
herein
especi
use
agent
ori
display
concentrationdepend
pattern
bactericid
activ
long
halflif
predict
frontload
ori
regimen
result
improv
respons
rate
patient
csssi
rel
regimen
previous
studi
data
use
support
dose
select
phase
csssi
studi
guid
develop
agent
treat
skin
skin
structur
infect
sssi
fda
creat
two
categori
uncompl
infect
eg
simpl
abscess
impetigin
lesion
furuncl
cellul
complic
infect
deeper
tissu
involv
often
requir
signific
surgic
intervent
eg
abscess
extens
cellul
diabet
foot
infect
necrotis
infect
latter
infect
often
associ
underli
diseas
carri
increas
risk
gramposit
gramneg
copathogen
infect
occur
hospitalis
patient
unlik
rapidli
resolv
surgic
measur
alon
assess
sever
may
help
determin
emerg
surgeri
antibiot
requir
sever
assess
sssi
includ
clinic
sign
system
inflamm
local
find
particularli
size
abscess
cellul
sign
necrotis
infect
includ
bulla
subcutan
haemorrhag
sever
csssi
empir
therapi
effect
organ
subsequ
identifi
cultur
import
limit
extent
tissu
loss
rapidli
resolv
acut
ill
us
european
area
frequenc
mrsa
associ
sssi
risen
dramat
past
year
reach
high
preval
resist
strain
commun
communityacquir
mrsa
recommend
us
treat
staphylococcu
aureu
infect
agent
activ
mrsa
assess
microbiolog
sensit
avail
vancomycin
standard
parenter
treatment
mrsa
concern
exist
regard
toxic
increas
heteroand
form
resist
new
cephalosporin
activ
mrsa
may
provid
clinician
use
option
treatment
csssi
ceftobiprol
investig
broadspectrum
antimrsa
cephalosporin
demonstr
efficaci
two
multicentr
doubleblind
activ
control
trial
variou
type
sever
skin
soft
tissu
infect
includ
diabet
foot
infect
pneumonia
acquir
outsid
hospit
identifi
within
hour
admiss
presum
acquisit
prior
hospitalis
defin
communityacquir
pneumonia
cap
pneumonia
acquir
hospit
week
discharg
presum
acquisit
hospitalis
defin
hospitalacquir
pneumonia
hap
healthcareassoci
pneumonia
hcap
acquir
patient
frequent
contact
healthcar
system
eg
haemodialysi
patient
nurs
home
patient
hcap
deserv
separ
recognit
treatment
issu
similar
hap
cap
score
system
may
aid
decis
eg
outpati
set
hospit
aggress
treat
pneumonia
patient
appropri
sampl
suffici
sputum
cultur
obtain
half
pneumonia
patient
antibiot
therapi
often
base
suspect
infect
knowledg
probabl
pathogen
preval
cap
streptococcu
pneumonia
follow
haemophilu
influenza
gramneg
bacilli
staphylococcu
aureu
common
hap
risk
pseudomona
aeruginosa
aureu
highest
pneumonia
develop
day
week
hospitalis
pneumonia
nurs
home
patient
elderli
multimorbid
patient
commonli
due
gramneg
bacilli
aureu
pneumonia
includ
multidrug
resist
pneumonia
mdrsp
prior
antibiot
treatment
increas
risk
meticillinresist
aureu
mrsa
p
aeruginosa
pneumonia
set
staphylococcu
aureu
may
caus
sever
cap
especi
influenza
infect
resist
increas
mortal
cost
report
commun
acquir
ca
mrsa
increas
unit
state
alreadi
high
european
countri
eg
greec
uk
howev
european
countri
lower
resist
pattern
also
report
case
camrsa
suggest
pathogen
import
futur
spectrum
meticillinresist
staphylococcu
aureu
mrsa
pneumonia
extend
across
categori
pneumonia
includ
cap
hap
hcap
pneumonia
immunocompromis
patient
origin
may
import
formerli
distinct
cap
hcap
hap
blur
strain
move
institut
commun
vice
versa
gener
resist
hcap
europ
less
common
us
due
differ
nurs
home
popul
definit
hcap
differ
us
nurs
home
patient
may
sicker
greater
frequenc
comorbid
chronic
tracheotomi
multipl
decub
impair
conscious
risk
factor
mrsa
hap
vap
similar
multidrug
resist
pathogen
except
reservoir
mrsa
often
nare
nasopharynx
reason
screen
mrsa
admiss
patient
high
risk
pneumonia
skin
softtissu
infect
increasingli
common
import
implic
vap
prevent
strategi
none
compon
vap
prevent
bundl
specif
address
issu
research
also
suggest
conventionallyaccept
risk
factor
camrsa
cap
may
good
predictor
time
first
antibiot
dose
measur
qualiti
care
pneumonia
delay
sever
day
initi
appropri
therapi
may
occur
await
cultur
result
associ
wors
outcom
given
difficulti
delay
low
yield
inher
diagnos
aetiolog
pneumonia
antibiot
treatment
often
empir
mrsa
common
pathogen
empir
antimrsa
coverag
increasingli
common
neg
predict
valu
mrsa
adequ
lower
respiratori
tract
sampl
high
howev
despit
microbiolog
result
clinician
often
reluct
narrow
antibiot
therapi
delay
respons
therapi
even
appropri
antibiot
use
common
vancomycin
commonli
use
antibiot
mrsa
success
rate
rang
mrsa
vap
treatment
failur
due
vancomycin
mic
upper
rang
sensit
may
overcom
without
push
vancomycin
level
toler
dose
vancomycin
also
affect
exotoxin
product
import
aspect
camrsa
current
avail
agent
develop
may
offer
advantag
older
agent
treatment
mrsa
pneumonia
report
communityassoci
meticillinresist
staphylococcu
aureu
camrsa
infect
among
healthi
person
recent
contact
healthcar
none
tradit
risk
factor
mrsa
infect
increas
substanti
rate
last
year
children
daycar
sport
particip
militari
recruit
prison
institut
set
pig
farmer
men
sex
men
among
mani
divers
group
appear
risk
camrsa
infect
primarili
skin
soft
tissu
infect
sever
rapidli
fatal
syndrom
includ
necrotis
pneumonia
also
report
particularli
among
young
adult
pulsedfield
gel
electrophoresi
type
sccmec
type
iv
promin
among
camrsa
infect
unit
state
recent
evid
confirm
spread
europ
south
america
pacif
island
genom
sequenc
data
multipl
isol
confirm
dramat
clonal
expans
mrsa
strain
predomin
strain
type
isol
patient
invas
camrsa
infect
patient
present
emerg
depart
uncompl
skin
infect
howev
data
virul
strain
outcom
camrsa
infect
quit
diverg
realli
fear
new
epidem
strain
camrsa
media
event
medic
problem
myth
realiti
decis
make
nation
vaccin
programm
fund
drug
base
costeffect
vaccin
warrant
differ
approach
vaccin
vaccin
programm
featur
requir
special
consider
assess
effect
costeffect
public
fund
special
featur
vaccin
relat
herd
immun
qualiti
life
loss
young
children
parent
care
work
loss
time
prefer
uncertainti
erad
macroeconom
tier
price
featur
discuss
relat
specif
topic
childhood
vaccin
rotaviru
human
papillomaviru
varicellazost
viru
influenza
pneumococcu
advisori
committe
public
fund
vaccin
often
give
advic
pharmaceut
countri
knowledg
natur
impact
special
featur
flexibl
enough
allow
featur
explor
costeffect
calcul
present
object
rapid
detect
mycobacterium
tuberculosi
complex
mtb
directli
clinic
respiratori
nonrespiratori
specimen
essenti
effici
manag
patient
suspect
tuberculosi
new
method
base
transcript
reversetranscript
concert
reaction
trc
tosoh
corpor
japan
enabl
one
step
amplif
realtim
detect
mtb
rrna
target
directli
respiratori
nonrespiratori
specimen
perform
extragen
mtb
kit
trcrapid
mtb
kit
analys
evalu
three
laboratori
method
analyt
sensit
assay
perform
ad
mtb
refer
strain
known
concentr
mtb
neg
sputum
sampl
assay
triplic
trc
result
compar
smear
cultur
exact
number
bacilli
determin
count
coloni
form
unit
cfu
solid
media
addit
respiratori
nonrespiratori
specimen
test
result
compar
smear
cultur
specimen
subject
standard
procedur
ml
process
sampl
use
rna
extract
follow
protocol
final
patient
pari
cohort
followedup
evalu
clinic
perform
trcmethod
analyt
sensit
assay
result
show
trc
method
detect
littl
cfuml
clinic
specimen
evalu
exclud
evalu
contamin
show
inhibit
identifi
mycobacteria
tuberculosi
mott
thu
total
respiratori
specimen
extrapulmonari
specimen
includ
overal
sensit
specif
trc
pulmonari
specimen
respect
sensit
specif
trc
extrapulmonari
specimen
respect
patient
analys
patient
present
treat
pulmonari
tuberculosi
twelv
treat
patient
posit
cultur
treat
patient
posit
trc
gave
sensit
cultur
trc
respect
specif
cultur
trc
respect
these
result
show
rapid
detect
mtb
possibl
less
process
hour
specimen
use
readi
use
reagent
real
time
detect
mtb
clinic
sampl
high
sensit
specif
object
molecular
assay
diagnosi
fungal
infect
clinic
specimen
increasingli
describ
howev
extent
adopt
clinic
staff
critic
extent
result
impact
therapeut
decis
well
describ
inform
import
justifi
cost
develop
deliv
novel
diagnost
test
aim
studi
evalu
extent
clinic
valid
pcr
assay
candidaemia
impact
antifung
drug
prescrib
method
prospect
observ
studi
conduct
mix
icu
assay
turnaroundtim
made
avail
period
six
month
physician
encourag
use
assay
particularli
consid
prescrib
antifung
drug
context
probabl
candida
infect
assay
request
record
well
whether
patient
receiv
antifung
drug
within
test
request
whether
prescrib
decis
reflect
test
result
prescrib
decis
assay
result
discord
reason
sought
result
pcr
test
request
patient
overal
pcr
test
appear
strongli
influenc
prescrib
decis
instanc
whether
neg
posit
antifung
drug
prescrib
within
pcr
request
instanc
pcr
request
posit
one
patient
posit
blood
cultur
within
neg
pcr
remain
nine
pcrneg
patient
receiv
antifung
drug
variou
factor
consid
overrul
pcr
test
includ
drug
prescrib
prior
test
order
complianc
ward
prophylaxi
polici
high
likelihood
infect
determin
extant
preemptiv
prescrib
practic
conclus
avail
rapid
molecular
assay
display
substanti
capac
modifi
antifung
drug
prescrib
certain
circumst
clear
physician
behaviour
complet
influenc
singl
test
result
regardless
factor
inde
unlik
desir
given
test
shown
perform
reliabl
nonetheless
rapid
diagnost
method
may
help
improv
antifung
conserv
contribut
model
therapeut
algorithm
merit
evalu
object
polymeras
chain
reaction
pcr
commonli
use
detect
microbi
nucleic
acid
clinic
sampl
howev
signific
risk
pcr
contamin
high
reagent
cost
signific
workload
preclud
wide
use
pcr
aetiolog
diagnosi
infecti
diseas
thu
establish
high
throughput
versatil
autom
molecular
platform
analys
perform
includ
critic
aspect
troubleshoot
method
dna
rna
extract
magnapur
roch
easymag
respect
rna
convert
cdna
prior
pcr
tecan
liquid
handl
system
lh
use
well
pcr
plate
setup
realtim
pcr
perform
abi
result
total
analys
run
done
studi
period
median
time
recept
sampl
result
overal
hour
time
result
significantli
longer
pathogen
detect
rna
viru
retrotranscript
step
fungu
lysi
step
dna
extract
cmvebv
quantit
pcr
run
perform
three
time
week
p
longer
time
result
also
due
invalid
run
need
repetit
pcr
reaction
subsequ
run
median
time
result
hour
analys
need
repeat
hour
analys
repeat
twice
hour
analys
repeat
three
time
among
run
run
invalid
run
mainli
consid
invalid
neg
ten
copi
posit
control
total
run
major
caus
invalid
run
hardwar
problem
liquid
handl
system
run
use
defect
real
time
pcr
master
mix
human
procedur
error
progress
degrad
posit
control
defect
primer
probe
contamin
detect
run
conclus
platform
allow
perform
comprehens
set
microbiolog
diagnost
test
high
success
rate
improv
term
time
result
reduct
repeat
address
thank
evalu
object
well
known
human
microbiota
play
import
role
health
diseas
howev
exact
role
commens
bacteria
way
influenc
wellb
remain
elus
one
major
obstacl
solv
relat
question
analysi
microbiom
new
insight
recent
gain
high
throughput
sequenc
analysi
although
valuabl
method
suit
larg
scale
screen
present
rapid
straightforward
assay
profil
human
microbiota
molecular
method
involv
two
featur
length
interspac
region
rdna
specif
primer
sequenc
discrimin
firmicuta
bacteroidet
two
major
phyla
human
colon
region
conserv
within
speci
vari
speci
thu
bacteria
principl
identifi
length
region
unknown
speci
recognis
use
specif
primer
sequenc
primer
combin
nonspecif
revers
primer
doubl
label
multiplex
pcr
size
colour
sort
fragment
perform
abi
sequenc
valid
purpos
silico
profil
bacteria
construct
base
known
sequenc
inform
test
cultur
bacteria
colon
mucos
biopsi
patient
analys
use
method
intraand
interpati
composit
colon
microbiota
analys
biopsi
per
patient
coecum
flexura
hepatica
flexura
lienali
sigmoid
rectum
result
cultur
bacteria
show
profil
ident
silico
profil
subsequ
excel
bacteri
profil
obtain
clinic
sampl
patient
uniqu
bacteri
profil
fragment
ident
patient
fragment
correspond
well
known
colon
bacteria
faecalibacterium
prausnitzii
bacteroid
thetaiotaomicron
pattern
obtain
differ
site
colon
singl
patient
almost
ident
bacteri
profil
method
prove
ident
expect
profil
base
sequenc
data
addit
method
suit
characteris
complex
human
microbiom
method
profil
human
colon
microbiota
obtain
straightforward
fashion
method
univers
fast
reproduc
ideal
suit
analysi
larg
sampl
set
conclus
conclus
main
predictor
pol
mutat
prolong
lam
exposur
hivpo
patient
multipl
mutat
preval
independ
hiv
posit
mutat
associ
hbeag
express
studi
need
clarifi
kinet
signific
differ
mutat
pattern
observ
monoinfect
hivhbvcoinfect
pt
microrna
deregul
hcvassoci
hepatocellular
carcinoma
sinigaglia
l
barzon
e
lavezzo
trevisan
f
farinati
g
padua
object
recent
evid
role
microrna
mirna
human
cancer
possibl
effect
hcv
replic
led
us
investig
mirna
express
profil
hcvrelat
hepatocellular
carcinoma
hcc
compar
adjac
nonneoplast
liver
relationship
presenc
hcv
infect
method
tissu
sampl
hcc
adjac
nontumor
tissu
obtain
surgic
specimen
remov
hcc
resect
rna
extract
sampl
perform
use
mirnacompat
protocol
reagent
mirna
express
profil
investig
microarray
analysi
confirm
realtim
rtpcr
hcv
detect
type
perform
rtpcrsequenc
use
pcr
primer
pair
target
differ
region
viral
genom
result
hcv
rna
detect
hcc
hcv
genotyp
account
posit
case
analysi
mirna
express
profil
hcc
show
deregul
group
mirna
includ
downregul
case
compar
nonneoplast
adjac
liver
sampl
consist
underexpress
hcc
underexpress
case
varianc
upregul
hcc
show
stronger
deregul
hcvposit
hcc
hcvneg
cancer
mirna
could
play
import
role
develop
hcc
sinc
target
mani
gene
involv
control
cell
cycl
cell
prolifer
predict
sanger
mirbas
sequenc
databas
among
target
gene
cyclin
regul
cyclin
potenti
regul
target
respect
junb
target
bclw
target
rasrel
protein
target
conclus
investig
larger
number
hcc
sampl
result
indic
hcc
particular
hcvrelat
hcc
characteris
deregul
set
mirna
involv
control
cell
cycl
backgroundaim
treatment
decis
eg
discontinu
shorten
therapi
base
plasma
hepat
c
hvc
rna
measur
quantit
qualit
detect
system
commerci
avail
system
reli
either
target
roch
coba
taqman
rtpcr
signal
amplif
bayer
versant
bdna
differ
linear
amplif
sensit
specif
lower
limit
detect
standard
autom
test
make
comparison
assay
mandatori
aim
studi
correl
plasma
hcv
rna
valu
coba
taqman
pcr
versant
bdna
pcr
assay
method
hcv
genotyp
posit
patient
treat
peginterferon
weightbas
ribavirin
plasma
sampl
baselin
day
week
treatment
week
therapi
collect
measur
plasma
hcvrna
load
total
pair
sampl
quantit
rang
undetect
iuml
compar
exclud
valu
undetect
coba
taqman
lower
limit
detect
iuml
versant
bdna
lower
limit
detect
iuml
ul
plasma
use
total
pair
sampl
analys
median
valu
taqman
assay
log
iuml
versu
median
valu
log
iuml
versant
bdna
assay
measur
taqman
pcr
show
higher
hcv
viral
load
bdna
pcr
mainli
measur
higher
viral
load
ie
iuml
excel
correl
assay
spearman
rank
coeffici
p
blandaltman
analysi
show
bia
iuml
standard
deviat
ci
iuml
conclus
excel
correl
coba
taqman
versant
bdna
assay
overal
compar
bdna
assay
coba
taqman
pcr
measur
higher
mainli
within
higher
viral
load
figur
patient
rvr
evr
trend
toward
faster
respons
first
phase
decay
differ
second
phase
declin
baselin
viral
load
iuml
bodi
weight
baselin
influenc
viral
kinet
first
second
phase
clinic
patient
group
faster
declin
plasma
hcv
rna
first
hour
therapi
differenti
patient
rvr
null
respond
tabl
group
show
signific
differ
mean
age
gender
though
signific
differ
observ
educ
level
hrqol
patient
show
profil
similar
gener
turkish
popul
normal
physic
function
vital
score
statist
signific
lower
role
limit
due
emot
problem
bodili
pain
gener
health
percept
social
function
role
limit
due
physic
health
problem
mental
health
domain
score
p
hrqol
patient
chronic
hbv
diseas
also
significantli
lower
role
limit
due
emot
problem
bodili
pain
gener
health
percept
social
function
role
limit
due
emot
problem
score
p
pantonvalentin
leukocidin
exampl
bacteri
toxin
underestim
clinic
relev
g
lina
dumitrescu
tristan
c
badiou
f
vandenesch
j
etienn
lyon
fr
histori
panton
valentin
leucocidin
pvl
one
toxin
staphylococcu
aureu
began
torch
pvl
research
hand
decad
small
group
scientist
fascin
aureu
toxin
knowledg
advanc
fit
start
notabl
advent
new
research
tool
first
studi
focus
effect
aureu
leukocyt
latest
year
involv
genet
characteris
leucocidin
addit
highli
epidem
pvl
posit
meticillinresist
aureu
strain
recent
emerg
worldwid
health
issu
lead
upsurg
interest
pvl
confus
recent
introduc
pvl
literatur
one
group
scientist
recent
fail
express
pvl
experiment
model
howev
epidemiolog
clinic
biolog
data
obtain
staphylococc
infect
human
concur
demonstr
pvl
virul
factor
human
involv
human
primari
skin
infect
necrotis
pneumonia
bone
joint
infect
diseas
relationship
pvl
virul
independ
meticillin
resist
phenotyp
fungal
infect
suspect
mani
critic
ill
patient
fail
respond
empir
treatment
nosocomi
infect
howev
substanti
proport
patient
becom
colonis
candida
icu
stay
minor
subsequ
develop
invas
candidiasi
clinic
sign
invas
candidiasi
manifest
late
repres
particular
challeng
diagnosi
remain
characteris
mortal
similar
septic
shock
improv
knowledg
pathogenesi
candidiasi
avail
new
compound
preemptiv
prophylact
therapi
contribut
improv
prognosi
sever
candida
infect
possibl
cost
emerg
nonalbican
candida
strain
reduc
suscept
imidazol
despit
grow
evid
literatur
guidelin
integr
systemat
antifung
prophylaxisfor
patient
risk
empir
treatment
septic
major
risk
factor
without
document
sourc
infect
figur
order
avoid
exposur
patient
lower
initi
risk
preemptiv
antifung
treatment
base
combin
presenc
risk
factor
dynam
candida
colonis
final
nonimmunocompromis
patient
critic
ill
patient
prophylaxi
strictli
restrict
highlyselect
group
patient
efficaci
proven
half
invas
fungal
infect
ifi
occur
nonneutropen
icu
patient
major
due
candida
speci
despit
incid
ifi
icu
low
rang
european
unit
mani
candid
infect
nosocomi
prevent
sever
rct
look
prophylaxi
predominantli
fluconazol
icu
patient
three
systemat
review
perform
metaanalys
reportedli
demonstr
reduct
proven
ifi
howev
icu
popul
heterogen
mark
differ
europ
north
america
diagnost
criteria
defin
prophylaxi
target
therapi
distinguish
widespread
use
azol
drug
promot
resist
pathogen
shift
advers
drug
relat
event
necessari
establish
method
identifi
patient
greatest
risk
ifi
benefit
antifung
drug
numer
risk
factor
identifi
includ
length
stay
colonis
antibiot
surgeri
central
venou
cathet
total
parenter
nutrit
gastric
acid
suppress
bacteri
sepsi
etc
none
accur
predict
ifi
fungal
relat
mortal
sever
predict
rule
score
system
propos
identifi
subpopul
icu
patient
would
benefit
prophylaxi
rule
identifi
differ
percentag
patient
centr
mani
creat
valid
within
databas
none
practic
proven
robust
across
icu
popul
cost
effect
never
evalu
number
need
treat
prevent
singl
case
remain
high
centr
preval
less
centr
report
high
preval
candid
infect
address
infect
control
issu
resort
prophylact
drug
diagnosi
still
reli
convent
microbiolog
techniqu
cultur
steril
site
role
biomark
antigen
pcr
test
merit
investig
icu
popul
high
neg
predict
valu
newer
assay
potenti
influenc
antifung
strategi
identifi
patient
fungal
infect
combin
robust
simpl
model
predict
risk
develop
invas
candida
infect
test
rapidli
exclud
fungal
infect
highrisk
group
allow
target
preemptiv
strategi
develop
supersed
unnecessari
prophylact
treatment
part
explan
refer
factor
within
patient
exampl
statu
innat
adapt
immun
part
explan
probabl
found
within
bacterium
object
present
studi
compil
describ
select
characterist
fatal
meningococc
isol
n
compar
invas
nonfat
one
n
collect
sweden
coverag
fatal
serogroup
b
isol
four
differ
outer
membran
vesicl
omv
vaccin
also
estim
method
isol
characteris
serogroup
serotyp
genosubtyp
multilocu
sequenc
type
antibiogram
basic
epidemiolog
data
also
gather
result
fatal
isol
fatal
rate
compris
serogroup
b
c
characterist
associ
higher
mortal
age
gender
serogroup
serotyp
genosubtyp
contrari
serotyp
genosubtyp
reduc
sensit
penicillin
g
associ
decreas
mortal
present
discuss
omv
vaccin
could
base
sole
complet
genosubtyp
theoret
cover
fatal
serogroup
b
case
everi
variabl
region
capabl
induc
protect
alarm
howev
fact
among
invas
nonfat
one
three
isol
express
function
pora
protein
therebi
cover
pora
compon
vaccin
present
fatal
respect
nonfat
isol
form
welldefin
basi
characteris
supplementari
method
exampl
investig
concern
new
vaccin
antigen
potenti
pathogenspecif
gene
object
aim
current
studi
determin
integr
site
exact
size
esp
contain
put
pathogen
island
pai
enterococcu
faecium
strain
investig
sequenc
heterogen
adjoin
pai
integr
site
pai
posit
neg
isol
genom
sequenc
paineg
strain
paiposit
strain
determin
laboratori
van
schaik
et
al
prepar
genom
sequenc
region
homolog
flank
sequenc
esp
contain
pai
identifi
anoth
pai
neg
strain
e
faecium
publicli
avail
genom
sequenc
allow
us
identifi
pai
integr
site
subsequ
pai
integr
sequenc
heterogen
adjoin
integr
site
determin
use
normal
longrang
pcr
paiposit
paineg
strain
use
combin
pai
specif
primer
primer
specif
flank
gene
result
dna
align
reveal
integr
larg
dna
fragment
contain
esp
gene
end
open
read
frame
high
ident
e
faecium
integr
result
duplic
end
pai
region
high
similar
e
faecali
mobil
element
found
end
homolog
interestingli
strain
anoth
element
homolog
pai
integr
posit
pcr
demonstr
paiposit
isol
pai
integr
homolog
paineg
strain
pcr
confirm
integr
site
howev
one
isol
pcr
indic
integr
fragment
least
strain
pcr
product
use
primer
span
integr
site
obtain
suggest
either
integr
dna
element
larg
amplifi
polymorph
primer
anneal
site
strike
varieti
mobil
dna
insert
homolog
suggest
site
may
hot
spot
integr
exogen
acquir
genet
element
e
faecium
method
pcr
map
dna
sequenc
use
detect
localis
identif
gene
studi
conjug
perform
broth
use
e
coli
rifrazr
recipi
strain
antimicrobi
resist
phenotyp
determin
broth
microdilut
plasmid
dna
extract
method
kado
liu
plasmid
incompat
inc
group
identif
determin
pcrbase
replicon
type
carattoli
et
al
result
isol
examin
carri
blactxm
gene
larg
plasmid
kb
sixti
plasmid
confirm
conjug
restrict
fragment
length
polymorph
rflp
analysi
indic
sever
differ
subgroup
among
plasmid
equival
size
plasmid
appear
belong
differ
inc
group
vari
genu
blactxm
allel
incf
major
conjug
plasmid
group
e
coli
produc
enzym
includ
muca
structur
inclm
major
plasmid
group
k
pneumonia
strain
demonstr
gene
arrang
variant
addit
combin
small
insert
gene
environ
gene
includ
structur
incf
incac
e
coli
incn
k
pneumonia
plasmid
uniqu
e
coli
strain
upstream
gene
plasmid
conclus
nosocomi
e
coli
k
pneumonia
isol
differ
region
russia
carri
blactxm
gene
highmolecular
weight
plasmid
belong
variou
inc
group
ctxm
gene
environ
differ
blactxm
subgroup
bacteri
genera
indic
differ
gene
transmiss
mechan
acknowledg
studi
done
frame
ist
project
howev
larger
divers
emmtyp
found
develop
countri
notabl
brazil
gain
insight
molecular
base
differ
genet
related
whole
surfac
expos
part
protein
belgian
brazilian
isol
investig
method
multipl
align
sequenc
nterminu
conserv
sequenc
repeat
aa
repres
emmtyp
select
among
wellcharacteris
belgian
brazilian
epidemiolog
collect
cluster
method
perform
phylogenet
tree
construct
use
neighbourjoin
algorithm
sever
method
assay
dataset
congruent
result
preval
belgian
brazilian
isol
similar
clade
b
clade
b
contain
two
monophylet
group
show
geograph
prefer
subclad
mainli
compos
brazilian
isol
subclad
contain
belgian
isol
brazilian
one
present
particular
compos
isol
distantli
relat
multipl
align
reveal
genet
divers
mostli
gener
high
degre
sequenc
variat
c
repeat
region
ii
increas
number
b
repeat
lead
overal
increas
size
protein
dnd
analysi
show
purifi
select
drive
evolut
conclus
despit
small
number
differ
emmtyp
consequ
appar
low
divers
overal
genet
divers
protein
belgian
isol
compar
brazilian
one
evalu
whole
surfac
expos
sequenc
variat
shed
light
molecular
mechan
involv
virul
host
colonis
well
select
pressur
drive
antigen
variat
evolut
protein
genet
divers
protein
among
belgian
brazilian
ga
isol
emmtyp
sequenc
indic
next
bar
green
red
squar
indic
brazilian
belgian
strain
respect
rea
indic
rearrang
emm
pattern
evolutionari
histori
infer
use
neighborjoin
method
bootstrap
valu
higher
shown
next
branch
replic
tree
drawn
scale
branch
length
unit
evolutionari
distanc
use
phylogenet
tree
evolutionari
distanc
comput
use
poisson
correct
method
unit
number
amino
acid
substitut
per
site
rate
variat
among
site
model
gamma
distribut
shape
paramet
thirteen
cluster
defin
base
arbitrari
defin
maxim
genet
distanc
substitut
per
site
cluster
clade
b
group
sofposit
neg
emmtyp
respect
sof
activ
unknown
eccmid
oral
present
object
mycoplasma
pneumonia
previous
characteris
microorgan
genet
highli
stabl
spite
genet
stabil
homolog
dna
recombin
hypothesis
lie
basi
antigen
variat
major
surfac
protein
pneumonia
order
identifi
protein
may
involv
homolog
dna
recombin
pneumonia
set
characteris
open
read
frame
orf
orf
bear
sequenc
similar
gene
encod
singlestrand
dnabind
ssb
protein
escherichia
coli
known
play
vital
role
dna
recombin
well
dna
replic
repair
method
orf
amplifi
pcr
genom
dna
pneumonia
strain
mac
clone
protein
express
vector
express
high
level
e
coli
result
protein
term
mpn
ssb
purifi
activ
determin
variou
dna
bind
recombin
assay
orf
capac
encod
acid
protein
calcul
molecular
mass
kda
amino
acid
sequenc
protein
mpn
ssb
close
relat
protein
predict
encod
gene
mycoplasma
genitalium
ident
mpn
ssb
express
e
coli
purifi
homogen
purifi
protein
found
exist
primarili
dimer
solut
ii
strongli
select
bind
singlestrand
dna
ssdna
dival
cationand
dna
substrat
sequenceindepend
manner
iii
stimul
e
coli
recapromot
dna
strand
exchang
conclus
mpn
ssb
protein
repres
pneumonia
counterpart
ssb
protein
bacteria
protein
effici
bind
ssdna
stimul
e
coli
recapromot
homolog
dna
recombin
consequ
activ
mpn
ssb
protein
may
play
crucial
role
dna
recombinatori
pathway
pneumonia
result
studi
pave
way
unravel
pathway
assess
role
antigen
variat
pneumonia
creactiv
protein
sever
meningococc
diseas
long
pentraxin
import
element
innat
immun
system
potenti
diagnost
tool
inflammatori
condit
studi
patient
admit
icu
sever
meningococc
diseas
compar
short
pentraxin
crp
patient
meningococc
diseas
studi
patient
present
meningococc
septic
shock
shock
group
patient
meningococc
mening
bacteraemia
shock
group
crp
measur
elisa
high
plasma
concentr
median
mgl
seen
admiss
patient
meningococc
diseas
concentr
significantli
higher
patient
shock
compar
patient
without
shock
median
mgl
median
mgl
p
respect
contrast
crp
admiss
lower
shock
group
compar
shock
group
median
mgl
median
mgl
p
respect
time
cours
crp
show
patient
shock
concentr
highest
admiss
wherea
crp
peak
hour
admiss
patient
mening
howev
crp
peak
within
first
hour
admiss
figur
high
low
crp
concentr
admiss
discrimin
presenc
absenc
shock
area
roc
curv
p
p
crp
correl
diseas
sever
prism
day
spent
icu
crp
concentr
admiss
show
strong
neg
correl
paramet
diseas
sever
conclus
earli
indic
shock
patient
sever
meningococc
diseas
follow
pattern
induct
distinct
crp
high
low
crp
plasma
concentr
discrimin
presenc
absenc
shock
thu
high
level
admiss
may
alert
clinician
immin
deterior
shock
object
despit
high
incid
acut
pyelonephr
commun
set
consensu
optim
durat
treatment
knowledg
quantit
synthesi
previous
perform
investig
issu
shorten
prevail
therapeut
scheme
treatment
diseas
method
search
pubm
cochran
central
regist
control
trial
identifi
extract
data
relev
rct
metaanalysi
compar
effect
toxic
short
versu
long
regimen
treatment
acut
pyelonephr
inclus
criteria
rct
involv
adult
patient
acut
pyelonephr
compar
regimen
antibiot
daili
dosag
administ
differ
durat
time
shortcours
longcours
result
accord
initi
search
potenti
relev
articl
retriev
pubm
cochran
central
regist
control
trial
final
rct
elig
inclus
metaanalysi
differ
short
cours
treatment
day
long
cours
treatment
day
acut
pyelonephr
regard
clinic
success
odd
ratio
confid
interv
ci
microbiolog
erad
ci
relaps
ci
also
differ
short
cours
long
cours
treatment
regard
advers
event
ci
withdraw
due
advers
event
ci
conclus
find
metaanalysi
suggest
short
cours
regimen
effect
safe
long
cours
regimen
treatment
acut
pyelonephr
howev
due
rel
scarciti
data
rct
focus
import
clinic
question
need
order
come
definit
conclus
introduct
procalcitonin
pct
use
marker
differenti
sepsi
noninfecti
caus
system
inflammatori
respons
syndrom
sir
creactiv
protein
crp
also
use
marker
sepsi
sever
diseas
surviv
sepsi
campaign
ssc
develop
improv
manag
diagnosi
treatment
sepsi
march
ssc
guidelin
introduc
icu
depart
intern
medicin
surgeri
hospit
studi
clinic
applic
pct
crp
plasma
concentr
detect
sever
sepsi
septic
shock
assess
sever
diseas
hypothesi
pct
crp
use
discrimin
bacteri
infect
caus
sir
use
marker
mortal
method
prospect
observ
studi
patient
admit
depart
intern
medicin
surgeri
icu
larg
nonacadem
teach
hospit
enrol
ssc
pct
crp
plasma
level
determin
inclus
hour
inclus
de
ssc
registr
patient
classifi
accord
outcom
hospit
discharg
mortal
presenc
infect
confirm
microbiolog
cultur
pct
cpr
level
data
analys
use
nonparametr
statist
method
pearson
chisquar
kruskalw
test
result
nineti
one
patient
age
male
includ
admit
icu
patient
treat
ward
infect
confirm
cultur
patient
differ
pct
patient
without
microbiolog
cultur
proven
infect
patient
classifi
sever
sepsi
septic
shock
overal
hospit
mortal
differ
pct
crp
survivor
nonsurvivor
conclus
pct
differenti
patient
cultur
confirm
infect
sever
sepsissept
shock
patient
sever
sir
suspect
proven
infect
pct
crp
indic
outcom
patient
sever
sepsi
septic
shock
w
wangsomboonsiri
luksananun
saksornchai
k
ketwong
sungkanuparph
bangkok
nakornsawan
th
object
describ
clinic
characterist
streptococcu
sui
infect
reemerg
zoonot
diseas
northern
thailand
determin
risk
factor
death
diseas
method
retrospect
cohort
studi
conduct
among
patient
diagnos
cultureconfirm
sui
infect
sawanpracharak
hospit
tertiari
care
centr
nakornsawan
provinc
northern
thailand
januari
octob
medic
record
review
clinic
data
extract
risk
factor
death
determin
multivari
analysi
result
patient
mean
sd
age
year
male
common
risk
sui
infect
eat
unwellcook
pork
intern
organ
clinic
present
includ
acut
mening
sepsi
without
localis
infect
septic
shock
endocard
septic
arthriti
hear
loss
observ
significantli
associ
mening
posit
cultur
sui
recov
blood
cerebrospin
fluid
csf
strain
suscept
penicillin
cefotaxim
levofloxacin
csf
profil
median
valu
among
patient
mening
follow
white
blood
cell
cellsmm
pmn
l
protein
mgdl
glucos
mgdl
posit
gram
stain
mortal
rate
death
occur
first
hour
patient
die
like
occup
contact
raw
pork
p
headach
p
gastroenter
p
septic
shock
p
low
platelet
p
low
serum
bicarbon
p
low
albumin
p
high
alt
p
high
total
bilirubin
p
multivari
analysi
reveal
occup
contact
raw
pork
p
high
alt
p
signific
risk
factor
death
conclus
sui
infect
commonli
present
acut
mening
sepsi
without
localis
infect
common
risk
sui
infect
eat
unwellcook
pork
risk
factor
death
occup
contact
raw
pork
high
alt
educ
peopl
northern
thailand
eat
wellcook
pork
part
safe
contact
raw
pork
crucial
patient
present
high
alt
need
intens
care
close
monitor
prospect
intervent
studi
need
minim
incid
diseas
death
sui
infect
cultur
agent
recommend
unless
symptom
recur
persist
despit
treatment
late
note
high
isol
rate
nongroup
b
c
f
g
betahaemolyt
streptococci
fluor
vaginali
sampl
women
recurr
vulvovagin
region
group
streptococci
known
caus
vulvovagin
children
evid
infect
adult
women
limit
case
report
two
methodolog
flaw
studi
lack
welldefin
control
group
signific
group
c
f
g
streptococci
vagin
flora
unclear
investig
associ
nongroup
b
betahaemolyt
streptococci
vulvovagin
adult
women
conduct
case
control
studi
method
case
n
women
consult
gp
abnorm
nonbloodi
vagin
discharg
without
itch
irrit
red
pain
fluor
sampl
cultur
control
n
asymptomat
women
consult
gp
smear
taken
cervic
cancer
screen
programm
consent
vagin
swab
taken
addit
asymptomat
volunt
among
hospit
personnel
submit
selfobtain
vagin
swab
age
case
well
control
rang
year
result
nongroup
b
streptococci
isol
case
control
ci
p
signific
differ
caus
group
streptococci
isol
case
control
p
isol
rate
group
c
f
g
streptococci
case
low
respect
differ
statist
control
respect
conclus
group
betahaemolyt
streptococci
associ
persist
vagin
discharg
women
age
diagnos
report
pathogen
vulvovagin
role
nongroup
b
streptococci
requir
studi
low
number
isol
adequ
manag
vagin
discharg
cultur
necessari
initi
treatment
fail
guidelin
adapt
effect
background
p
aeruginosa
ceftazidim
caz
cefepim
fep
show
similar
suscept
pattern
isol
fep
less
activ
caz
relat
activ
efflux
product
oxacillinas
studi
level
express
two
efflux
pump
clinic
p
aeruginosa
isol
mic
fep
higher
caz
method
nine
p
aeruginosa
isol
differ
patient
mic
fep
dilut
higher
caz
product
oxacillinas
exclud
multiplex
polymeras
chain
reaction
pcr
select
mic
caz
fep
determin
triplic
three
differ
day
microdilut
clsi
guidelin
object
plasmidmedi
quinolon
resist
increas
worldwid
enterobacteriacea
pentapeptid
repeat
protein
qnra
qnrb
qnr
confer
reduc
suscept
quinolon
studi
genet
evolut
quinolon
resist
mediat
chang
code
sequenc
promot
region
gene
analys
vitro
method
qnr
gene
contain
code
sequenc
put
promot
region
clone
express
e
coli
random
mutagenesi
assay
perform
mutant
obtain
select
plate
without
quinolon
compar
aminoacid
sequenc
pentapeptid
protein
activ
quinolon
sever
conserv
posit
found
role
posit
activ
protein
quinolon
evalu
site
direct
mutagenesi
residu
analys
accord
sequenc
quinolon
suscept
mutant
obtain
random
site
direct
mutagenesi
analys
disk
diffus
etest
microdilut
method
result
three
differ
phenotyp
obtain
random
mutagenesi
assay
compar
wildtyp
phenotyp
similar
activ
nalidix
acid
ciprofloxacin
ii
higher
activ
nalidix
acid
ciprofloxacin
iii
lower
activ
nalidix
acid
ciprofloxacin
two
mutant
increas
quinolon
resist
contain
two
fold
nalidix
acid
contain
four
fold
ciprofloxacin
site
direct
mutagenesi
one
chang
sever
conserv
posit
produc
complet
lost
activ
effect
activ
protein
ident
differ
posit
conclus
aminoacid
sequenc
pentapeptid
repeat
protein
could
optimis
activ
quinolon
one
sever
chang
seem
insuffici
obtain
variant
produc
fluoroquinolon
clinic
resist
spite
high
aminoacid
variabl
pentapeptid
protein
sever
conserv
residu
analys
critic
activ
protein
quinolon
method
effect
sever
subinhibitori
concentr
diazepam
haloperidol
strain
evalu
outer
membran
protein
omp
express
cyclohexan
toler
express
mara
sox
rob
sdia
gene
omp
express
analys
sdspage
express
mara
sox
rob
sdia
gene
studi
revers
transcript
total
rna
pcr
cdna
rtpcr
use
gapa
gene
intern
control
express
pcr
product
separ
sdspage
silver
stain
quantifi
level
gene
express
use
imagequ
tl
induc
noninduc
mm
salicyl
mm
paraquat
control
strain
result
mar
phenotyp
induc
grow
concentr
diazepam
haloperidol
accompani
signific
increas
express
sdia
sox
gene
coincid
previou
result
mar
increas
activ
efflux
induc
subinhibitori
concentr
drug
larg
upregul
sdia
gene
sox
gene
induc
mm
haloperidol
induc
decreas
express
ompf
increas
cyclohexan
toler
well
increas
express
sdia
sox
gene
occur
revers
concentrationdepend
manner
induc
diazepam
haloperidol
show
signific
increment
express
level
mara
rob
sdia
homolog
luxr
famili
quorumsens
transcript
factor
well
sox
involv
mar
phenotyp
induc
diazepam
haloperidol
ii
mar
phenotyp
increas
cyclohexan
toler
upregul
sdia
sox
gene
alway
induc
two
studi
drug
revers
concentrationdepend
manner
iii
decreas
express
ompf
induc
diazepam
haloperidol
could
relat
sox
overexpress
object
pseudomona
aeruginosa
pa
import
nosocomi
pathogen
may
acquir
resist
expandedspectrum
cephalosporin
mostli
overproduc
cephalosporinas
andor
acquir
ambler
class
b
blactamas
sever
clavulan
acidinhibit
ambler
class
extendedspectrum
blactamas
esbl
extendedspectrum
class
enzym
oxaesbl
isol
pa
peculiar
oxaesbl
sinc
point
mutant
deriv
broadspectrum
oxa
enzym
well
inhibit
clavulan
acid
initi
report
along
pa
mu
franc
recent
sever
pa
isol
involv
outbreak
tunisia
method
genet
structur
surround
gene
prototyp
pa
mu
strain
characteris
clone
pcr
analysi
sequenc
compar
found
three
pa
isol
belgium
strain
analys
plasmid
extract
conjug
electropor
assay
pfge
three
belgian
isol
origin
sputum
blood
specimen
three
patient
hospitalis
differ
ward
sixmonth
period
presenc
esbl
detect
doubledisk
diffus
test
cloxacillincontain
plate
pcr
follow
sequenc
reveal
presenc
gene
chromosomallyencod
pcr
map
reveal
ident
genet
environ
pa
mu
belgian
isol
oxacillinas
integron
locat
lack
gene
cassett
specif
sequenc
insert
ib
gene
cassett
addit
bracket
two
novel
insert
sequenc
iscr
famili
like
iss
origin
gene
mobilis
furthermor
detail
analysi
clone
genom
fragment
contain
gene
reveal
colinear
gene
integron
contain
gene
pfge
defin
genet
related
three
belgian
pa
isol
pa
mu
strain
recent
identifi
pa
isol
tunisia
posit
either
genet
differ
pa
mu
thu
suggest
least
two
pa
clone
current
spread
object
human
bocaviru
hbov
newli
discov
parvoviru
role
caus
agent
respiratori
diseas
remain
unclear
investig
presenc
hbov
quantit
pcr
nasopharyng
sampl
french
consecut
children
hospitalis
acut
bronchiol
detect
common
respiratori
virus
perform
use
classic
immunofluoresc
antigen
cell
cultur
detect
rtpcr
assay
result
hbov
uniqu
viral
pathogen
detect
associ
anoth
viral
respiratori
pathogen
studi
children
viru
identifi
third
aetiolog
caus
bronchiol
respiratori
syncyti
viru
rhinoviru
case
respect
occur
often
infant
age
month
p
median
level
hbov
dna
genom
respiratori
sampl
appear
significantli
higher
patient
singl
hbov
infect
observ
patient
mix
respiratori
viral
infect
hbov
copiesml
vs
copiesml
p
conclus
data
suggest
hbov
high
viral
load
could
aetiolog
agent
respiratori
tract
diseas
wherea
exact
role
hbov
low
viral
load
aetiolog
caus
pathophysiolog
cofactor
respiratori
diseas
remain
determin
felip
noguera
c
fortuni
e
n
rovira
esplugu
barcelona
es
object
liver
function
abnorm
clinic
hepat
associ
nvp
use
also
paediatr
age
nvp
cross
placenta
achiev
neonat
blood
concentr
equival
mother
cordtomatern
blood
ratio
nvp
elimin
prolong
infant
singledos
nvp
regimen
deliveri
prove
safe
littl
known
chronic
utero
exposur
nvp
hepatotox
otherwis
healthi
hivuninfect
infant
method
prospect
observ
studi
cohort
hivuninfect
healthi
infant
born
hivinfect
mother
expos
utero
either
nvpbase
nonnvpbas
haart
regimen
infant
perinat
infect
hiv
andor
hcv
receiv
neonat
nvp
exclud
plasmat
alanin
aminotransferas
alt
normal
valu
iul
level
obtain
age
compar
group
expos
total
time
utero
haart
exposur
less
also
taken
account
student
ttest
parametr
test
use
result
overal
infant
femal
includ
femal
expos
utero
nvpbase
haart
regimen
n
n
commonli
use
nucleosid
analogu
backbon
mother
nonexpos
group
mostli
receiv
pibas
therapi
gestat
nfv
n
lpvr
n
mean
durat
haart
pregnanc
rang
mean
gestat
age
weight
birth
respect
deliveri
mother
receiv
intraven
zdv
infant
receiv
cours
oral
zdv
none
patient
show
clinic
symptom
consist
hepat
followup
except
patient
expos
nonexpos
develop
selflimit
neonat
jaundic
alt
plasmat
level
obtain
median
age
day
rang
day
differ
report
alt
level
expos
mean
valu
rang
iul
nonexpos
mean
valu
rang
iul
nonexpos
group
differ
neither
observ
length
exposur
week
less
consid
three
infant
nonexpos
group
develop
nonsymptomat
elev
alt
valu
spontan
normalis
age
month
studi
chronic
utero
exposur
nvp
caus
elev
alt
level
hivuninfect
infant
deviceassoci
infect
involv
biofilm
remain
persist
clinic
problem
research
group
recent
report
meticillinresist
staphylococcu
aureu
mrsa
strain
form
biofilm
independ
icaadbcencod
exopolysaccharid
report
mutat
sortas
anchor
lpxtgcontain
protein
peptidoglycan
impair
mrsa
biofilm
develop
furthermor
delet
fnba
fnbb
encod
lpxtganchor
multifunct
fibrinogen
fibronectinbind
protein
fnbpa
fnbpb
impair
mrsa
meticillinsensit
aureu
mssa
biofilm
develop
appar
level
intercellular
accumul
primari
attach
mrsa
fnbab
biofilm
defect
complement
fnba
fnbb
alon
correspondingli
mutat
fnba
fnbb
alon
substanti
affect
biofilm
overexpress
either
gene
alon
mrsa
mssa
activ
biofilm
interestingli
fnbppromot
biofilm
depend
sara
level
fnba
fnbb
transcript
use
plasmid
construct
lack
region
fnbpa
complement
fnbab
mutant
reveal
domain
alon
bcd
domain
requir
fibronectin
bind
could
promot
biofilm
addit
domain
substitut
abolish
fibrinogen
bind
affect
biofilm
data
identifi
novel
aureu
biofilm
phenotyp
promot
fnbpa
fnbpb
appar
independ
known
ligandbind
activ
multifunct
surfac
protein
given
implant
surgic
medic
biomateri
rapidli
coat
condit
film
compos
primarili
extracellular
matrix
protein
find
suggest
cellwallanchor
protein
import
virul
factor
devicerel
aureu
infect
particularli
caus
mrsa
strain
may
repres
attract
therapeut
target
object
assess
role
agr
biofilm
format
studi
gene
express
agr
wellestablish
biofilm
vivo
rat
model
method
agra
rnaiii
express
evalu
vivo
foreign
bodi
colonis
period
week
cathet
fragment
n
inocul
low
inoculum
epidermidi
implant
subcutan
rat
describ
vandecasteel
et
al
bbrc
explant
gdna
rna
isol
adher
biofilmassoci
bacteria
n
detach
bacteria
bacteria
loos
adher
cathet
remov
wash
n
bacteria
colonis
surround
tissu
n
gene
express
quantifi
realtim
pcr
amount
bacteria
calcul
absolut
quantif
gdna
copi
housekeep
gene
gmk
recalcul
bacteriamm
cathet
surfac
mm
result
bacteri
densiti
decreas
till
h
postimplant
increas
old
biofilm
subsequ
slowli
decreas
howev
still
higher
plankton
cultur
spite
express
quorumsens
system
gene
arga
rnaiii
low
day
implant
rnaiii
express
decreas
minimum
week
old
biofilm
wherea
agra
express
remain
low
level
whole
implant
period
number
bacteria
detach
colonis
surround
tissu
significantli
decreas
toward
week
post
implant
number
biofilmform
bacteria
stabl
suggest
stabl
wellform
biofilm
week
implant
agra
rnaiii
express
significantli
higher
detach
bacteria
tissuecolonis
bacteria
agra
rnaiii
express
compar
biofilmassoci
bacteria
conclus
express
agr
low
biofilm
high
detach
bacteria
correl
role
agr
activ
tissu
invas
biofilm
format
object
recent
data
indic
pneumococci
otiti
media
pneumonia
mening
may
form
biofilm
vivo
order
better
characteris
pneumococc
biofilm
format
evalu
differ
model
analys
variou
phase
biofilm
develop
method
static
biofilm
model
develop
microtit
plate
use
low
inocula
rich
media
high
inocula
poor
media
pneumococc
cell
adher
solid
support
characteris
viabil
extracellular
matrix
product
respons
quorum
sens
signal
result
adher
pneumococci
could
recov
hour
incub
use
low
incula
biofilm
found
increas
exponenti
phase
declin
half
log
remain
stabl
time
stabil
stationari
cultur
depend
addit
csp
growth
medium
addit
growth
medium
blp
second
type
cellcel
signal
peptid
pneumonia
effect
biofilm
format
stabil
mutant
cp
locu
capsul
comc
csp
comd
csp
receptor
blph
receptor
blp
bacteriocin
lux
quorum
sens
molecul
tc
assay
abil
form
biofilm
comd
mutant
found
impair
format
matur
biofilm
independ
form
capsul
express
type
cellcel
signal
mechan
shown
phase
pneumococc
biofilm
model
reli
high
inocula
poor
media
show
stabl
biofilm
format
week
independ
addit
exogen
csp
despit
differ
csp
depend
biofilm
model
system
comd
mutant
show
ident
defici
extracellular
matrix
product
indic
probabl
reason
instabl
biofilm
quantit
analysi
gene
express
panel
gene
show
signific
variat
two
model
system
conclus
pneumococc
biofilm
format
assay
differ
system
provid
altern
model
analysi
complex
phenotyp
cellcel
signal
system
relat
compet
develop
significantli
involv
stabilis
pneumococc
biofilm
probabl
involv
extracellular
matrix
product
staphylococci
produc
wide
rang
antigen
compon
includ
macromolecul
found
cell
wall
peptidoglycan
teichoic
acid
surfac
protein
wallassoci
capsular
slime
polysaccharid
well
rang
potent
export
toxin
knowledg
antigen
properti
staphylococci
health
diseas
import
develop
protect
vaccin
antibodi
passiv
therapi
design
kit
sensit
specif
serodiagnosi
infect
detect
microbi
contamin
microbi
identif
also
requir
detail
understand
antigen
properti
staphylococci
serolog
method
appli
studi
staphylococci
mani
year
indic
complex
divers
antibodi
respons
follow
exposur
staphylococci
either
infect
respons
commens
organ
administr
exploratori
vaccin
variat
occur
antibodi
level
staphylococc
peptidoglycan
ribitol
wall
teichoic
acid
lipo
membran
teichoic
acid
sera
blood
donor
patient
verifi
suspect
staphylococc
infect
antigen
short
chain
excret
form
cellular
lipoteicho
acid
call
lipid
shown
valu
diagnosi
infect
associ
orthopaed
prosthes
nativ
prosthet
valv
endocard
sepsi
associ
central
venou
cathet
experi
staphvax
aureu
capsular
polysaccharid
conjug
vaccin
veron
polyclon
antibodi
product
direct
protein
virul
factor
also
suggest
activ
passiv
protect
staphylococc
infect
complex
number
product
clinic
evalu
includ
aurograb
antibodi
target
abc
transport
aureu
altastaph
capsular
polysaccharid
vaccin
aurexi
monoclon
antibodi
fragment
target
aureu
clump
factor
pagibaximab
target
lipoteicho
acid
may
also
give
clearer
indic
possibl
antigen
use
serolog
test
mani
commerci
serolog
kit
alreadi
avail
identif
staphylococci
includ
rapid
latex
agglutin
test
exampl
slidex
staph
plu
staphaurex
plu
murex
diagnost
staphytect
oxoid
bacti
staph
remel
pastorex
staphplu
sanofi
diagnost
pasteur
test
detect
clump
factor
staphylococc
protein
addit
slidex
staph
plu
staphaurex
plu
test
detect
groupspecif
antigen
aureu
cell
surfac
pastorex
staphplu
detect
capsular
polysaccharid
wound
biofilmrel
infect
becom
chronic
lead
econom
loss
secondari
patient
morbid
possibl
mortal
mani
infect
involv
staphylococci
spp
capabl
develop
antibiot
resist
commun
nosocomi
acquir
microbi
antibiot
resist
erod
miracl
antibiot
jeopardis
human
anim
welfar
evid
increas
frequenc
resist
vancomycin
current
potent
antibiot
drive
develop
novel
therapeut
agent
rnaiii
inhibit
peptid
rip
therapi
repres
excit
altern
staphylococci
like
aureu
epidermidi
becom
virul
caus
diseas
format
biofilm
product
toxin
process
regul
cellto
cell
commun
mechan
term
quorum
sens
qs
recent
year
resist
macrolid
streptococcu
pneumonia
increas
mani
area
world
includ
europ
accord
european
antibiot
resist
surveil
system
collect
data
invas
isol
european
countri
report
proport
erythromycinresist
pneumococc
isol
countri
includ
itali
report
proport
higher
bimod
distribut
erythromycin
minim
inhibitori
concentr
resist
isol
reflect
wellknown
resist
phenotyp
correspond
genotyp
highlevel
macrolid
resist
associ
resist
lincosamid
streptogramin
b
mlsb
phenotyp
confer
erm
b
ribosom
methylas
lowlevel
resist
macrolid
phenotyp
due
efflux
pump
encod
mefmsr
gene
rel
proport
isol
carri
either
mechan
vari
differ
countri
chang
time
addit
isol
carri
resist
mechan
becom
increasingli
common
uncommon
genotyp
gener
associ
low
moderatelevel
erythromycin
resist
repres
point
mutat
domain
v
rrna
gene
ribosom
protein
erm
gene
encod
induc
methylas
although
main
genotyp
respons
erythromycin
resist
pneumonia
well
known
genet
element
resist
gene
resid
repres
vehicl
transmiss
recent
start
elucid
element
carri
macrolid
efflux
pump
pneumonia
defect
transposon
mef
carri
mef
e
carri
mega
two
element
similar
distribut
properti
differ
characterist
serotyp
intern
clone
insert
compet
gene
make
isol
unabl
transform
therefor
mefacarri
isol
usual
suscept
penicillin
nonmacrolid
antibiot
isol
carri
mef
e
mega
heterogen
serotyp
genet
background
tend
multidrugresist
due
capabl
mega
associ
antibioticresist
transposon
notabl
carri
tetracyclin
resist
transposon
famili
vehicl
also
highlevel
macrolid
resist
due
erm
b
recent
studi
shown
erm
b
often
associ
transposon
although
tetracyclin
resist
phenotyp
unexpress
composit
transposon
modular
structur
repres
backbon
modul
includ
one
macrolid
resist
element
mega
erm
b
element
although
composit
transposon
conjug
pneumonia
natur
transform
pneumococcu
ensur
transmiss
within
speci
studi
resist
element
carri
particular
clone
contribut
understand
evolut
macrolid
resist
pneumonia
instanc
lowlevel
erythromycinresist
intern
clone
evolv
doublemacrolid
gene
isol
complex
de
la
campa
l
balsalobr
majadahonda
es
resist
fluoroquinolon
fq
pneumonia
spn
occur
mainli
alter
target
dna
topoisomeras
iv
dna
gyras
essenti
enzym
resist
mutat
found
quinoloneresist
determin
region
qrdr
parc
pare
gyra
acquir
point
mutat
intraspecif
recombin
interspecif
recombin
viridan
streptococci
miti
group
smg
current
preval
fqresist
fqr
spn
lower
smg
higher
acquisit
resist
interspecif
recombin
could
much
common
point
mutat
consid
frequenc
event
laboratori
condit
respect
infect
bone
foot
patient
diabet
occur
patient
develop
foot
wound
infect
usual
occur
contigu
spread
soft
tissu
infect
markedli
increas
risk
hospitalis
amput
infect
caus
staphylococci
organ
involv
sometim
polymicrobi
infect
first
task
treat
clinician
diagnos
bone
infect
accur
best
done
obtain
bone
specimen
either
percutan
surgeri
cultur
histolog
among
avail
imag
test
mri
clearli
best
bone
scan
nonspecif
clinic
sign
symptom
unreli
probetobon
test
easi
rel
help
recent
intern
work
group
diabet
foot
propos
diagnost
scheme
estim
likelihood
osteomyel
base
combin
variou
clinic
laboratori
test
result
confirm
bone
infect
clinician
must
plan
treatment
author
recommend
resect
necrot
mani
case
grossli
infect
bone
evid
support
advic
spars
recent
retrospect
case
seri
shown
case
presum
osteomyel
put
longterm
remiss
antibiot
therapi
alon
usual
highli
bioavail
antibiot
eg
fluoroquinolon
given
prolong
period
month
longer
one
remov
infect
necrot
bone
durat
treatment
consider
shorter
day
week
avail
data
support
parenter
oral
antibiot
therapi
one
antibiot
agent
found
superior
other
evid
suggest
includ
rifampin
combin
least
one
antistaphylococc
antibiot
improv
outcom
clindamycin
blactam
agent
also
frequent
use
adjunct
treatment
eg
hyperbar
oxygen
granulocyt
coloni
stimul
factor
larval
biotherapi
proven
benefici
treatment
osteomyel
fail
surgeon
opt
minor
amput
compat
good
residu
foot
function
clinician
monitor
patient
least
year
ensur
achiev
appar
resolut
infect
nowaday
aureu
lead
caus
infect
endocard
ie
region
develop
world
consequ
increas
rate
healthcareassoci
staphylococc
bacteraemia
also
increas
number
patient
implant
medic
devic
nonaddict
infect
primarili
involv
left
side
heart
associ
mortal
rate
rang
wherea
addict
often
involv
tricuspid
valv
mortal
rate
much
lower
increas
percentag
aureu
strain
hospit
commun
set
meticillinresist
recent
seri
aureu
endocard
mrsa
account
around
case
patient
mrsaie
like
chronic
condit
healthcareassoci
infect
persist
bacteraemia
higher
mortal
rate
leftsid
endocard
especi
among
patient
mainten
hemodialysi
mortal
may
high
accord
current
guidelin
vancomycin
remain
refer
standard
treatment
prosthet
nativ
rightsid
leftsid
mrsaie
slow
bactericid
activ
poor
penetr
veget
advoc
main
reason
explain
limit
efficaci
drug
recent
emerg
isol
reduc
suscept
vancomycin
observ
excess
failur
among
patient
mrsa
bacteraemia
caus
suscept
strain
mic
mgml
emphasis
need
altern
therapi
addit
aminoglycosid
mrsa
usual
nonsuscept
rifampin
associ
better
outcom
among
older
antibiot
trimethoprimsulfamethoxazol
combin
fosfomycin
carbapenem
highli
synergist
strain
might
reason
altern
select
patient
new
therapeut
option
includ
quinupristindalfopristin
linezolid
tigeciclin
daptomycin
drug
shown
efficaci
equal
better
vancomycin
experiment
model
mrsa
hgisa
gisa
endocard
clinic
experi
scarc
among
daptomycin
approv
use
aureu
rightsid
endocard
probabl
best
altern
due
rapid
bactericid
effect
howev
best
dose
regimen
daptomycin
set
risk
develop
resist
therapi
potenti
combin
agent
larg
unknown
addit
number
new
antimrsa
compound
good
vitro
activ
promis
result
experiment
model
develop
includ
novel
glycopeptid
dalbavancin
telavancin
oritavancin
ceftobiprol
iclaprim
earli
identif
patient
persist
mrsa
bacteraemia
aggress
multidisciplinari
manag
endocard
may
help
improv
prognosi
especi
import
surgic
valv
replac
may
play
relev
role
maximis
outcom
mrsa
leftsid
prosthet
valv
endocard
patient
fail
vancomycin
therapi
prompt
expert
evalu
receiv
altern
compassion
drug
select
isol
c
difficil
test
suscept
rang
antibiot
use
agar
dilut
e
test
method
isol
known
pcr
ribotyp
mainli
origin
surveil
studi
isol
symptomat
patient
hospit
england
agent
test
includ
metronidazol
vancomycin
erythromycin
imipenem
moxifloxacin
levofloxacin
coamoxyclav
penicillin
piperacillin
tazobactam
separ
select
european
isol
c
difficil
present
cultur
collect
anaerob
refer
laboratori
uk
cardiff
also
studi
suscept
drug
repres
austria
germani
itali
poland
hungari
netherland
sweden
spain
includ
data
present
uk
isol
strong
relationship
note
resist
certain
agent
pcr
ribotyp
particularli
amongst
common
strain
known
type
rais
question
resist
mechan
harbour
strain
c
difficil
offer
select
advantag
strain
suscept
older
isol
given
pcr
ribotyp
compar
contemporari
isol
investig
resist
increas
discuss
high
percentag
c
difficil
strain
resist
antimicrobi
cephalosporin
clindamycin
macrolid
aminoglycosid
tetracyclin
cotrimoxazol
ertapenem
imipenem
chloramphenicol
contrari
microorgan
show
vitro
suscept
ampicillin
meropenem
metronidazol
penicillin
piperacillin
teicoplanin
vancomycin
recent
activ
firstlin
drug
therapi
cdad
vancomycin
metronidazol
argu
suscept
test
even
routin
recommend
present
metronidazol
resist
uncommon
present
heterogen
resist
clinic
consequ
yet
elucid
metronidazol
vancomycin
remain
drug
choic
treatment
cdad
import
limit
advers
effect
metronidazol
link
high
rate
nonrespons
relaps
mainli
patient
infect
epidem
strain
patient
sever
recurr
diseas
requir
vancomycin
higher
dose
longer
period
time
new
antimicrobi
agent
activ
vitro
c
difficil
includ
teicoplanin
ramoplanin
daptomycin
telavancin
linezolid
nitazoxanid
tiacumicin
b
c
rifaximin
role
altern
antimicrobi
agent
c
difficil
still
defin
nitazoxanid
antihelminth
antiprotozo
agent
least
effect
metronidazol
treat
c
difficil
coliti
intraven
immunoglobulin
use
patient
sever
diseas
multipl
recurr
prospect
compar
studi
establish
role
treatment
diseas
hyperimmun
bovin
gammaglobulin
neutral
effect
c
difficil
toxin
develop
data
regard
role
oligofructos
prevent
relaps
cdad
still
conflict
tolevam
polyanion
polym
chain
high
molecular
weight
clinic
cure
rate
similar
oral
vancomycin
administ
human
gday
fail
achiev
noninferior
use
recent
clinic
trial
local
bacteriotherapi
name
lavag
lumen
colon
administr
enema
prepar
fresh
faec
healthi
volunt
report
almost
alway
isol
case
short
seri
relev
studi
allow
give
recommend
method
obviou
drawback
therapi
addit
risk
transmiss
infecti
agent
exchang
resin
colestipol
colestyramin
abl
bind
c
difficil
toxin
may
also
bind
antimicrobi
use
treat
cdad
therefor
clinic
use
recommend
surgeri
last
resourc
treatment
unmanag
cdad
toxic
megacolon
colon
perfor
final
perspect
c
difficil
vaccin
look
promis
present
time
pseudomona
aeruginosa
airway
epitheli
cell
enhanc
inflammatori
respons
background
associ
surfact
protein
p
aeruginosa
enhanc
uptak
alveolar
macrophag
modul
inflammatori
respons
includ
cytokin
product
oxid
burst
howev
role
associ
interact
airway
epitheli
cell
poorli
investig
object
aim
studi
characteris
role
surfact
protein
interact
p
aeruginosa
airway
epitheli
cell
biolog
signific
pulmonari
pathogenesi
microorgan
method
surfact
protein
purifi
affin
chromatographi
human
bronchoalveolar
lavag
bind
purifi
surfact
protein
genet
unrel
p
aeruginosa
isol
chronic
infect
acut
infect
analys
elisa
western
blot
analysi
use
specif
monoclon
antisurfact
protein
antibodi
investig
role
surfact
protein
interact
p
aeruginosa
airway
epitheli
cell
standard
adhes
invas
assay
perform
use
cell
pneumocyt
type
ii
cell
incub
p
aeruginosa
preopsonis
surfact
protein
either
presenc
calcium
edta
product
tnfalfa
airway
epitheli
cell
determin
elisa
accord
manufactur
instruct
result
bind
purifi
surfact
protein
vari
wide
among
p
aeruginosa
clinic
isol
howev
isol
acut
infect
bound
surfact
protein
effici
chronic
infect
surfact
protein
opsonis
p
aeruginosa
presenc
calcium
enhanc
dramat
bacteri
attach
internalis
bronchoepitheli
cell
pneumocyt
type
ii
interact
facilit
airway
epitheli
cell
mediat
inflammatori
respons
increas
synthesi
tnfalfa
conclus
surfact
protein
promot
interact
p
aeruginosa
airway
epitheli
cell
enhanc
product
tnfalfa
cell
mechan
effect
isol
acut
infect
chronic
infect
provid
detail
survey
adapt
p
aeruginosa
chronic
infect
cystic
fibrosi
cf
lung
perform
compar
proteom
transcriptom
analysi
isogen
nonmut
mutat
isol
three
select
cf
patient
recent
show
cf
lung
persist
pa
mutat
converg
virulenceattenu
phenotyp
studi
demonstr
adapt
process
pa
predominantli
compris
metabol
pathway
endstag
mutat
strain
sever
transcript
gene
protein
involv
metabol
fatti
acid
nucleotid
amino
acid
gener
energi
increas
particular
interest
increas
express
level
gene
involv
anaerob
argininedeiminas
pathway
ii
anaerob
respir
iii
tricarboxyl
acid
cycl
tca
glyoxyl
shunt
iv
uptak
dicarboxyl
chang
transcriptom
proteom
indic
adapt
shift
toward
constitut
express
gene
metabol
pathway
obvious
requir
growth
microaerob
nutrit
condit
suppur
cf
lung
tissu
strikingli
data
provid
us
new
potenti
target
antimicrobi
agent
combat
chronic
cf
lung
diseas
mic
antibiot
use
quantit
rtpcr
specif
luksfpv
gyra
primer
result
effect
subinhibitori
concentr
depend
antibiot
oxacillin
enhanc
pvl
level
clindamycin
linezolid
fusid
acid
rifampicin
inhibitori
vancomycin
pristinamycin
tetracyclin
ofloxacin
cotrimoxazol
roughli
effect
examin
whether
inhibitoriest
molecul
pvl
could
abolish
pvl
increas
induc
oxacillin
subinhibitori
concentr
clindamycin
rifampicin
dramat
inhibit
pvl
induct
oxacillin
linezolid
slighter
dosedepend
inhibitori
effect
pvl
releas
contrast
fusid
acid
abl
inhibit
pvl
induct
oxacillin
except
mic
rtpcr
result
confirm
pvl
induct
oxacillin
luksfpv
inhibit
transcript
clindamycin
rifampicin
rtpcr
result
cultur
grown
antibiot
associ
show
luksfpv
inhibit
transcript
oxacillin
clindamycin
oxacillin
rifampicin
pvl
induct
oxacillin
fusid
acid
conclus
data
support
staphylococc
infect
relat
pvl
product
antibiot
either
upregul
downregul
pvl
releas
pvlproduc
mssa
blactam
associ
either
clindamycin
rifampicin
pvlproduc
mrsa
infect
linezolid
may
benefit
vancomycin
escherichia
coli
murin
microgli
cell
object
bacteri
phagocytosi
microglia
infect
contribut
resist
brain
microglia
cell
express
tolllik
receptor
tlr
stimul
pathogenassoci
molecular
pattern
pamp
escherichia
coli
one
lead
gramneg
bacteria
caus
sepsi
neonat
mening
hypothesis
pamp
may
stimul
microglia
therebi
increas
abil
phagocytos
bacteria
method
primari
cultur
mous
microglia
expos
tlr
agonist
tripalmitoylsglycerylcystein
tlr
endotoxin
lp
tlr
oligonucleotid
contain
unmethyl
cytosinguanosin
motif
cpg
tlr
alon
combin
interferongamma
ifng
stimul
cultur
challeng
e
coli
ratio
bacteria
per
cell
phagocytosi
left
proceed
min
wash
microgli
cultur
incub
medium
contain
gentamicin
mgl
h
kill
extracellular
bacteria
thereaft
cell
wash
lyse
distil
water
phagocytosi
inhibit
studi
cytochalasin
cd
use
microm
viabl
intracellular
bacteria
enumer
quantit
plate
serial
dilut
monitor
intracellular
surviv
microglia
cell
allow
ingest
bacteria
h
incub
medium
gentamicin
cd
perform
thereaft
intracellular
bacteria
determin
variou
time
point
quantit
plate
cell
lysi
kruskallw
test
follow
dunn
multipl
comparison
test
perform
analys
differ
phagocytos
bacteria
group
n
p
consid
statist
signific
background
acrab
efflux
pump
activ
critic
mediat
antimicrobi
resist
k
pneumonia
howev
role
efflux
pump
virul
opportunist
pathogen
poorli
investig
object
aim
studi
investig
role
acrab
efflux
pump
k
pneumonia
respiratori
infect
caus
microorgan
construct
insertiondupl
mutagenesi
specif
acrb
mutant
design
k
pneumonia
virul
strain
characteris
mutant
perform
southern
blot
analysi
rtpcr
analysi
acrb
express
determin
mic
sever
antimicrobi
agent
investig
virul
acrbdefici
mutant
standard
surviv
assay
perform
incub
bacteri
cell
human
bronchoalveolar
lavag
polymyxin
b
human
betadefensin
virul
also
test
murin
model
pneumonia
result
southern
blot
rtpcr
analysi
confirm
interrupt
acrb
gene
abolish
express
acrb
mutant
suscept
cefoxitin
erythromycin
nalidix
acid
parent
strain
mic
mgl
antibiot
strain
mutant
respect
cefoxitin
erythromycin
nalidix
acid
mutant
exhibit
signific
reduct
threefold
capac
surviv
presenc
bronchoalveolar
lavag
polymixin
human
betadefensin
compar
parent
strain
furthermor
mutant
less
virul
parent
strain
murin
model
pneumonia
balbc
mice
iv
infect
inocula
five
ten
femal
per
isol
agr
dysfunct
may
enhanc
adhes
virul
factor
capsular
type
cp
toxin
gene
profil
screen
isol
interpret
result
result
comparison
mssa
group
higher
adhes
mean
versu
adher
bacteria
per
cell
p
figur
panel
higher
virul
mous
sepsi
model
p
p
balbc
observ
mrsa
group
figur
panel
b
mrsa
group
significantli
less
adhes
haec
mean
p
figur
panel
induc
high
mortal
day
nine
figur
panel
b
sepsi
model
comparison
mssa
p
observ
heterogen
result
obtain
mrsa
group
adhes
sepsi
model
three
mrsa
isol
lethal
higher
adhes
mrsa
isol
correl
agr
dysfunct
virul
mrsa
isol
may
due
least
part
combin
express
product
superantigen
toxin
inde
mrsa
isol
express
contrari
four
mssa
ii
harbor
gene
encod
sea
mrsa
mrsa
wherea
none
mssa
isol
posit
gene
two
pandem
mrsa
clone
franc
exhibit
specif
adhes
virul
properti
may
explain
success
product
superantigen
toxin
may
key
virul
factor
pandem
mrsa
clone
object
urinari
tract
infect
uti
common
infect
patient
indwel
urinari
cathet
bacteri
biofilm
format
major
problem
type
infect
bacteri
biofilm
highli
resist
toward
fierc
flow
high
concentr
antibiot
understand
mechan
behind
biofilm
format
necessari
order
combat
infect
method
microarray
analysi
perform
sampl
e
coli
uti
strain
grown
mopsshak
flask
urineshak
flask
urinebiofilm
biofilm
format
knockout
mutant
wildtyp
strain
investig
microtitr
plate
flowcel
chamber
ferric
yersiniabactin
uptak
receptor
fyua
encod
high
pathogen
island
hpi
found
highli
import
biofilm
format
uti
e
coli
human
urin
global
gene
express
profil
uti
strain
biofilm
format
urin
show
gene
locat
hpi
significantli
upregul
interestingli
iron
acquisit
system
display
upregul
biofilm
urin
growth
compar
plankton
urin
upregul
plankton
urin
compar
minim
medium
fyua
gene
among
highest
upregul
gene
furthermor
fyua
mutant
show
signific
reduct
biofilm
format
compar
parent
polystyren
microtitr
plate
glass
flow
chamber
urin
flowcel
chamber
mutant
show
less
biofilm
compar
wildtyp
fig
howev
complement
tran
suppli
extra
iron
mutant
regain
biofilmform
faculti
also
introduct
fyuaencod
plasmid
three
upec
strain
increas
biofilm
format
significantli
conclus
free
iron
strictli
limit
human
urinari
tract
fierc
competit
host
infecti
bacteria
essenti
metal
uti
e
coli
highli
effici
mechan
iron
acquisit
one
yersiniabactin
encod
hpi
demonstr
direct
link
fyua
biofilm
format
ironpoor
environ
human
urin
also
show
avail
iron
greatli
influenc
uti
strain
abil
form
biofilm
object
high
lethal
cerebr
aspergillosi
urgent
ask
deeper
insight
pathogen
mechan
diseas
therefor
studi
whether
mycotoxin
especi
gliotoxin
contribut
neural
damag
ineffici
immun
respons
cerebr
aspergillosi
furthermor
test
put
capac
antioxid
compon
interfer
harm
activ
gliotoxin
secret
gliotoxin
fungal
growth
cerebrospin
fluid
csf
measur
use
hplc
tandem
mass
spectrometri
effect
gliotoxin
viabil
prolifer
astrocyt
neuron
microglia
test
mt
assay
phagocyt
activ
cell
presenc
gliotoxin
quantifi
use
fluoresc
latex
bead
subsequ
microscop
analysi
oxid
burst
studi
fac
result
pathogen
aspergillu
speci
like
fumigatu
secret
signific
level
gliotoxin
cultiv
csf
correspond
concentr
gliotoxin
suffici
affect
viabil
astrocyt
neuron
microgli
cell
neuron
microglia
sensit
cell
type
subtox
concentr
gliotoxin
diminish
capac
microglia
phagocyt
pathogen
furthermor
gliotoxin
exagger
oxid
burst
infiltr
granulocyt
induc
stimuli
pma
therapeut
approach
might
aim
neutral
inhibitori
even
toxic
effect
gliotoxin
thu
reconstitut
potenc
cerebr
immun
use
glutathion
purpos
tripeptid
made
cystein
glutam
glycin
act
reduc
compound
first
promis
experi
glutathion
abl
protect
brain
cell
gliotoxin
concentr
otherwis
shown
kill
cell
furthermor
glutathion
reconstitut
phagocyt
activ
immun
cell
presenc
gliotoxin
data
indic
essenti
contribut
gliotoxin
pathogenesi
cerebr
aspergillosi
therapeut
approach
neuroprotect
substanc
glutathion
might
use
neutral
toxic
immuneinhibitori
activ
gliotoxin
vari
wide
none
countri
latvia
countri
mainli
strong
microbiolog
support
report
mild
case
diphtheria
caus
toxigen
c
diphtheria
c
ulceran
interestingli
isol
toxigen
c
ulceran
increas
rel
toxigen
c
diphtheria
countri
member
countri
provid
inform
current
surveil
system
diphtheria
potenti
collect
casebas
data
part
standardis
european
dataset
conclus
whilst
diphtheria
gener
well
control
vaccin
european
countri
continu
threat
reemerg
absenc
report
case
countri
may
reflect
lack
appropri
epidemiolog
microbiolog
investig
increas
preval
countri
c
ulceran
infect
present
symptom
classic
diphtheria
also
highlight
need
increas
understand
pathogen
associ
contact
domest
anim
develop
integr
surveil
databas
provid
use
tool
monitor
chang
epidemiolog
increas
understand
c
diphtheria
c
ulceran
infect
object
commun
acquir
pneumia
cap
remain
major
caus
morbid
mortal
netherland
howev
littl
known
recent
tempor
trend
gener
popul
essenti
adequ
polici
infecti
diseas
conduct
populationbas
retrospect
studi
examin
compar
recent
trend
netherland
method
analys
three
nation
databas
assess
incid
gener
practition
consult
hospitalis
mortal
rate
due
pneumonia
found
clearli
increas
risk
pneumonia
among
individu
bmi
men
also
among
bmi
background
object
belgium
high
antibiot
prescrib
countri
europ
outpati
clin
infect
di
trigger
develop
nation
guidelin
ambulatori
practic
use
evidencebas
medicin
data
support
offici
belgian
antibiot
polici
coordin
committe
ii
send
gener
practition
gp
individu
feedback
compar
herhi
person
prescrib
habit
averag
gp
herhi
region
want
assess
guidelin
feedback
perceiv
gp
determin
follow
respiratori
tract
infect
rti
method
ssa
indepth
analysi
actor
behaviour
aim
identifi
rational
decis
face
actual
data
use
retrospect
cohort
patient
contact
n
antibiot
prescript
rti
gp
n
randomli
select
approach
data
collect
medic
record
direct
interview
n
document
medic
histori
reason
encount
symptom
clinic
examin
patient
demand
imag
laboratori
test
diagnost
prescrib
antibiot
complianc
guidelin
data
anonym
analys
doubleblind
fashion
two
independ
research
gp
assess
guidelin
observ
antibiot
need
choic
method
previou
studi
show
parent
whose
children
receiv
bug
need
drug
dbnd
instruct
school
daycar
better
inform
appropri
antibiot
use
control
trainthetrain
programm
design
increas
capac
deliv
dbnd
key
messag
handwash
prevent
infect
bacteria
virus
differ
use
antibiot
wise
dbnd
programm
fund
alberta
health
well
base
interest
enthusiasm
express
pharmacist
dbnd
train
workshop
provid
pharmacist
five
commun
marchjun
monitor
survey
pharmacist
trainer
receiv
antimicrobi
handbook
educ
tool
honoraria
teach
other
includ
nurs
earli
childhood
educ
ece
student
daycar
manag
subsequ
nurs
student
use
dbnd
kit
teach
year
old
grade
two
classroom
ece
student
daycar
manag
given
kit
teach
children
staff
daycar
sign
booklet
provid
school
daycar
parent
result
train
session
pharmacist
knew
significantli
antibiot
use
confid
recommend
treatment
option
comfort
contact
prescrib
chang
antibiot
prescript
fig
pharmacist
attend
train
workshop
becam
dbnd
trainer
lectur
provid
dbnd
trainer
nurs
school
ece
programm
target
nurs
ece
student
manag
classroom
childcar
agenc
particip
programm
impact
children
teacher
famili
feedback
pharmacist
trainer
nurs
instructor
student
children
teacher
posit
programm
open
new
line
commun
school
board
public
health
depart
conclus
multistep
approach
improv
pharmacist
knowledg
antibiot
resist
confid
commun
other
involv
nurs
ece
student
increas
capac
provid
commun
educ
appropri
antibiot
use
alberta
aim
reduc
rate
antibiot
resist
mh
nabuursfranssen
g
weerspothoff
car
groot
r
besselink
p
steenberg
g
morrow
f
dijkstra
horrevort
nijmegen
den
bosch
oss
herpen
bilthoven
nl
object
q
fever
worldwid
zoonosi
caus
coxiella
burnetii
goat
sheep
cattl
describ
common
anim
reservoir
birth
product
infect
anim
import
sourc
environment
contamin
transmiss
human
occur
aerosol
rout
ingest
non
pasteuris
milk
product
late
spring
outbreak
q
fever
south
east
netherland
result
januari
novemb
confirm
probabl
case
q
fever
south
east
netherland
wherea
normal
case
would
expect
annual
whole
countri
area
popul
primarili
rural
patient
report
sudden
onset
high
fever
sweat
cough
headach
muscl
pain
everi
femal
median
age
year
histori
smoke
fortynin
percent
patient
admit
hospit
pneumonia
except
two
patient
hepat
one
patient
endocard
patient
treat
moxifloxacin
mg
daili
day
recov
within
hour
howev
patient
still
complaint
mainli
fatigu
may
develop
chronic
q
fever
pregnant
women
screen
activ
infect
treat
cotrimoxazol
rest
pregnanc
long
dri
hot
spell
spring
year
coxiella
burnetii
highli
resist
chemic
heat
surviv
long
period
environ
may
contribut
outbreak
sourc
outbreak
still
investig
transmiss
almost
certainli
way
aerosol
conclus
larg
outbreak
q
fever
south
east
netherland
patient
suffer
pneumonia
implic
transmiss
probabl
caus
aerosol
rout
climat
chang
may
contribut
except
larg
outbreak
q
fever
netherland
object
varicella
infect
pregnanc
pose
seriou
risk
foetu
mother
current
uk
practic
regard
exposur
pregnanc
immun
test
varicella
immunoglobulin
vzig
administr
nonimmun
women
may
provid
best
patient
care
sinc
vaccin
avail
addit
verbal
follow
serolog
screen
primigravida
give
neg
histori
antenat
book
postnat
vaccin
nonimmun
may
costeffect
current
polici
studi
aim
retrospect
compar
cost
current
polici
cost
estim
antenat
screen
postpartum
vaccin
n
ireland
conclus
high
immunis
coverag
prevent
parot
outbreak
although
complic
seem
occur
rare
expect
although
preliminari
data
suggest
cohort
effect
point
problem
occur
specif
vaccin
year
investig
plan
explain
event
avoid
futur
epidem
antibiot
stewardship
icu
today
tomorrow
symposium
arrang
esgap
futur
antibiot
intens
care
patient
although
good
treatment
option
avail
common
infect
antibacteri
resist
risen
dramat
icu
need
new
compound
without
crossresist
exist
drug
appar
meticillinresist
staphylococcu
aureu
panresist
pseudomona
acinetobact
recognis
major
resist
threat
mani
icu
patient
left
without
therapeut
option
resist
avail
antibiot
doubt
resist
outrun
antibacteri
research
develop
sinc
focu
pharmaceut
compani
shift
antibacteri
lucr
diseas
area
promis
meet
financi
target
big
compani
reduc
risk
speed
develop
time
mani
compani
present
limit
antibacteri
programm
build
exist
class
antibiot
develop
analogu
lead
second
third
gener
origin
compound
thu
crossresist
newer
agent
develop
short
order
abund
pool
exist
resist
gene
gener
develop
effort
mainli
focus
antistaphylococc
drug
target
suffici
larg
market
new
drug
analogu
known
antibacteri
group
case
medic
need
new
antistaphylococc
drug
met
sever
new
antibiot
expect
launch
within
next
two
year
clinic
develop
activ
multiresist
gramneg
pathogen
includ
pseudomona
acinetobact
virtual
nonexist
look
toward
come
year
new
antibiot
anticip
new
scaffold
close
preclin
stage
develop
recent
sign
regain
interest
field
resist
gramneg
infect
compani
compani
also
academ
research
site
exploit
unconvent
highrisk
approach
pursu
new
target
difficult
assess
potenti
new
approach
remain
seen
yield
use
antibiot
icu
futur
case
take
least
year
see
fruit
current
research
effort
gramneg
field
therefor
prudent
use
exist
antibiot
improv
dosag
regim
surveil
effort
stringent
adher
infect
control
guidelin
essenti
preserv
power
exist
antibiot
critic
illpati
admit
icu
highli
suscept
infect
predispos
ill
use
invas
procedur
therefor
expos
high
antibiot
pressur
high
increas
preval
antibiot
resist
bacteria
among
patient
admit
european
hospit
addit
high
antibiot
consumpt
shortcom
infect
control
measur
increas
risk
signific
outbreak
caus
antibioticresist
pathogen
among
critic
ill
countri
previous
low
resist
level
scandinavia
finland
netherland
frequenc
multidrug
resist
mdr
particularli
mrsa
may
increas
rapidli
surveil
measur
combat
outbreak
fail
need
earli
warn
system
emerg
andor
increas
antibiot
resist
local
nation
intern
use
appar
programm
continu
yearli
registr
antibiot
use
resist
clinic
practic
automat
feedback
websit
develop
use
icu
launch
careicu
antibiot
isol
speci
suscept
defin
treatment
altern
novel
index
suscept
measur
magnitud
mdr
thirti
four
icu
countri
particip
larg
pilot
median
yearli
admiss
admiss
day
respect
four
import
main
find
first
report
careicu
first
antibiot
consumpt
vari
wide
rel
high
median
consumpt
second
level
antibiot
resist
high
mani
set
vari
also
greatli
speci
icu
countri
find
half
particip
icu
one
treatment
altern
p
aeruginosa
least
suscept
aminoglycosid
ceftazidim
ciprofloxacin
carbapenem
alarm
third
lack
room
isol
precaut
cohort
care
patient
colonis
infect
alert
organ
four
antibiot
guidelin
includ
routin
discontinu
antibiot
avail
high
antibiot
consum
icu
low
complianc
show
need
effect
tool
chang
prescript
behaviour
sustain
surveil
complianc
guidelin
gener
role
pneumococc
conjug
vaccin
protect
adult
diseas
antibiot
resist
despit
extens
global
contribut
paediatr
vaccin
health
age
last
decad
adult
infecti
diseas
expert
commun
continu
show
lack
interest
paediatr
vaccin
yet
licens
paediatr
vaccin
tremend
effect
morbid
adult
two
main
mechan
respons
effect
childhood
vaccin
adult
vaccin
child
grow
vaccin
adult
instanc
adult
may
protect
hesh
might
show
modifi
diseas
vaccin
children
often
show
reduct
carriag
spread
pathogen
adult
protect
diseas
herd
immun
time
effect
benefici
adult
instanc
pertussi
varicella
vaccin
effect
could
increas
diseas
adult
vaccin
programm
implement
properli
complex
relationship
paediatr
vaccin
adult
diseas
demonstr
exampl
pertussi
varicella
pneumococc
hepat
vaccin
time
come
chang
term
paediatr
vaccin
appropri
term
vaccin
life
c
weilolivi
colomb
fr
children
especi
infant
toddler
schoolag
one
high
attack
rate
yearli
influenza
season
epidem
epidemiolog
data
confirm
anterior
children
epidem
peak
adult
adult
care
paediatr
vaccin
one
two
week
longer
durat
viral
shed
higher
viral
titr
nasopharynx
compar
adult
associ
promiscu
day
care
centr
school
explain
children
major
vector
role
respiratori
transmiss
intervent
childhood
limit
influenza
viru
circul
commun
provid
indirect
protect
herd
immun
adult
larg
immunis
programm
children
investig
differ
set
measur
protect
contact
household
commun
larg
far
routin
immunis
schoolag
children
appear
effect
prevent
diseas
burden
commun
adult
contact
sever
studi
nevertheless
methodolog
discrep
render
imprecis
estim
strategi
effect
prevent
fraction
achiev
adult
impact
commun
depend
coverag
rate
achiev
vaccin
efficaci
contact
pattern
simul
model
take
account
differ
efficaci
figur
influenza
vaccin
assum
protect
efficaci
efficaci
infecti
differ
coverag
level
suggest
coverag
rate
schoolchildren
would
result
much
mortal
reduct
elderli
vaccin
person
age
nevertheless
univers
influenza
immunis
strategi
schoolchildren
demonstr
benefit
term
reduct
diseas
burden
either
observ
studi
mathemat
model
adult
elderli
point
must
rais
routin
vaccin
school
age
children
shown
decreas
indirect
effect
burden
diseas
infant
younger
children
highli
infecti
thu
transmit
viru
risk
hospitalis
sever
influenza
diseas
far
american
recommend
immunis
first
month
age
sinc
month
age
mainli
base
reduct
morbid
hospitalis
mortal
target
group
sourc
concern
low
coverag
rate
achiev
postrecommend
us
especi
full
primovaccin
demand
two
dose
year
age
demonstr
yet
routin
vaccin
children
year
age
indirect
impact
popul
europ
inject
trival
inactiv
influenza
vaccin
tiv
sole
avail
rais
issu
accept
famili
nation
public
health
point
view
feasibl
programm
huge
increas
resourc
adequ
inform
strategi
tiv
efficaci
may
vari
depend
child
age
match
strain
wildvaccin
although
mathemat
model
assum
upper
rang
never
conserv
hypothesi
real
life
clearli
avail
intranas
live
attenu
influenza
vaccin
europ
could
opportun
enlarg
strategi
due
higher
protect
efficaci
easi
administr
pertussi
human
respiratori
diseas
due
bacterium
bordetella
pertussi
sinc
generalis
use
newborn
children
first
pertussi
vaccin
call
pertussi
wholecel
pw
vaccin
compos
inactiv
bacteri
suspens
pertussi
still
endem
use
pw
vaccin
led
dramat
decreas
incid
diseas
children
conduct
demonstr
confirm
pertussi
paediatr
diseas
pertussi
infect
children
well
adolesc
adult
diseas
dramat
newborn
also
person
risk
elderli
pregnant
women
one
characterist
pertussi
induc
short
immun
well
pw
vaccin
human
infect
two
three
time
life
twenti
year
introduct
pw
vaccin
children
adult
immun
contamin
newborn
young
vaccin
reason
introduct
vaccin
booster
need
possibl
develop
pertussi
acellular
pa
vaccin
compos
purifi
inactiv
bacteri
protein
sinc
vaccin
use
newborn
children
also
adolesc
adult
mani
develop
countri
australia
north
america
europ
howev
vaccin
coverag
adolesc
adult
still
low
mortal
newborn
less
month
age
observ
develop
countri
adequ
pertussi
surveil
report
system
import
implement
vaccin
strategi
must
reinforc
evalu
consequ
chang
pertussi
vaccin
use
pa
instead
pw
ii
vaccin
strategi
addit
adolesc
adult
booster
iii
characterist
diseas
necessit
develop
new
specif
sensit
standardis
biolog
diagnos
iv
bacteria
circul
sinc
herd
immun
modifi
univers
immunis
might
impact
properti
agent
diseas
vesikari
tamper
fi
worldwid
rotavirus
respons
half
million
death
sever
acut
childhood
gastroenter
annual
develop
countri
death
rare
hospitalis
rotavirusassoci
dehydr
common
dehydr
correct
diseas
wellnourish
children
selflimit
hospitalis
occur
children
month
age
suscept
life
threaten
dehydr
highest
howev
rotaviru
infect
rotaviru
gastroenter
continu
occur
older
children
well
adult
adult
rotaviru
infect
occasion
may
lead
symptomat
diseas
evid
endem
circul
rotaviru
adult
independ
winter
epidem
cycl
children
addit
adult
expos
children
rotaviru
gastroenter
frequent
infect
often
come
symptom
rotavirus
may
also
caus
outbreak
adult
close
commun
particularli
elderli
two
live
oral
rotaviru
vaccin
licens
recent
rotarix
tm
gsk
human
vaccin
given
two
dose
rotateq
tm
merck
co
inc
humanbovin
reassort
vaccin
given
three
dose
induc
protect
sever
rotaviru
gastroenter
caus
multipl
serotyp
rotaviru
neither
protect
rotaviru
infect
vaccin
shed
might
rare
transmit
remain
circul
vaccin
induc
protect
sustain
year
enough
pass
suscept
age
dehydr
howev
asymptomat
rotaviru
infect
mild
breakthrough
case
rotaviru
gastroenter
occur
vaccin
children
univers
mass
vaccin
rotaviru
introduc
number
countri
includ
usa
brazil
venezuela
mexico
europ
austria
belgium
licens
rotaviru
vaccin
effect
protect
immunis
individu
long
term
consequ
mass
vaccin
uncertain
pure
specul
evid
herd
immun
result
vaccin
exposur
adult
wild
type
rotaviru
gastroenter
children
might
result
wane
immun
actual
increas
rotaviru
gastroenter
adult
popul
prospect
immunis
target
popul
adult
rotaviru
vaccin
remain
distant
possibl
explor
futur
convent
approach
studi
transmiss
dynam
control
infecti
diseas
rest
principl
popul
ecolog
degre
tradit
statist
method
rise
rise
ever
cheaper
tool
examin
structur
chang
time
space
pathogen
host
genom
need
aris
modifi
popul
transmiss
dynam
framework
encompass
natur
select
act
host
pathogen
gener
concept
evolutionari
chang
talk
discuss
recent
work
examin
evolutionari
concept
base
stimul
phylogenet
tree
pathogen
within
transmiss
framework
b
evolut
drug
resist
pathogen
popul
includ
virus
bacteria
parasit
tropic
diseas
catastroph
failur
mrsa
control
hospit
myth
realiti
success
control
infecti
diseas
precis
mathemat
definit
mean
number
secondari
case
caus
typic
infecti
case
maintain
one
epidem
said
control
condit
met
though
transmiss
may
still
occur
infect
rate
may
temporarili
increas
well
decreas
longterm
reduct
incid
ultim
termin
chain
transmiss
guarante
provid
immigr
infecti
agent
popul
prevent
intervent
hand
hygien
may
expect
equal
effect
regardless
number
case
resourcelimit
control
measur
nurs
cohort
sideroom
isol
becom
less
effect
number
case
increas
exampl
lowlevel
mrsa
set
isol
facil
staf
level
may
suffici
allow
detect
case
effect
promptli
isol
contrast
highlevel
mrsa
set
resourc
limit
eg
limit
avail
isol
bed
insuffici
staf
level
delay
time
effect
isol
make
intervent
nurs
cohort
entir
unfeas
circumst
intervent
result
epidem
control
set
low
mrsa
preval
fail
high
preval
set
thu
two
stabl
outcom
possibl
even
ident
control
measur
place
intervent
put
place
earli
enough
success
maintain
infect
low
level
prevent
highlevel
mrsa
becom
establish
put
place
late
compromis
immigr
mrsa
set
ident
intervent
much
smaller
effect
slightli
suppress
mrsa
level
fail
reduc
preval
low
level
transit
two
outcom
known
mathemat
catastroph
also
catastroph
consequ
patient
welfar
simul
model
shown
stochast
fluctuat
immigr
mrsa
case
set
principl
lead
catastroph
shift
success
control
control
failur
talk
evid
catastroph
transit
also
occur
practic
review
make
use
new
statist
develop
analys
hospit
infect
data
highli
detail
mrsa
transmiss
data
enterococci
first
identifi
late
blood
patient
infect
endocard
ie
sinc
enterococci
primarili
e
faecali
recognis
caus
case
ie
behind
staphylococci
streptococci
also
report
common
caus
nosocomi
ie
cellwal
activ
agent
bactericid
mani
enterococci
recommend
therapi
enterococc
ie
mani
decad
synergist
combin
includ
week
cellwal
activ
agent
plu
aminoglycosid
ag
recent
studi
suggest
shorter
ag
regimen
strain
highlevel
resist
ag
combin
ampicillin
ceftriaxon
may
also
adequ
efficaci
e
faecali
ie
therapi
endocard
caus
vancomycin
resist
e
faecium
remain
problemat
rel
littl
known
pathogenesi
enterococc
ie
recent
studi
identifi
pili
e
faecali
encod
ubiquit
ebp
endocard
biofilm
relat
pili
locu
made
subunit
characterist
cell
wall
anchor
mscramm
show
import
pili
initi
biofilm
experiment
ie
eie
seruminduc
adher
fibrinogen
suggest
pilu
structur
involv
initi
e
faecali
ie
ebp
locu
regul
part
fsr
system
homologu
agr
system
staphylococci
also
identifi
ubiquit
collagen
adhesin
ace
also
mscramm
whose
express
induc
serum
collagen
found
adhesin
also
import
e
faecali
eie
similarli
shown
homologu
acm
adhesin
collagen
e
faecium
import
pathogenesi
e
faecium
eie
adher
heart
valv
first
factor
shown
import
virul
speci
preliminari
data
suggest
immunis
recombin
ace
acm
protect
eie
produc
speci
base
genom
search
e
faecali
e
faecium
number
mscramm
gene
encod
adhesin
ecm
protein
futur
studi
may
reveal
addit
contribut
ie
anoth
factor
shown
import
e
faecali
ie
gelatinas
proteas
produc
e
faecali
despit
fact
encod
gene
gele
found
stain
delet
part
regulatori
locu
fsr
explain
lack
gelatinas
product
mani
strain
aggreg
substanc
encod
pheromon
respons
plasmid
found
e
faecali
cytolysinhemolysin
may
influenc
size
eie
veget
mortal
produc
e
faecali
respect
addit
studi
need
defin
role
factor
enterococc
eie
abil
passiv
activ
immunis
prevent
diseas
enterococcu
faecali
enterococcu
faecium
evolv
socal
highrisk
enterococc
clonal
complex
hirecc
defin
specif
clade
isol
multipl
antibiot
resist
trait
epidemiolog
associ
either
colonis
infect
hospitalis
patient
one
hirecc
e
faecium
repres
distinct
pandem
clonal
complex
extrem
success
hospit
acquir
isol
also
e
faecali
specif
genet
subpopul
exist
like
enrich
among
nosocomi
isol
classifi
hirecc
thu
e
faecali
e
faecium
isol
belong
hirecc
share
nich
potenti
virul
gene
exchang
extent
genet
exchang
especi
virul
gene
two
speci
unknown
disclos
assess
presenc
ortholog
e
faecali
e
faecium
clinic
isol
compar
genom
hybridis
whole
genom
sequenc
implement
identifi
gene
specif
distinguish
gene
notabl
specif
element
resist
gene
gene
put
encod
cell
surfac
protein
metabol
pathway
subset
e
faecium
gene
ortholog
gene
identifi
among
e
faecali
bloodstream
isol
eight
ortholog
highli
similar
gene
previous
found
e
faecali
element
contain
sever
gene
relat
virul
speci
sequenc
ident
ortholog
gene
e
faecali
e
faecium
consider
higher
sequenc
ident
core
genom
two
speci
base
silico
comparison
reflect
rel
high
averag
rrna
sequenc
diverg
low
averag
nucleotid
ident
housekeep
gene
e
faecium
ortholog
though
highli
similar
e
faecali
element
similarli
organis
one
cluster
separ
stretch
gene
order
partial
invert
presenc
highli
similar
gene
hirecc
e
faecium
e
faecali
suggest
genet
exchang
preval
clinic
enterococc
subpopul
common
element
addit
e
faecium
e
faecali
specif
virul
determin
might
contribut
pandem
spread
nosocomi
enterococc
infect
enterococci
among
three
common
nosocomi
pathogen
due
multipl
antibiot
resist
caus
substanti
morbid
mortal
especi
among
intens
care
patient
immunocompromis
sever
new
antibiot
introduc
last
decad
resist
new
drug
develop
spread
rapidli
altern
treatment
prevent
strategi
desper
need
counter
rise
multipli
resist
clone
hospit
nurs
home
worldwid
basic
understand
mechan
respons
transit
normal
benign
commens
danger
pathogen
better
understand
virul
factor
enabl
enterococci
access
bloodstream
caus
system
infect
help
target
new
therapeut
prophylact
approach
compar
gramposit
pathogen
rel
littl
know
surfac
antigen
enterococci
may
use
vaccin
target
sever
protein
aggreg
substanc
ace
adhesin
collagen
efaa
abc
transport
complex
esp
studi
although
data
exist
protect
efficaci
antigen
appropri
anim
model
newli
identifi
pili
e
faecali
associ
adhes
biofilm
format
pathogen
sinc
antigen
highli
immunogen
antibodi
structur
may
promis
candid
immunotherapi
sever
carbohydr
antigen
identifi
e
faecali
far
inform
exist
e
faecium
similar
gramposit
bacteria
enterococci
possess
membraneassoci
lipoteicho
acid
lta
peptidoglycanassoci
wall
teichoic
acid
wta
lta
shown
target
protect
antibodi
e
faecali
e
faecium
infect
inform
exist
wta
addit
capsular
polysaccharid
antigen
consist
diheteroglycan
identifi
e
faecali
strain
antigen
also
elicit
opson
antibodi
make
like
candid
vaccin
approach
taken
togeth
sever
promis
vaccin
candid
among
surfac
carbohydr
antigen
well
among
protein
antigen
studi
far
conjug
protein
target
carbohydr
compon
may
enhanc
immunogen
broaden
coverag
vaccin
knowledg
clinic
applic
mode
vaccin
passiv
vs
activ
immunotherapi
time
applic
identif
patient
popul
profit
need
acquir
order
develop
success
immunotherapi
strategi
epidemiolog
vancomycinresist
enterococci
vre
europ
recent
chang
initi
scenario
consist
polyclon
enterococc
popul
high
divers
strain
transpos
element
encod
vancomycin
resist
commun
scarc
presenc
nosocomi
set
last
year
six
european
countri
report
preval
rate
hospit
nosocomi
vre
outbreak
frequent
describ
clonal
plasmid
outbreak
document
european
hospit
complex
epidemiolog
situat
involv
strain
enterococcu
faecali
andor
enterococcu
faecium
differ
mobil
genet
element
frequent
report
institut
high
vre
rate
popul
genet
studi
shown
vre
isol
hospitalis
patient
belong
worldwid
dissemin
hospit
highrisk
clonal
complex
hhrcc
e
faecali
e
faecium
often
resist
multipl
antibiot
vre
nonhospitalis
individu
anim
belong
cc
addit
specif
hhrcc
clone
within
hhrcc
becom
relev
persist
dissemin
vre
horizont
transfer
also
import
recent
spread
vre
european
hospit
although
plasmid
outbreak
describ
sinc
earli
frequent
type
acquir
glycopeptid
resist
found
vana
gene
code
resist
part
usual
locat
conjug
plasmid
variant
contain
mutat
delet
differ
insert
sequenc
describ
appar
high
divers
host
specif
genet
element
suggest
howev
detect
differ
variant
common
plasmid
platform
suggest
frequent
genet
exchang
event
within
particular
wide
dissemin
plasmid
chang
epidemiolog
vre
european
hospit
seem
occur
emerg
dissemin
specif
plasmid
hhrcc
resist
multipl
antibiot
possibl
transmiss
virulentthan
other
situat
endem
polyclon
outbreak
difficult
handl
sinc
limit
therapeut
option
requir
genotypingtarget
infect
contain
detail
characteris
epidem
vre
strain
mobil
element
help
understand
reason
involv
evolutionari
outcom
hhrcc
differ
countri
background
insert
sequenc
belong
famili
identifi
repeatedli
acinetobact
baumannii
often
associ
antibiot
resist
gene
particular
shown
provid
promot
sequenc
enhanc
express
natur
cephalosporinas
ampc
oxacillinas
baumannii
addit
two
copi
bracket
may
form
composit
transposon
origin
acquisit
carbapenemhydrolys
oxacillinas
gene
transposas
form
two
open
read
frame
like
give
rise
function
transposas
frameshift
occur
studi
aim
evalu
transposit
abil
method
evalu
experiment
abil
transpos
escherichia
coli
first
step
blactamas
gene
insert
provid
ampicillin
resist
marker
allow
trace
structur
clone
ptopo
vector
transform
reca
e
coli
harbor
conjug
plasmid
use
target
transposit
event
transposit
event
onto
select
conjug
plasmid
azideresist
e
coli
techniqu
use
evalu
transposit
abil
also
role
frameshift
transposas
express
evalu
elimin
frameshift
transposas
encod
gene
sitedirect
mutagenesi
result
transposit
obtain
frequenc
per
e
coli
donor
sequenc
target
site
transposit
reveal
systemat
duplic
upon
transposit
adeninerich
hotspot
target
transposit
transposit
frequenc
mutat
transposas
gene
made
uniqu
frame
mobil
demonstr
frequenc
transposit
estim
conclus
studi
iss
first
demonstr
function
widespread
mobil
element
frameshiftmedi
downregul
transposit
assess
well
function
composit
transposon
invivo
model
allow
experi
abl
evalu
possibl
select
factor
antibiot
enhanc
object
acinetobact
baumannii
becom
preval
nosocomi
pathogen
due
spread
major
epidem
lineag
divers
intrins
gene
may
provid
insight
evolut
speci
studi
aim
examin
relationship
sequenc
enzym
famili
properti
collect
baumannii
isol
method
sixti
baumannii
isol
gene
amplifi
pcr
use
extern
primer
product
sequenc
identifi
use
blast
multalin
softwar
extern
primer
allow
simultan
identif
upstream
gene
mic
imipenem
meropenem
determin
accord
british
societi
antimicrobi
chemotherapi
bsac
guidelin
isol
assign
sequenc
group
sg
base
pcr
amplif
fragment
ompa
csue
gene
publicli
avail
aminoacid
sequenc
retriev
use
construct
linkag
map
show
relationship
enzym
one
anoth
result
linkag
map
reveal
enzym
form
close
relat
cluster
other
less
close
relat
largest
number
isol
includ
european
clone
ii
contain
enzym
cluster
assign
second
largest
group
isol
includ
european
clone
contain
enzym
cluster
assign
third
largest
isol
group
includ
european
clone
iii
assign
contain
enzym
eight
isol
contain
enzym
found
major
cluster
could
assign
sg
found
upstream
gene
ten
isol
associ
enzym
branch
tip
cluster
mic
imipenem
meropenem
rang
mgl
respect
mgl
antibiot
isol
upstream
gene
tend
mic
toward
higher
end
rang
mgl
mgl
conclus
repres
preval
epidem
lineag
baumannii
encod
specif
subset
enzym
preval
also
associ
specif
enzym
minor
isol
group
use
type
scheme
evolut
enzym
appear
occur
real
time
object
acinetobact
baumannii
ab
well
recognis
nosocomi
pathogen
especi
criticallyil
patient
emerg
multidrug
resist
mdr
carbapenemresist
ab
isol
constitut
major
therapeut
challeng
outbreak
caus
mdr
ab
mostli
report
tropic
subtrop
area
mediterranean
countri
report
characteris
produc
ab
strain
isol
acut
belgian
hospit
method
mdr
ab
isol
recov
patient
environ
phenotyp
genet
pcrsequenc
pfge
characteris
resist
pattern
analys
disc
diffus
mic
determin
pcrsequenc
perform
blaimp
blavim
gene
gene
blatem
gene
chromosom
class
c
blactamas
blaampc
gene
presenc
insert
sequenc
element
upstream
detect
blactamas
gene
also
analys
mdrand
carbapenemresist
ab
recov
one
belgian
resid
transfer
morocco
diagnosi
pneumonia
subsequ
month
period
similar
mdrab
isol
found
patient
pneumonia
asymptomat
throat
colonis
five
patient
hospitalis
pneumolog
ward
intens
care
unit
outbreak
secondarili
spread
mdrab
clinic
isol
posit
sequenc
present
immedi
upstream
gene
environment
sampl
obtain
outbreak
also
yield
mdr
ab
clinic
environment
isol
confirm
pfge
clonal
relat
implement
reinforc
infect
control
measur
addit
mdr
ab
isol
neither
patient
environ
conclus
data
highlight
import
intercountri
transfer
spread
mdr
carbapenemresist
produc
ab
propens
opportunist
pathogen
caus
major
nosocomi
outbreak
systemat
screen
implement
addit
precaut
mandatori
patient
transfer
highrisk
area
object
investig
control
outbreak
carbapenemresist
acinetobact
baumannii
method
outbreak
investig
descript
analysi
casecontrol
studi
environment
sampl
molecular
type
acinetobact
baumannii
isol
use
randomli
amplifi
polymorph
dna
rapd
primer
pulsedfield
gel
electrophoresi
pfge
carri
detect
oxatyp
carbapenemas
perform
multiplex
pcr
casecontrol
studi
case
defin
patient
outbreak
strain
control
defin
patient
minimum
durat
intens
care
unit
icu
stay
day
select
mainli
affect
icu
outbreak
period
odd
ratio
calcul
univari
analysi
multipl
logist
regress
analysi
perform
identifi
independ
risk
factor
acquisit
outbreak
strain
result
patient
acquir
carbapenemresist
baumannii
similar
antibiogram
five
icu
two
ward
two
differ
tertiari
care
hospit
within
time
period
ten
month
two
isol
resist
penicillin
cephalosporin
ciprofloxacin
gentamicin
tobramycin
imipenem
meropenem
remain
suscept
colistin
tigecyclin
ie
isol
pandrugresist
isol
belong
one
major
strain
type
rapd
pattern
pulsotyp
subtyp
two
isol
belong
subtyp
carri
gene
addit
intrins
gene
like
mode
transmiss
crosstransmiss
colonis
infect
patient
environ
via
hand
personnel
multipl
logist
regress
analysi
show
sever
ill
mean
daili
sap
ii
score
median
intens
care
mean
daili
score
median
independ
risk
factor
acquisit
outbreak
strain
variabl
enhanc
infect
control
measur
enforc
standard
precaut
educ
personnel
cohort
patient
outbreak
strain
separ
ward
area
screen
icu
patient
baumannii
admiss
weekli
success
control
outbreak
conclus
first
report
outbreak
acinetobact
baumannii
carri
carbapenemas
germani
acinetobact
baumannii
within
hospit
set
object
endem
baumannii
clone
observ
numer
hospit
within
iberian
peninsula
associ
mortal
event
portug
studi
epidemiolog
evolut
within
univers
hospit
baumannii
imipenemresist
clone
describ
throughout
period
six
consecut
year
resist
blactam
includ
carbapenem
variabl
suscept
aztreonam
amikacin
tobramycin
common
clone
b
c
clone
show
lower
resist
profil
eg
suscept
ceftazidim
netilmicin
minocyclin
variabl
suscept
meropenem
cefepim
aztreonam
curious
exclud
one
isol
remain
irab
isol
n
recov
produc
oxacarbapenemas
first
time
hospit
produc
characteris
pulsotyp
clone
b
c
detect
strong
select
forc
within
hospit
set
histor
implic
establish
resist
phenotyp
evolut
bacteri
resist
togeth
aggress
therapeut
strategi
envis
mainten
best
adapt
abl
cope
variou
stress
agent
data
highlight
appar
success
irab
popul
suscept
bacteria
establish
produc
clone
express
wider
resist
profil
sever
antibiot
includ
tigecyclin
background
acinetobact
baumannii
import
opportunist
pathogen
respons
seriou
nosocomi
infect
multidrug
resist
common
carbapenem
often
remain
among
therapeut
option
product
acquir
oxatyp
carbapenemas
ambler
class
lineag
appear
major
mechan
acquir
carbapenem
resist
baumannii
report
first
detect
carbapenemresist
baumannii
produc
carbapenemas
itali
method
bacteri
identif
carri
phenotyp
molecular
approach
suscept
test
carri
broth
microdilut
etest
genotyp
carri
rapd
type
csue
ompa
gene
oxatyp
metallocarbapenemas
determin
investig
pcr
sequenc
result
two
carbapenemresist
baumannii
isol
vares
univers
hospit
northern
itali
bal
two
icupati
isol
differ
carbapenemresist
baumannii
hospit
high
level
carbapenem
resist
imipenem
meropenem
mic
mgl
also
resist
expandedspectrum
cephalosporin
aminoglycosid
amikacin
gentamicin
ciprofloxacin
suscept
colistin
characteris
carbapenemas
gene
reveal
presenc
allel
isol
genotyp
show
two
isol
ident
belong
european
clone
ii
also
clonal
relat
lowerlevel
carbapenemresist
isol
hospit
found
produc
determin
surround
genet
context
similar
previous
describ
plasmidmedi
determin
conclus
best
knowledg
first
report
baumannii
produc
itali
isol
notic
exceedingli
high
level
carbapenem
resist
spread
hospit
interestingli
clonal
relat
european
clone
ii
exhibit
remark
propens
evolv
carbapenem
resist
differ
mechan
object
class
carbapenemas
carri
acinetobact
spp
confin
portug
produc
recent
identifi
first
baumannii
clinic
isol
aim
work
characteris
recent
isol
strain
baumannii
associ
outbreak
portugues
hospit
investig
clonal
relatd
endem
clone
method
nineteen
imipenemresist
isol
baumannii
revov
four
portugues
hospit
ambulatori
patient
studi
isol
identifi
sequenc
rrna
gene
suscept
antibiot
test
disk
diffus
method
vitek
system
mic
tigecyclin
colistin
determin
agar
dilut
method
oxacillinas
gene
sought
multiplex
pcr
insert
sequenc
upstream
gene
also
search
pcr
pfge
apai
perform
comparison
isol
endem
clone
baumannii
isol
resist
blactam
antibiot
test
tigecyclin
colistin
isol
involv
hospit
outbreak
mostli
suscept
aminoglicosid
one
suscept
amikacin
anoth
one
resist
antibiot
pcr
assay
detect
presenc
detect
upstream
gene
isol
except
one
pfge
show
isol
profil
relat
imipenemresist
baumannii
clone
dissemin
throughout
countri
includ
endem
produc
baumannii
clone
conclus
emerg
produc
baumannii
occur
sever
portugues
hospit
associ
outbreak
sporad
case
interest
relatd
endem
clone
although
enlarg
resist
profil
support
plasmid
acquisit
two
oxacillinas
well
adapt
baumannii
clone
note
recoveri
produc
ambulatori
patient
promot
commun
dissemin
object
upregul
rndtype
efflux
system
adeabc
implic
reduc
suscept
tigecyclin
baumannii
adeabc
express
control
twocompon
regulatori
system
ader
investig
role
pump
emerg
tigecyclin
resist
use
preand
posttreat
pair
clinic
isol
method
isol
identifi
profil
suscept
first
determin
bsac
disc
methodolog
agar
dilut
etest
isosensitest
agar
pfge
use
determin
related
express
efflux
pump
adeabc
regulatori
protein
ader
examin
realtim
revers
transcriptas
rt
pcr
use
primer
specif
adeb
ader
respect
quantifi
rel
rna
polymeras
beta
subunit
gene
rpob
use
refer
two
baumannii
isol
recov
abdomin
drain
fluid
old
woman
undergon
cholecystectomi
inter
alia
receiv
cours
tigecyclin
differ
suscept
observ
preand
posttreat
isol
mic
mgl
mgl
respect
patient
sinc
made
full
recoveri
isol
ident
pfge
profil
belong
preval
uk
strain
clone
carbapenemas
initi
suscept
tigecyclin
polymyxin
realtim
rtpcr
identifi
increas
adeb
gene
express
posttreat
isol
concomit
differ
ader
express
observ
conclus
clone
widespread
multiresist
lineag
report
emerg
resist
tigecyclin
therapi
repres
resist
associ
increas
express
adeabc
efflux
system
alter
express
known
regulatori
gene
ader
suggest
may
crosstalk
adeabc
transact
regulatori
factor
object
signific
increas
acinetobact
resist
carbapenem
note
czech
republ
aim
studi
assess
preval
epidemiolog
resist
among
hospit
strain
acinetobact
spp
method
isol
collect
prospect
via
network
diagnost
laboratori
januari
april
laboratori
ask
send
clinic
isol
acinetobact
spp
intens
care
unit
icu
one
isol
per
patient
isol
per
icu
isol
identifi
speci
aflp
assess
related
use
aflp
pfge
suscept
antimicrobi
agent
primarili
effect
baumannii
test
disk
diffus
mic
determin
carbapenem
result
total
acinetobact
isol
obtain
icu
hospit
citi
identifi
baumannii
n
genom
sp
n
genom
sp
tu
n
speci
n
use
aflp
cluster
analysi
baumannii
isol
alloc
eu
clone
ii
n
eu
clone
n
cluster
isol
n
uniqu
genotyp
nearli
clone
ii
isol
yield
ident
highli
similar
pfge
aflp
pattern
total
isol
resist
least
one
carbapenem
seventi
isol
suscept
antimicrobi
isol
show
resist
agent
isol
resist
agent
resist
agent
andor
carbapenem
mic
mgl
found
eu
clone
four
uniqu
strain
resist
one
two
carbapenem
mic
mgl
confin
eu
clone
ii
eu
clone
ii
isol
origin
icu
citi
show
follow
suscept
rate
piperacillin
ceftazidim
ampicillinsulbactam
imipenem
meropenem
gentamicin
tobramycin
amikacin
netilmicin
ofloxacin
doxycyclin
cotrimoxazol
increas
acinetobact
resist
carbapenem
czech
republ
associ
spread
multidrug
resist
baumannii
strain
belong
eu
clone
ii
high
genotyp
similar
isol
suggest
repres
recent
subgroup
within
clone
support
grant
ministri
health
czech
republ
object
detail
characteris
immun
respons
mycobacterium
tuberculosi
mtb
antigen
would
provid
new
insight
complex
hostparasit
interact
take
place
cours
tuberculosi
tb
offer
new
tool
accur
diagnosi
differ
stage
characteris
tb
diseas
method
measur
tcell
respons
bacillu
bcg
purifi
protein
deriv
ppd
earli
secretori
antigen
protein
cultur
filtrat
kda
measur
interferon
ifn
gamma
interleukin
il
releas
use
flow
cytometr
cellssecret
cytokin
detect
techniqu
peripher
blood
mononuclear
cell
pbmc
obtain
activ
tb
patient
latent
mtb
infect
individu
patient
pulmonari
diseas
differ
tb
healthi
donor
also
measur
test
possibl
role
indic
diseas
activ
result
confirm
enumer
ifngamma
releas
cell
upon
mtbspecif
stimul
suffici
identifi
tb
patient
cell
contribut
specif
respons
secret
cell
frequent
observ
latent
tb
infect
individu
activ
tb
patient
suggest
measur
cell
secret
cytokin
could
marker
diseas
stage
discrimin
role
associ
releas
tb
patient
conclus
togeth
data
indic
flow
cytometr
cytokinesecret
cell
detect
techniqu
power
tool
tb
diagnosi
allow
analysi
immun
respons
mtbrelat
antigen
differ
stage
tb
object
major
breakthrough
clinic
manag
tuberculosi
infect
develop
vitro
diagnost
test
measur
ifng
respons
stimul
antigen
igra
test
test
perform
excel
specif
concern
sensit
optim
especi
patient
immunesuppress
children
identifi
chemokin
novel
potenti
diagnost
biomark
tb
aim
studi
establish
diagnost
test
algorithm
base
compar
qftit
result
measur
level
plasma
supernat
quantiferon
tube
qftit
stimul
whole
blood
patient
cultur
andor
pcr
proven
activ
tb
unexpos
danish
high
school
student
unexpos
high
school
teacher
base
roc
curv
analysi
establish
two
cutoff
point
construct
diagnost
test
algorithm
inspir
qftit
test
posit
neg
indetermin
test
outcom
result
tb
patient
produc
significantli
higher
level
ifng
compar
control
ifng
median
pgml
iqr
pgml
vs
pgml
iqr
pgml
median
pgml
iqr
pgml
vs
pgml
iqr
pgml
ifng
respons
highli
correl
p
base
roc
curv
analysi
select
sensit
cutoff
pgml
specif
cutoff
pgml
cut
indetermin
test
establish
compar
mitogen
ratio
qftit
specif
test
show
compar
perform
equal
sensitivityspecif
agreement
kappa
tabl
sensit
test
higher
sensit
also
high
degre
posit
respond
among
control
primarili
among
older
teacher
discuss
express
respons
antigen
consist
signific
higher
level
ifng
properti
enabl
develop
diagnost
test
algorithm
posit
neg
indetermin
outcom
perform
excel
concord
compar
even
superior
discriminatori
power
compar
qftit
express
high
amount
hold
promis
develop
new
gener
sensit
tb
test
simpler
potenti
fieldfriendli
read
format
later
flow
dipstick
ca
famili
preval
studi
popul
follow
eai
lam
famili
compris
total
isol
respect
ca
eai
strain
domin
patient
born
indian
subcontin
east
africa
southeast
asia
lam
famili
common
patient
born
europ
uk
part
world
analysi
allel
divers
within
certain
loci
combin
result
spoligotyp
delet
map
allow
select
loci
greater
phylogenet
relev
etra
b
c
propos
vntr
code
combin
allel
variant
potenti
use
identif
famili
major
lineag
speci
within
mtbc
aim
studi
investig
signific
multiplemut
katg
gene
predomin
nucleotid
chang
correl
high
level
resist
isoniazid
mycobacterium
tuberculosi
isol
randomli
collect
sputa
patient
primari
secondari
activ
pulmonari
tuberculosi
differ
geograph
region
belaru
drug
suscept
test
determin
use
cdc
standard
convent
proport
method
dna
extract
katg
gene
amplif
dna
sequenc
analysi
perform
thirti
four
isol
found
multiplemut
compos
mutat
katg
gene
increas
number
predomin
mutat
nucleotid
chang
demonstr
codon
agc
acc
ggc
agc
ggt
gtt
higher
frequenc
among
patient
bear
secondari
tuberculosi
infect
elev
level
resist
isoniazid
mic
mgml
furthermor
demonstr
combin
mutat
predomin
nucleotid
chang
also
observ
codon
indic
higher
frequenc
mutat
among
patient
secondari
infect
respect
studi
n
multimut
isol
found
combin
mutat
predomin
nucleotid
chang
codon
agc
acc
ggc
gtt
ggt
ggt
also
demonstr
frequent
isol
patient
secondari
infect
bear
higher
level
resist
isoniazid
mgml
introduct
date
littl
inform
report
outcom
treatment
xdrtb
case
around
world
report
outcom
first
cohort
xdrtb
patient
iran
materi
method
patient
document
mdrtb
base
drug
suscept
test
dst
treat
standard
secondlin
regimen
consist
cycloserin
prothionamid
amikacin
ofloxacin
sinc
iran
perform
second
line
drug
suscept
xdrtb
case
identifi
treatment
outcom
extract
medic
record
result
patient
mdrtb
identifi
masih
daneshvari
hospit
tehran
iran
patient
seven
diagnos
xdrtb
four
patient
male
three
femal
seven
patient
hivneg
mean
age
patient
iranian
howev
republ
azerbaijan
one
afghanistan
one
seven
patient
primari
xdrtb
histori
previou
treatment
known
close
contact
remain
six
patient
histori
antitb
treatment
cure
failur
death
occur
case
treatment
outcom
unknown
one
patient
republ
azerbaijan
conclus
studi
show
poor
prognosi
patient
xdrtb
sinc
two
patient
seven
success
treat
without
relaps
major
posit
qft
tst
person
found
index
class
neighbour
class
logist
regress
analysi
show
signific
associ
posit
tst
result
bcg
vaccin
conclud
prior
bcg
vaccin
could
explain
high
preval
tst
posit
staff
qft
posit
individu
also
tst
posit
indic
suboptim
sensit
tst
among
person
risk
two
test
found
equal
amount
tuberculosi
infect
amongst
young
non
bcg
vaccin
group
take
account
everyon
volunt
test
qft
posit
student
detect
tst
among
staff
high
frequenc
tst
posit
explain
former
bcg
vaccin
choic
test
prefer
tb
contact
investig
base
profil
screen
popul
bcg
statu
age
countri
origin
use
test
time
two
step
evalu
accord
risk
popul
develop
tb
diagnosi
tuberculosi
tb
resourcepoor
countri
almost
exclus
base
microscopi
ziehlneelsen
stain
zn
sputum
smear
set
supplement
chest
xray
object
aim
studi
determin
accuraci
diagnosi
tb
zambia
era
increas
hiv
preval
appli
mgit
liquid
cultur
techniqu
studi
distinguish
tb
case
confirm
posit
mycobacterium
tuberculosi
cultur
ii
mycobacteriosi
caus
nontubercul
mycobacteria
ntm
iii
tuberculosislik
diseas
caus
organ
mycobacteria
method
adult
patient
includ
diagnos
tb
basi
respiratori
complaint
last
two
week
failur
improv
two
cours
empir
antibiot
posit
zn
sputum
smear
andor
find
chest
xray
consist
tb
sputa
presumpt
diagnos
tb
case
subject
mgit
liquid
cultur
mycobacterium
isol
identifi
use
nucleic
acid
amplif
method
dna
sequenc
presumpt
diagnos
tb
case
tuberculosi
cultur
exclus
ntm
found
anoth
presumpt
case
combin
tuberculosi
ntm
isol
remain
case
tb
diagnos
mycobacteria
cultiv
hiv
posit
significantli
correl
isol
ntm
sputum
invers
associ
isol
exclus
tuberculosi
p
base
diagnosi
tuberculosi
symptom
sputum
smear
andor
chest
xray
may
lead
signific
number
falseposit
case
tuberculosi
zambia
due
increas
preval
hiv
background
current
method
detect
determin
drug
resist
mycobacterium
tuberculosi
mtb
insensit
slow
pcr
accur
rapid
techniqu
requir
substanti
labour
technic
compet
pcr
also
affect
inhibitor
sampl
crosscontamin
limit
abil
concentr
sampl
limit
overcom
genexpert
system
autom
system
use
lowcost
plastic
cartridg
concentr
bacilli
present
sputum
sampl
remov
inhibitor
lyse
cell
transfer
dna
integr
pcr
tube
dna
amplifi
nest
realtim
pcr
use
optimis
sixcolour
molecular
beacon
assay
detect
rifampinresist
tb
strain
intern
sampl
process
reagent
control
also
includ
sampl
process
nest
pcr
occur
within
cartridg
extern
manipul
requir
sampl
initi
load
object
comprehens
evalu
genexpert
mtb
assay
use
sputum
sputum
pellet
sampl
simultan
detect
rifampin
resistanceassoci
mutat
rpob
core
region
key
evalu
criteria
analyt
perform
stabil
reagent
sampl
inactiv
combin
sampl
process
realtim
pcr
singl
autom
step
make
assay
simpl
perform
nearpati
laboratori
set
minim
effort
h
object
determin
frequenc
clinic
characterist
antituberculosi
drug
resist
pattern
mortal
hiv
tb
coinfect
patient
cohort
hiv
infect
patient
follow
tertiari
care
referr
centr
mexico
citi
specif
endpoint
defin
analys
relat
tuberculosi
infect
comorbid
lost
followup
primari
resist
antitb
drug
wherea
secondari
resist
two
case
mdrtb
detect
patient
relaps
poor
complianc
antitb
treatment
mortal
observ
case
last
visit
tuberculosi
caus
death
median
time
death
attribut
tb
day
iqr
frequenc
coinfect
popul
lower
expect
medium
incom
countri
primari
resist
antitb
drug
similar
observ
mexico
mortal
attribut
tb
low
happen
shortli
diagnosi
note
extrapulmonari
tb
common
cohort
mycobacterium
bovi
frequent
pathogen
object
mesotherapi
increas
use
techniqu
involv
subcutan
inject
minut
quantiti
variou
medic
drug
cosmet
rheumat
purpos
practic
alreadi
report
relat
infect
risk
januari
gener
practition
notifi
health
author
region
centr
infect
control
cluster
subcutan
infect
due
nontuberculosi
mycobacteria
ntm
follow
mesotherapi
epidemiolog
investig
perform
describ
outbreak
identifi
sourc
mechan
contamin
determin
risk
factor
case
definit
base
typic
clinic
subcutan
lesion
associ
posit
specimen
ntm
assess
practic
studi
perform
determin
potenti
risk
factor
test
compar
epidemiolog
studi
data
collect
includ
schedul
outpati
visit
localis
inject
type
inject
product
invas
candidiasi
candidaemia
common
system
fungal
infect
observ
hospit
increas
preval
risk
factor
infect
past
two
decad
dramat
increas
incid
period
infect
frequent
sever
crude
mortal
rate
natur
system
candida
infect
appear
chang
recent
major
infect
caus
candida
albican
speci
becom
less
common
nonalbican
candida
speci
begin
prolifer
particularli
certain
patient
type
recent
survey
epidemiolog
mycolog
profil
candida
speci
europ
candida
albican
still
common
caus
infect
overal
infect
caus
nonalbican
candida
speci
furthermor
surgic
patient
solid
tumour
patient
age
year
preval
c
glabrata
approach
see
tabl
signific
chang
candida
epidemiolog
may
profound
sinc
nonalbican
candida
speci
seem
associ
increas
risk
mortal
compar
c
albican
c
krusei
c
glabrata
c
tropicali
c
albican
howev
differ
may
explain
increas
preval
speci
patient
sever
underli
ill
isol
c
albican
gener
suscept
antifung
agent
nonalbican
candida
speci
particularli
c
glabrata
c
krusei
often
nonsuscept
older
agent
fluconazol
import
implic
select
appropri
antifung
therapi
patient
system
candida
infect
vitro
activ
import
measur
potenc
antifung
agent
well
use
guid
rel
clinic
activ
extent
resist
develop
recent
decad
increas
proport
candidaemia
case
involv
speci
fulli
suscept
fluconazol
mainli
c
glabrata
c
krusei
furthermor
although
candida
isol
acquir
azol
resist
still
observ
sporad
recent
studi
document
increas
emerg
c
glabrata
isol
voriconazol
elev
convers
amphotericin
b
echinocandin
anidulafungin
caspofungin
micafungin
potent
cidal
vitro
isol
major
candida
spp
includ
c
glabrata
although
slightli
higher
mic
observ
echinocandin
less
virul
speci
c
parapsilosi
see
tabl
vitro
activ
alon
use
measur
potenc
suscept
data
appli
develop
suscept
breakpoint
studi
examin
correl
pkpd
mic
clinic
success
rate
result
establish
breakpoint
fluconazol
candida
spp
microgml
eucast
microgml
clsi
clsi
suggest
breakpoint
microgml
microgml
voriconazol
echinocandin
respect
howev
recent
larg
populationbas
survey
includ
micafungintr
patient
lower
suscept
breakpoint
micafungin
microgml
suggest
clinic
experi
still
limit
regard
isol
mic
normal
rang
predict
speci
identif
studi
warrant
result
vitro
activ
studi
substanti
impact
treatment
choic
system
candida
infect
era
nonalbican
candida
speci
preval
suscept
test
method
applic
routin
test
avail
speci
identif
often
rapidli
avail
echinocandin
like
play
import
role
treatment
system
candida
infect
increas
use
continu
close
monitor
suscept
epidemiolog
necessari
micafungin
demonstr
efficaci
adult
invas
candidiasi
candidaemia
also
echinocandin
extens
experi
children
neonat
infect
furthermor
micafungin
shown
effect
neutropen
nonneutropen
patient
deep
invas
candida
infect
candidaemia
micafungin
also
broadspectrum
efficaci
across
major
candida
speci
data
suggest
micafungin
valuabl
option
treatment
seriou
invas
candida
infect
effect
treatment
invas
candidiasi
candidaemia
current
limit
lack
accur
reliabl
diagnost
tool
although
step
toward
ideal
taken
present
furthermor
resist
certain
candida
speci
c
glabrata
c
krusei
signific
grow
problem
antifung
treatment
particularli
fluconazol
agent
azol
class
micafungin
new
echinocandin
agent
offer
much
promis
treatment
invas
candidiasi
candidaemia
demonstr
high
treatment
success
rate
adult
children
neonat
micafungin
approv
treatment
system
candida
infect
japan
number
year
account
patientmonth
exposur
time
shown
effect
excel
toler
global
micafungin
administ
around
patient
includ
patient
clinic
studi
pool
analys
safeti
data
clinic
studi
conduct
wide
rang
indic
includ
system
candida
infect
prophylaxi
fungal
infect
haematopoiet
stem
cell
transplant
recipi
treatment
oesophag
candidiasi
demonstr
excel
toler
associ
micafungin
treatment
broad
rang
patient
type
see
tabl
saw
develop
mani
cephalosporin
fluoroquinolon
briefli
appear
beaten
gramneg
pathogen
often
occur
battl
man
microb
victori
prove
illusori
resist
widespread
seriou
clinic
implic
inadequ
treatment
owe
resist
correl
increas
mortal
among
serious
ill
patient
recent
critic
shift
europ
elsewher
includ
huge
increas
quinolon
resist
enterobacteriacea
particularli
escherichia
coli
rate
among
bacteraemia
isol
mostli
exceed
cephalosporin
resist
increas
larg
via
spread
plasmid
encod
extendedspectrum
blactamas
esbl
esbl
europ
mutant
old
tem
shv
penicillinas
larg
occur
nosocomi
klebsiella
spp
subsequ
ctxm
esbl
spread
extens
becom
frequent
e
coli
well
klebsiella
spp
produc
caus
infect
complic
commun
patient
well
hospit
predomin
ctxm
type
clonal
produc
vari
among
countri
takeov
remark
consist
mani
produc
resist
antibiot
except
carbapenem
fosfomycin
nitrofurantoin
accumul
cephalosporin
quinolon
resist
drive
use
carbapenem
larg
evad
esbl
ampc
enzym
although
resist
aris
strain
one
enzym
unusu
imperm
present
true
acquir
carbapenemas
remain
rare
speci
disturb
pointer
futur
spread
first
acinetobact
baumannii
clone
oxa
carbapenemas
alreadi
preval
intens
care
unit
icu
worldwid
secondli
klebsiella
clone
kpc
carbapenemas
spread
unit
state
report
europ
thirdli
grow
scatter
enterobacteriacea
nonferment
imp
vim
metalloblactamas
particularli
greec
itali
perhap
disturb
new
consist
activ
famili
antigramneg
agent
reserv
behind
carbapenem
like
becom
avail
next
decad
hospitalacquir
pneumonia
hap
common
healthcareacquir
infect
contribut
death
estim
increas
length
hospitalis
day
ventilatorassoci
pneumonia
vap
also
associ
increas
mortal
increas
length
stay
need
continu
mechan
ventil
therefor
present
uniqu
manag
challeng
key
pathogen
associ
nosocomi
pneumonia
includ
meticillinresist
staphylococcu
aureu
pseudomona
aeruginosa
acinetobact
baumannii
effect
manag
involv
accur
diagnosi
time
select
initi
appropri
antibiot
effect
dose
administr
rout
implement
optim
prevent
strategi
due
variabl
offend
organ
within
differ
treatment
set
initi
therapi
hap
vap
individualis
select
broadspectrum
agent
base
mani
variabl
includ
patient
risk
factor
eg
recent
antibiot
exposur
comorbid
durat
hospitalis
suspect
pathogen
pharmacokinet
consider
resist
dynam
follow
hour
therapi
patient
assess
deescal
strategi
base
clinic
respons
laboratori
test
dose
flexibl
patient
vap
sever
sepsi
crucial
ensur
optim
resolut
recent
clinic
trial
suggest
doripenem
might
provid
addit
valu
therapi
hap
includ
vap
multidisciplinari
approach
implement
paneuropean
guidelin
hap
base
care
bundl
view
opportun
optimis
manag
hap
europ
complic
intraabdomin
infect
ciai
therapeut
challeng
consum
signific
hospit
resourc
infect
organ
often
suspect
base
like
sourc
infect
eg
commun
acquir
healthcar
associ
locat
insult
intestin
perfor
therapi
complic
infect
polymicrobi
natur
continu
rise
resist
organ
commun
eg
escherichia
coli
hospit
set
eg
pseudomona
aeruginosa
made
antibiot
select
even
challeng
effect
manag
strategi
treatment
ciai
includ
limit
rapid
accur
diagnosi
antisepsi
therapi
time
administr
empir
antimicrobi
therapi
clinic
featur
associ
poor
outcom
includ
acut
physiolog
sever
inabl
obtain
adequ
control
sourc
infect
patient
sever
ciai
may
benefit
broadspectrum
activ
agent
agent
includ
carbapenem
blactamblactamas
inhibitor
combin
select
cephalosporin
combin
class
agent
recent
clinic
trial
suggest
doripenem
may
effect
initi
therapi
ciai
due
enhanc
microbiolog
potenc
resist
profil
p
aeruginosa
well
dose
optimis
flexibl
resist
antimicrobi
drug
grow
health
econom
concern
rate
resist
communityand
hospitalacquir
gramneg
gramposit
pathogen
risen
significantli
past
sever
year
infect
caus
drugresist
pathogen
associ
greater
morbid
mortal
prolong
hospitalis
increas
cost
compar
infect
sensit
strain
earli
identif
patient
higher
risk
polymicrobialresist
infect
key
factor
guid
select
empir
antibiot
therapi
select
agent
variou
class
antibiot
individualis
base
patient
clinic
statu
renal
function
agent
microbiolog
activ
coverag
resist
characterist
therapeut
dynam
prompt
select
appropri
broadspectrum
empir
antibiot
therapi
essenti
provid
adequ
coverag
pathogen
concern
get
right
start
use
pharmacokinet
pk
pharmacodynam
pd
simul
help
guid
decisionmak
process
select
antibiot
dosag
durat
infus
exampl
extend
infus
time
may
lead
better
outcom
treatment
infect
caus
organ
high
minimum
inhibitori
concentr
mic
valu
extend
time
mic
without
requir
increas
dosag
use
pkpd
data
augment
antibiot
exposur
carbapenem
includ
doripenem
present
million
infant
die
annual
acut
respiratori
diarrhoeal
infect
could
prevent
infant
immunis
earlier
unfortun
immun
immatur
respons
increas
vulner
infect
also
limit
vaccin
respons
major
challeng
address
inform
rapidli
accumul
mechan
limit
vaccin
respons
earli
life
potenti
circumv
strategi
recognit
limit
b
cell
respons
bacteri
polysaccharid
led
develop
conjug
vaccin
major
impact
prevent
infant
diseas
encapsul
bacteria
howev
even
potent
conjug
protein
vaccin
requir
multipl
vaccin
dose
overcom
immun
immatur
given
earli
life
issu
limit
introduct
mani
countri
world
limit
infant
b
cell
respons
result
interfer
antibodi
matern
origin
also
weaker
induct
antibodysecret
plasma
cell
within
germin
centr
emerg
gener
determin
magnitud
earli
life
antibodi
respons
call
develop
specif
adjuv
formul
importantli
infant
antibodi
respons
also
much
shorter
durat
elicit
later
life
may
result
secondari
vaccin
failur
infant
mice
rapid
declin
vaccineinduc
antibodi
result
failur
bone
marrow
nich
effici
support
plasma
cell
surviv
product
suffici
level
april
limit
factor
unlik
easili
circumv
call
administr
earli
booster
dose
contrast
limit
antibodysecretingcel
induct
memori
b
cell
may
readili
elicit
alreadi
neonat
period
understand
led
clinic
studi
human
neonat
receiv
first
dose
pertussi
vaccin
first
week
life
markedli
enhanc
respons
subsequ
vaccin
dose
observ
certain
studi
wherea
other
confront
issu
vaccin
interfer
numer
question
therefor
remain
open
includ
rel
magnitud
persist
vaccin
memori
elicit
earli
later
life
decad
infect
prevent
control
commun
regard
nosocomi
infect
right
passag
especi
critic
ill
patient
invas
devic
caus
optim
increas
number
hospit
intens
care
unit
report
dramat
reduct
rate
catheterassoci
bloodstream
infect
ventilatorassoci
pneumonia
seriou
infect
last
evid
regard
effect
infect
control
process
care
translat
practic
progress
facilit
applic
principl
reliabl
scienc
failur
adher
best
practic
regard
defect
care
develop
concis
bundl
evidencebas
practic
cull
exhaust
somewhat
cumbersom
guidelin
applic
execut
framework
includ
clear
aim
support
leadership
multidisciplinari
team
employ
qualiti
improv
method
bedsid
clinic
microsystem
clear
measur
outcom
success
parsimoni
set
driver
requir
achiev
outcom
advanc
technolog
principl
illustr
examin
method
use
reduc
major
nosocomi
infect
problem
mrsa
catheterassoci
bloodstream
infect
ventilatorassoci
pneumonia
deploy
strategi
import
underestim
complex
work
multipl
problem
time
well
impact
costresourc
potenti
unintend
consequ
laboratori
theoret
approach
shown
particular
circumst
exposur
new
environ
stress
condit
cell
increas
spontan
mutat
rate
hypermut
mutat
frequent
select
bacteri
popul
speed
bacteri
evolut
adapt
environ
first
survey
natur
bacteri
popul
conduct
e
coli
salmonella
spp
reveal
higher
expect
preval
mutat
around
support
hypothesi
hypermut
could
act
mechan
acceler
bacteri
evolut
natur
nevertheless
first
evid
specif
role
hypermut
human
infect
obtain
studi
p
aeruginosa
chronic
lung
infect
cystic
fibrosi
cf
patient
preval
hypermut
strain
far
highest
ever
found
natur
subsequ
studi
demonstr
hypermut
inde
common
featur
p
aeruginosa
chronic
respiratori
infect
occur
patient
chronic
underli
respiratori
diseas
cf
bronchiectasi
copd
preval
rang
patient
wherea
preval
mutat
strain
low
acut
infect
high
preval
mutat
cf
set
also
found
later
pathogen
aureu
h
influenza
result
recent
studi
involv
mous
model
chronic
infect
longterm
longitudin
studi
cf
isol
shown
hypermut
inde
play
relev
role
two
major
aspect
p
aeruginosa
chronic
respiratori
infect
bacteri
adapt
longterm
persist
infect
antimicrobi
resist
develop
molecular
basi
hypermut
defect
gene
involv
dna
repair
error
avoid
system
deepli
studi
e
coli
among
gene
code
epsilon
subunit
dna
polymeras
iii
dnaq
mutd
gene
involv
mismatch
repair
mmr
system
mut
mutl
muth
uvrd
mutu
gene
belong
go
system
dna
oxid
lesion
repair
mutt
mutm
muti
cf
p
aeruginosa
strain
well
natur
bacteri
popul
frequent
mechan
lead
hypermut
inactiv
mmr
system
along
mutat
rate
increas
also
rate
recombin
diverg
dna
sequenc
mutat
play
import
role
evolut
antibiot
resist
mechan
bacteria
either
refin
exist
horizont
acquir
genet
determin
eg
encod
blactamas
give
rise
variant
drug
target
decreas
affin
antibiot
point
mutat
eg
case
resist
fluroquinolon
rifampicin
mupirocin
fusid
acid
therefor
bacteria
exhibit
elev
mutat
frequenc
known
mutat
hypermut
may
select
advantag
expos
antibiot
clinic
set
natur
occur
hypermut
describ
number
pathogen
gramneg
speci
appear
particularli
promin
isol
pseudomona
aeruginosa
cystic
fibrosi
patient
possibl
molecular
basi
select
environ
discuss
although
aureu
hypermut
defici
methyldirect
mismatch
repair
mmr
system
creat
laboratori
eg
mut
mutl
mutant
occurr
staphylococc
hypermut
clinic
set
appear
variabl
group
report
presenc
other
furthermor
aureu
mutl
mutant
recent
report
exhibit
decreas
fit
model
chronic
bone
infect
evid
intermedi
suscept
vancomycin
clinic
isol
aureu
visa
evolv
hypermut
host
despit
fact
resist
vancomycin
strain
probabl
requir
multipl
mutat
chromosom
gene
therefor
hypermut
may
play
major
role
develop
antibiot
resist
aureu
possibl
reason
situat
discuss
osteomyel
establish
anaesthetis
cd
rat
inject
ml
sodium
morrhuat
follow
ml
cell
aureu
medullar
caviti
tibia
group
rat
n
receiv
treatment
singl
dose
parent
drug
mox
gat
rfb
rfz
prodrug
intraven
iv
administ
infect
treatment
initi
mox
iv
moxbp
mgkg
parent
equival
eq
day
mgkg
eq
gat
iv
gatbp
mgkg
eq
day
rfb
subcutan
sc
rfbbp
mgkg
eq
day
rfz
sc
rfzbp
mgkg
eq
tibia
harvest
infect
ground
determin
bacteri
titer
cfug
bone
result
prophylact
treatment
result
greater
efficaci
log
cfug
mox
also
remain
statist
p
activ
even
inject
day
infect
prophylaxi
gat
complet
ineffect
mgkg
eq
result
dose
depend
efficaci
log
cfug
respect
prophylaxi
reduc
bacteri
load
log
cfug
compar
rfb
rat
treat
rfz
sterilis
tibia
untreat
rat
log
cfug
conclus
bisphosphon
prodrug
test
format
highli
efficaci
demonstr
potenti
singl
dose
prodrug
prevent
osteomyel
spreer
r
lugert
v
stoltefaut
hoecht
h
eiffert
r
nau
de
object
bacteri
mening
sever
system
local
inflammatori
process
caus
longterm
impair
death
current
standard
therapi
reli
member
group
blactam
antibiot
ceftriaxon
inhibit
cell
wall
synthesi
antibiot
induc
bacteriolysi
lead
sudden
releas
high
amount
proinflammatori
toxic
bacteri
product
includ
bacteri
dna
haemolysin
eg
pneumolysin
produc
pneumonia
bactericid
proteinsynthesi
inhibit
antibiot
like
rifampicin
prevent
bacteriolysi
result
burst
inflamm
respect
certain
risk
secondari
resist
develop
rifampicin
monotherapi
combin
rifampicin
antibiot
mandatori
therefor
evalu
sequenti
combin
regimen
shorttim
rifampicin
pretreat
follow
addit
ceftriaxon
method
vitro
analys
releas
pneumolysin
bacteri
dna
pneumococc
broth
cultur
quantit
immunoblot
realtimepcr
vivo
evalu
rabbit
model
pneumococc
mening
influenc
rifampicin
pretreat
cerebrospin
fluid
csf
inflamm
hippocamp
neuron
damag
pneumococc
broth
cultur
rifampicin
pretreat
minut
significantli
reduc
ceftriaxoneinduc
releas
pneumolysin
bacteri
dna
likewis
vivo
rifampicin
pretreat
hour
follow
addit
ceftriaxon
significantli
reduc
marker
neuroinflamm
csf
ie
prostaglandin
total
protein
hour
initi
antibiot
therapi
reduc
inflamm
result
significantli
reduc
densiti
apoptot
neuron
hippocamp
dentat
gyru
compar
anim
treat
ceftriaxon
alon
combin
antibiot
treatment
result
slight
decreas
speed
bacteri
kill
nevertheless
rapidli
bactericid
pretreat
hour
bactericid
broadspectrum
antibiot
rifampicin
prior
therapi
blactam
antibiot
reduc
releas
proinflammatori
bacteri
product
vitro
attenu
inflamm
neuron
damag
vivo
concept
hold
promis
reduc
inflammationassoci
damag
sever
bacteri
infect
therefor
evalu
mening
therapi
clinic
trial
van
gennip
c
moser
l
dahl
christensen
bjarnsholt
h
calum
p
jensen
b
lee
ciofu
givskov
molin
n
copenhagen
lyngbi
dk
object
chronic
pulmonari
infect
cystic
fibrosi
cf
patient
continu
adapt
pseudomona
aeruginosa
one
import
trait
overproduct
algin
result
appear
mucoid
phenotyp
contribut
protect
antibiot
treatment
host
immun
respons
recent
introduc
novel
chronic
p
aeruginosa
lung
infect
model
mice
use
three
pair
sequenti
isol
isotyp
nonmucoid
mucoid
strain
one
patient
compar
degre
inflamm
treatment
initi
hour
result
less
inflamm
compar
untreat
group
isol
p
import
earli
treatment
compar
delay
treatment
seen
two
late
isol
signific
reduct
observ
p
isol
show
reduct
degre
inflamm
treatment
initi
hour
untreat
group
p
present
histopatolog
studi
emphas
import
earli
treatment
aim
mucoid
phenotyp
patient
cf
strategi
reduc
inflamm
therebi
decreas
lung
tissu
damag
martin
viveiro
l
amar
lisbon
pt
object
emerg
multidrug
resist
extensivelydrug
resist
mycobacterium
tuberculosi
mdrtbxdrtb
repres
major
threat
public
health
worldwid
mani
resist
strain
untreat
avail
drug
order
control
infect
need
new
nontox
antimicrobi
compound
phenothiazin
shown
direct
indirect
activ
larg
gamut
bacteria
may
consid
therapi
infect
demonstr
previou
studi
thioridazin
tz
enhanc
kill
mdrtb
phagocytos
human
monocytederiv
macrophag
howev
mechan
agent
enhanc
kill
intracellular
bacteria
fulli
understood
kill
activ
phagocyt
cell
neutrophil
demonstr
correl
k
avail
depend
upon
transport
process
affect
agent
inhibit
k
pump
order
clarifi
mechan
tz
enhanc
kill
activ
infect
macrophag
studi
activ
tz
twentytwo
tz
deriv
ouabain
reserpin
verapamil
known
inhibitor
k
transport
intracellular
bacteria
method
ex
vivo
studi
conduct
use
human
monocytederiv
macrophag
infect
mdrtb
subsequ
treat
tz
deriv
inhibitor
k
transport
anim
studi
conduct
use
balbc
mice
infect
tuberculosi
daili
treat
differ
dose
tz
bacteri
load
lung
monthli
assess
cfu
count
result
compound
enhanc
kill
intracellular
mdrtb
ex
vivo
tz
show
signific
effect
mous
cure
tuberculosi
infect
conclus
compound
also
inhibit
k
transport
process
enhanc
kill
postul
due
inhibit
k
transport
process
inhibit
promot
activ
hydrolas
subsequ
kill
intracellular
bacteria
model
provid
sequenc
event
lead
kill
intracellular
bacteria
nonkil
human
macrophag
present
detail
relat
cure
balbc
mice
infect
tuberculosi
administr
tz
dose
interv
equival
employ
therapi
psychosi
object
previous
report
exposur
clinic
isol
communityassoci
isol
staphylococcu
aureu
camrsa
daptomycin
dap
compar
vancomycin
van
result
dampen
macrophag
inflammatori
respons
reduc
product
tumour
necrosi
factor
tnf
nitric
oxid
hypothesis
daptomycin
therapi
soft
tissu
infect
caus
camrsa
would
associ
blunt
host
inflammatori
respons
result
less
sever
soft
tissu
lesion
less
dermonecrosi
method
inject
group
charl
river
hairless
immunocompet
mice
right
upper
thigh
muscl
cfu
three
differ
clinic
isol
camrsa
two
isol
employ
previouslystudi
clinic
isol
paediatr
patient
memphi
osteomyel
bacteraemia
lac
wellcharacteris
california
isol
one
usa
isol
usedth
wellcharacteris
minnesota
strain
inocul
initi
antibiot
treatment
either
dap
van
either
hour
hour
bacteri
inocul
anim
observ
daili
lesion
size
charact
record
result
mice
inject
higher
inoculum
cfu
either
two
isol
lac
isol
consist
develop
larg
soft
tissu
lesion
dermonecrosi
lesion
mice
treat
dap
compar
van
develop
markedli
less
dermonecrosi
also
somewhat
smaller
approxim
reduct
size
found
mous
model
dap
effect
van
treatment
sever
soft
tissu
infect
caus
strain
camrsa
novai
coma
r
tm
coqu
f
baquero
moya
jc
madrid
valencia
es
object
defin
differ
mutat
pathway
drive
diversif
gene
establish
hypothet
evolutionari
scenario
among
enzym
method
known
sequenc
align
use
clustalw
modeltest
programm
use
establish
best
model
dna
substitut
paramet
phylogenet
reconstruct
maximum
likelihood
tree
estim
phyml
obtain
consensu
tree
use
reconstruct
like
ancestr
sequenc
mesquit
softwar
chang
posit
consid
frequent
found
among
enzym
distinct
phenotyp
profil
might
observ
depend
allel
background
epistasi
combin
mutat
posit
construct
sitedirect
mutagenesi
use
templat
dna
blactxm
mutant
clone
plasmid
transform
e
coli
deltaampc
cefotaxim
ctx
ceftazidim
caz
cefepim
fep
mic
determin
etest
result
phylogenet
reconstruct
analysi
predict
might
ancestor
enzym
except
branchsit
model
indic
strong
posit
select
subbranch
five
posit
implic
four
mutat
requir
success
step
obtain
show
highest
caz
mic
mgml
distinct
evolutionari
pathway
obtain
possibl
moreov
chang
also
present
highli
benefici
cazctx
resist
phenotyp
introduc
last
step
although
presenc
intermedi
mutant
yield
neutral
even
deleteri
effect
sign
epistasi
evolutionari
rout
involv
chang
lower
increas
mic
valu
observ
among
rout
observ
presenc
chang
background
select
inaccess
result
would
suggest
fit
landscap
cluster
twopeak
conclus
aminoacid
chang
associ
posit
select
bioinformat
tool
contribut
favour
resist
phenotyp
specif
context
differ
evolutionari
path
lead
effici
enzym
identifi
indic
rug
fit
landscap
enzym
plasmid
rflp
pattern
j
show
two
replicon
repfiirepfia
size
kb
plasmid
belong
pattern
epidem
environ
highli
relat
plasmid
transform
two
escherichia
coli
isogen
strain
ara
competit
experi
perform
davi
minim
dm
broth
supplement
glucos
seven
day
day
mcl
cocultur
inocul
fresh
dm
anoth
sampl
spread
onto
macconkey
plate
arabinos
estim
rel
fit
w
plasmid
alon
case
mgl
cefotaxim
ad
plate
valu
express
mean
six
independ
experi
magnitud
fit
differ
correspond
much
slowli
one
strain
grew
rel
cours
experi
result
strain
harbour
epidem
plasmid
pattern
yield
growth
rate
slower
parent
strain
contrari
strain
harbour
nonepidem
plasmid
pattern
j
show
higher
cost
epidem
plasmid
grow
slower
parent
strain
respect
howev
competit
assay
isogen
strain
harbour
epidem
pattern
nonepidem
plasmid
pattern
rel
fit
next
competit
assay
strain
harbour
plasmid
belong
pattern
j
show
slight
advantag
plasmid
carri
two
replicon
although
advantag
detect
five
day
competit
conclus
epidem
plasmid
show
higher
fit
might
facilit
dissemin
although
posibl
exclud
presenc
plasmid
multireplicon
could
give
even
advantag
stabl
environ
object
ask
fluoroquinoloneresist
clinic
isol
e
coli
maintain
fit
despit
accumul
sever
mutat
affect
dna
gyras
topoisomeras
iv
drug
efflux
investig
possibl
differ
resistanceassoci
mutat
might
mutual
compens
fit
cost
also
ask
whether
bacteri
fit
might
select
paramet
drive
evolut
fluoroquinolon
resist
test
experiment
construct
set
isogen
strain
carri
combin
resist
mutat
found
commonli
clinic
isol
measur
associ
level
resist
fit
fit
measur
pairwis
growth
competit
vitro
mean
mic
ciprofloxacin
increas
simpl
function
number
resist
mutat
isogen
strain
expect
mean
rel
fit
decreas
function
addit
first
three
resist
mutat
howev
downward
trend
revers
addit
mutat
identifi
strain
addit
resist
mutat
increas
resist
fit
strain
deconstruct
reconstruct
confirm
relationship
resist
mutat
present
result
fitnessresist
phenotyp
also
evolv
strain
increas
fit
absenc
drug
observ
select
variant
decreas
suscept
fluoroquinolon
conclus
bacteria
use
differ
strategi
minim
fit
cost
genet
alter
select
drug
resist
two
well
document
select
lowcost
mutat
select
addit
fit
compens
mutat
identifi
third
strategi
reduc
fit
cost
resist
fluoroquinolon
particular
resist
mutat
combin
increas
resist
level
bacteri
fit
relationship
drugresist
mutat
improv
bacteri
fit
could
one
forc
drive
evolut
fluoroquinolon
resist
import
implic
strain
carri
low
level
resist
mutat
could
evolv
darwinian
select
higher
level
resist
absenc
direct
select
drug
impact
acquisit
mutat
depend
number
mutat
copi
rrna
environ
cost
resist
test
presenc
mutat
copi
seem
confer
advantag
e
faecali
contrari
presenc
one
mutat
copi
lead
disadvantag
growth
fit
could
explain
scarciti
type
mutant
clinic
isol
select
treatment
rodriguezdominguez
ripol
mc
turrient
jc
galan
f
baquero
madrid
es
object
describ
robust
molecular
protocol
base
realtim
pcr
method
abl
discrimin
strain
pairwis
competit
experi
order
estim
easili
rel
fit
method
two
e
coli
isogen
strain
differ
one
base
pair
snp
use
snp
locat
arabinos
operon
allow
us
discrimin
strain
phenotyp
capac
use
arabinos
energi
sourc
genotyp
method
rtpcr
two
forward
primer
differ
snp
one
revers
primer
design
amplifi
specif
one
strain
amplifi
product
detect
sybrgreen
detector
dye
calibr
curv
made
experi
use
chromosom
dna
known
concentr
valid
method
quantifi
rel
fit
w
standard
competit
experi
wildtyp
strain
moreov
two
rifampicinresist
spontan
mutant
carri
mutat
rpob
obtain
respect
cocultur
parent
strain
three
day
plate
day
take
aliquot
dna
extract
six
replic
competit
experi
perform
w
calcul
method
magnitud
fit
differ
correspond
much
slowli
one
strain
grew
rel
competit
assay
ara
wildtyp
strain
yield
differ
fit
plate
rtpcr
rifr
strain
grew
slower
plate
rtpcr
respect
vs
hand
strain
grew
plate
rtpcr
slower
vs
final
competit
experi
rifr
rifr
show
plate
rtpcr
respect
concluison
similar
valu
w
found
use
classic
method
new
protocol
base
rtpcr
propos
use
rtpcr
technolog
estim
fit
cost
present
sever
advantag
respect
tradit
one
huge
manipul
lot
plate
complet
reduc
ii
possibl
carri
one
experi
time
iii
possibl
specif
detect
strain
insid
heterogen
popul
r
szczepanowski
goesmann
l
kraus
bielefeld
de
wastewat
treatment
plant
wwtp
reservoir
bacteria
harbour
antibiot
resist
plasmid
genom
resist
plasmid
isol
wwtp
bacteria
reveal
high
divers
plasmid
replicon
accessori
genet
modul
carri
resist
gene
five
complet
sequenc
plasmid
confer
resist
macrolid
antimicrobi
compound
two
plasmid
name
belong
incompat
group
combin
promiscu
selftransmiss
broadhostrang
plasmid
tripartit
multidrug
efflux
system
consist
permeas
resistancenodulationdivis
rnd
famili
periplasm
membran
fusion
protein
mfp
outer
membran
factor
omf
confer
resist
erythromycin
roxithromycin
plasmid
encod
macrolid
phosphotransferas
transmembran
transport
protein
requir
highlevel
macrolid
resist
differ
variant
enzym
also
encod
mobilis
multidrug
resist
plasmid
incflik
plasmid
also
contain
virulenceassoci
modul
final
erythromycin
resist
plasmid
harbour
resist
gene
mel
mph
encod
respect
predict
abctyp
efflux
permeas
mani
macrolid
resist
gene
could
detect
plasmiddna
prepar
wwtp
bacteria
hybridis
experi
use
resist
gene
microarray
repres
differ
resist
gene
among
differ
ere
gene
encod
erythromycin
esteras
erm
gene
rrna
adenin
mef
gene
specifi
macrolid
efflux
protein
get
complet
pictur
plasmid
metagenom
wwtp
bacteria
ultrafast
sequenc
approach
appli
carri
bioinformat
analysi
obtain
sequenc
data
set
also
confirm
wwtp
bacteria
reservoir
differ
macrolid
resist
determin
blactamas
gene
concern
clinic
isol
sinc
hydrolys
blactam
commonli
use
antibiot
human
medicin
four
molecular
class
blactamas
exist
possess
variabl
hydrolysi
spectra
includ
penicillinas
expandedspectrum
blactamas
carbapenemas
clinicallyrelev
speci
produc
natur
blactamas
ie
shv
klebsiella
pneumonia
natur
produc
non
pathogen
natur
produc
demonstr
sourc
blactamas
gene
known
spread
speci
thu
origin
acquir
resist
blactam
kluyvera
spp
good
exampl
sinc
environment
speci
possess
natur
chromosom
ctxmlike
encod
gene
emerg
worldwid
enterobacteriacea
anoth
exampl
acinetobact
radioresisten
progenitor
carbapenemas
gene
known
origin
carbapenem
resist
acinetobact
baumannii
worldwid
also
possibl
observ
environment
speci
intermedi
reservoir
dissemin
plasmidmedi
blactamas
gene
progenitor
clinicallyrelev
speci
identif
carbapenemas
encod
gene
plasmid
enterobact
asburia
strain
differ
us
river
good
exampl
threat
identif
plamid
harbor
blactamas
gene
wastewat
treatment
plant
sewag
sludg
also
concern
role
genet
structur
like
insert
sequenc
transposon
integron
mobilis
blactamas
gene
environment
bacteria
clinic
one
seem
crucial
well
plasmid
phage
diffus
studi
need
better
evalu
epidemiolog
blactamas
gene
environ
cours
evalu
factor
favouris
dissemin
antibiot
select
pressur
temperatur
intern
comparison
yield
interest
insight
regard
qualiti
care
beyond
field
healthcar
associ
infect
hai
prevent
therefor
exchang
experi
nation
surveil
system
encourag
howev
interpret
differ
hai
rate
made
care
differ
healthcar
system
legal
cultur
aspect
well
differ
method
surveil
system
may
enorm
influenc
crucial
aspect
surveil
data
valid
evalu
difficult
european
surveil
system
interest
patient
group
risk
without
exist
system
patient
group
countri
order
creat
problem
due
need
modif
exist
system
eg
bone
marrow
transplant
patient
low
birth
weight
newborn
etc
talk
discuss
advantag
disadvantag
differ
strategi
order
stimul
discuss
method
retrospect
case
descript
studi
among
patient
serolog
confirm
puuv
infect
seropreval
studi
highrisk
popul
orient
live
train
island
funen
studi
period
result
serolog
verifi
puuv
infect
found
patient
mean
age
year
malefemal
ratio
domin
initi
symptom
acut
onset
fever
abdomin
lowerback
pain
blur
vision
rare
patient
requir
dialysi
ne
case
found
distribut
throughout
whole
year
highest
number
case
novemberfebruari
mark
region
differ
within
funen
found
case
occur
rural
part
southern
southeastern
funnel
cyclic
variat
annual
number
ne
case
seen
period
year
among
orient
seroposit
none
histori
ne
conclus
find
indic
clinic
manifest
puuv
infect
denmark
similar
describ
fennoscandinavia
signific
number
infect
may
asymptomat
distribut
ne
remain
mainli
focal
limit
part
funen
studi
clarifi
ecolog
factor
respons
puuv
distribut
need
enabl
better
risk
evalu
zulz
mg
bruce
park
tam
f
stenz
nystedt
lovel
aj
parkinson
anchorag
us
ottawa
ca
nuuk
gl
lulea
se
oslo
background
intern
circumpolar
surveil
ic
system
conduct
populationbas
surveil
invas
bacteri
diseas
greenland
gn
northern
canada
n
northern
sweden
n
swe
norway
us
arctic
alaska
ak
haemophilu
influenza
hi
neisseria
meningitidi
nm
group
streptococcu
ga
group
b
streptococcu
gb
forward
refer
laboratori
ak
ak
n
n
gn
n
swe
confirm
serotyp
norway
provid
data
ga
gb
clinic
demograph
inform
collect
use
standardis
surveil
form
gene
posit
specimen
partial
subtyp
use
monoplex
realtim
pcr
identifi
group
contain
isol
stec
strain
perform
posit
specimen
cultur
sorbitol
macconkey
agar
coloni
screen
pcr
result
total
specimen
show
stec
specif
amplif
signal
subtyp
success
specimen
reveal
n
third
preval
genotyp
n
n
genotyp
detect
includ
n
n
n
n
patient
posit
uncompl
diarrhoea
n
bloodi
diarrhoea
bd
n
although
bd
could
also
explain
coinfectionmorbid
patient
isol
stec
strain
success
specimen
yield
serotyp
eae
gene
intimin
posit
case
strain
also
shown
highli
relat
base
puls
field
gel
electrophoresi
although
epidemiolog
link
appar
patient
conclus
stec
carri
gene
third
preval
stxgenotyp
netherland
studi
result
suggest
stec
may
overlook
caus
diarrhoea
diagnost
screen
strategi
need
adapt
detect
variant
routin
diagnost
laboratori
object
small
coloni
variant
scv
constitut
slowgrow
subpopul
bacteria
distinct
phenotyp
pathogen
trait
knowledg
scv
yet
describ
enterococci
discov
scv
enterococcu
faecali
blood
cultur
patient
aortic
valv
endocard
characteris
structur
particular
phenotyp
case
report
result
old
femal
patient
underw
aortic
valv
replac
bovin
bioprothesi
three
year
ago
present
emerg
depart
persist
fatigu
transoesophag
echocardiographi
veget
aortic
valv
document
two
two
blood
cultur
e
faecali
suscept
ampicillin
imipenem
intermedi
suscept
rifampicin
grown
addit
typic
e
faecali
coloni
scv
phenotyp
consist
small
pinpoint
coloni
detect
blood
cultur
type
pulsedfield
gel
electrophoresi
reveal
clonal
ident
phenotyp
antimicrobi
suscept
test
bloodcontain
muellerhinton
agar
compar
order
characteris
scv
perform
light
scan
electron
microscopi
sem
transmiss
em
tem
phenotyp
gramstain
scv
show
gramposit
inhomogen
cocci
irregular
size
isogen
normal
phenotyp
appear
homogen
sem
scv
vari
size
onefourth
eight
time
size
normal
phenotyp
irregular
multipl
divis
observ
scv
addit
debri
cover
scv
isol
intercellular
substanc
abund
scv
normal
phenotyp
tem
multipl
irregular
cross
wall
larg
swollenappear
cell
well
empti
cell
observ
scv
fig
growth
curv
phenotyp
reveal
mark
slower
growth
scv
patient
treat
imipenem
rifampicin
six
week
suffer
relaps
endocard
three
week
later
requir
replac
prosthet
aortic
valv
anoth
six
week
antimicrobi
therapi
ampicillin
gentamicin
patient
recov
enterococcu
faecali
abl
form
scv
phenotyp
impair
growth
characterist
distinct
ultrastructur
alter
observ
light
microscopi
em
studi
underway
investig
alter
cellular
metabol
enterococc
scv
object
compar
sequenc
analysi
larg
collect
microbi
isol
utilis
marker
region
provid
framework
molecular
type
combin
pcr
electron
access
databas
standardis
protocol
autom
highthroughput
technolog
make
analysi
region
easili
achiev
recent
develop
compar
sequenc
analysi
tool
base
mass
spectrometri
serv
need
technolog
success
appli
base
type
multilocu
sequenc
type
present
workflow
data
analysi
statist
measur
technolog
develop
novel
molecular
type
scheme
neisseria
gonorrhoea
method
marker
region
amplifi
pcr
tag
primer
system
facilit
vitro
transcript
dna
strand
subsequ
basespecif
endonucleas
digest
two
rna
transcript
base
cytosin
uracil
result
four
mixtur
rna
cleavag
product
high
precis
measur
obtain
mass
spectromet
use
resolv
mixtur
nucleic
acid
sequenc
identifi
correl
acquir
spectra
theoret
peak
pattern
predict
silico
cleavag
sequenc
contain
refer
sequenc
databas
microheterogen
best
refer
sampl
sequenc
identifi
deliv
new
refer
sequenc
result
marker
region
potenti
import
develop
molecular
type
scheme
n
gonorrhoea
set
phenotyp
characteris
sampl
subject
compar
sequenc
analysi
mass
spectrometri
marker
region
convert
pcr
assay
sampl
result
high
qualiti
data
throughout
set
marker
data
analysi
result
upgma
peak
pattern
cluster
sampl
group
statist
analysi
sequenc
analysi
timeeffici
snp
discoveri
algorithm
dideoxi
sequenc
use
resolv
sampl
high
varianc
show
concord
mass
spectrometri
data
introduc
mass
spectrometri
base
compar
sequenc
analysi
tool
provid
rapid
altern
dideoxi
sequenc
microbi
identif
develop
molecular
type
scheme
w
ruppitsch
j
calaway
van
ert
hadfield
k
grif
pietzka
f
allerberg
vienna
palm
bay
us
innsbruck
object
aim
studi
assess
use
highresolut
melt
hrm
curv
analysi
lightcycl
pcr
system
tool
correct
identif
bacillu
anthraci
assess
util
method
recognis
ame
strain
strain
use
anthrax
attack
usa
method
dna
nine
bacteri
isol
eight
b
anthraci
one
b
cereu
dsm
includ
one
strain
origin
american
diplomat
postal
bag
decemb
vienna
isol
use
qiagen
blood
bodi
fluid
spin
protocol
describ
manufactur
b
anthraci
isol
subtyp
vntr
analysi
describ
previous
use
vntr
system
hrm
curv
analysi
six
specif
primer
combin
chosen
test
identif
ame
strain
specif
singl
nucleotid
polymorph
use
lightcycl
high
resolut
melt
master
describ
manufactur
obtain
data
analys
hrm
gene
scan
softwar
roch
result
vntr
analysi
confirm
postal
bag
isol
b
anthraci
ame
strain
b
anthraci
isol
nonam
genotyp
hrm
curv
analysi
allow
differenti
b
cereu
dsm
b
anthraci
isol
rapid
accur
discrimin
b
anthraci
ame
strain
seven
b
anthraci
isol
interest
vntr
data
three
b
anthraci
isol
tyrol
austria
shown
european
strain
extrem
similar
french
italian
genotyp
two
b
anthraci
isol
countri
georgia
also
subtyp
one
ident
vaccin
strain
stern
isol
conclus
abl
show
hrm
curv
analysi
fast
simpl
cost
effect
screen
method
identif
b
anthraci
strain
hrm
curv
analysi
coupl
strainspecif
snp
signatur
allow
differenti
ame
strain
b
anthraci
strain
use
singl
pcr
sourc
intent
releas
b
anthraci
spore
never
elucid
technolog
innov
bacteri
type
abil
identifi
exclud
presenc
ame
strain
clinic
environment
sampl
great
import
object
compar
genom
hybridis
acgh
studi
use
microarray
evalu
distribut
gene
sequenc
bacteri
strain
among
unsequenc
strain
use
technolog
studi
differ
strain
speci
led
import
insight
identif
speci
coregenom
well
distribut
gene
accessori
genom
popul
genom
sequenc
multipl
strain
speci
becom
avail
multistrain
microarray
design
contain
spot
everi
uniqu
gene
sequenc
strain
twocolour
acgh
experi
multistrain
microarray
choic
control
sampl
genom
dna
one
strain
mix
genom
dna
strain
use
array
design
import
problem
univers
accept
solut
aim
studi
evalu
rel
perform
two
type
control
twocolour
acgh
experi
perform
compar
studi
two
control
sampl
option
microarray
design
three
fulli
sequenc
strain
hybridis
two
strain
test
sampl
use
third
strain
control
mix
three
strain
control
sampl
strain
use
singl
control
one
specif
spot
array
result
logratio
test
control
sampl
signal
use
classifi
gene
present
absent
evalu
classif
perform
area
receiv
oper
characterist
curv
auc
accuraci
sensit
specif
auc
measur
probabl
logratio
present
gene
higher
absent
gene
show
type
control
sampl
benefici
analys
spot
separ
class
accord
expect
control
channel
signal
auc
increas
use
mix
control
lead
higher
accuraci
increas
best
perform
due
gain
sensit
increas
p
compens
minor
loss
specif
decreas
p
moreov
use
singl
strain
control
increas
error
rate
gene
present
refer
strain
set
gene
variat
across
unsequenc
strain
expect
use
mix
control
multistrain
microarray
lead
better
perform
use
singl
strain
control
rapid
extendedspectrum
blactamas
detect
use
dna
chip
leinberg
v
grimm
rubtsova
henn
egorov
k
schroeppel
wichelhau
c
knabb
r
schmid
bachmann
edinburgh
uk
stuttgart
de
moscow
ru
frankfurt
de
object
convent
cultur
base
bacteri
identif
antimicrobi
suscept
test
method
slow
enabl
prospect
therapi
provid
limit
inform
depth
high
demand
improv
altern
molecular
method
dna
chip
open
way
rapid
test
prospect
therapi
continu
emerg
problem
microbi
resist
relat
extend
spectrum
betalactamas
esbl
major
clinic
relev
esbl
variant
deriv
gene
mutat
alter
amino
acid
configur
increasingli
acquisit
mutat
gene
ctxm
gene
famili
past
decad
enzym
like
oxa
lactamas
plasmidmedi
ampc
lactamas
emerg
clinic
new
sever
problem
like
hydrolys
modern
cephalosporin
present
demonstr
develop
made
german
pathogenomik
programm
exampl
esbl
chip
well
futur
rout
rapid
microbi
diagnost
clinic
special
focu
novel
technolog
faster
assay
time
microfluid
integr
describ
develop
applic
fluoresc
base
diagnost
oligonucleotid
microarray
genotyp
tem
shv
ctxm
blactamas
variant
base
allel
specif
hybridis
increas
coverag
develop
chip
modul
genotyp
plasmidmedi
ampc
oxatyp
beta
lactamas
enabl
singl
allinon
blactam
resist
test
clinic
fulli
integr
individu
chip
modul
tem
shv
ctxm
singl
esbl
chip
platform
esbl
chip
valid
use
clinic
sampl
taken
one
year
clinic
routin
differ
gramneg
organ
phenotyp
characteris
esbl
detect
variant
includ
analyt
difficult
sampl
correctli
identifi
mix
resist
variou
genotyp
esbl
phenotyp
could
ascrib
presenc
ctxm
variant
shv
variant
wherea
esbl
tem
variant
found
total
assay
could
perform
esbl
chip
present
promis
exampl
develop
panel
diagnost
microbi
chip
integr
whole
analyt
chain
provid
clinic
meaning
cost
effect
tool
soeltankaersenhout
h
panneman
h
akol
gierveld
catsburg
van
bodegraven
phm
savelkoul
amsterdam
wageningen
nl
object
termin
restrict
fragment
length
polymorph
trflp
utilis
type
method
examin
microbi
commun
structur
human
faecal
sampl
adher
microb
gastrointestin
mucosa
rather
lumin
presenc
howev
prerequisit
develop
intestin
diseas
date
trflp
method
yet
evalu
possibl
obtain
rapid
broad
view
adher
microbi
composit
human
intestin
dynam
diseas
state
evalu
might
result
screen
tool
abnorm
adher
gastrointestin
microflora
way
analys
chang
termin
restrict
fragment
trf
profil
studi
done
obtain
evid
perform
trflp
method
techniqu
involv
amplif
rrna
gene
two
differ
label
primer
digest
amplicon
restrict
endonucleas
retriev
molecular
weight
label
termin
restrict
fragment
outer
end
amplicon
autom
dna
sequenc
apparatu
label
forward
revers
primer
might
lead
accur
identif
speci
within
commun
profil
sinc
presenc
two
peak
instead
one
confirm
presenc
certain
speci
firstli
cultur
three
common
intestin
habit
human
gut
subject
trflp
analys
alon
mixtur
determin
competit
pcr
speci
effect
trflp
profil
secondli
mucos
biopsi
five
colon
locat
per
patient
gather
patient
analysi
trflp
three
aforement
speci
quantifi
sampl
quant
realtim
pcr
determin
adequ
amount
present
detect
trflp
shown
trflp
method
produc
consist
reproduc
profil
patient
sampl
show
littl
intrapati
varat
trflp
profil
compar
interpati
variat
reason
simplic
similar
trf
size
differ
genera
omit
reduc
minimum
way
care
restrict
enzym
select
furthermor
databas
contain
dna
sequenc
adher
human
intestin
microbi
commun
combin
adequ
comput
softwar
capabl
perform
metaanalys
forward
revers
peak
presenc
essenti
obtain
rapid
trflp
profil
result
vitro
suscept
mechan
resist
antifung
emerg
azol
crossresist
candida
glabrata
follow
exposur
azol
antifung
surgic
intens
care
unit
f
grenouillet
l
millon
x
fournel
g
blasco
roussel
piliflouri
e
samain
r
piarroux
besancon
fr
object
fluconazol
flc
wide
use
prophylact
preemptiv
cur
treatment
invas
candidiasi
surgic
intens
care
unit
sicu
patient
acquir
resist
azol
candida
glabrata
cg
strain
exposur
rare
data
incid
lack
aim
studi
assess
incid
acquir
flc
resist
azol
crossresist
cg
follow
azol
exposur
sicu
threeyear
prospect
survey
systemat
mycolog
screen
perform
patient
admit
sicu
immedi
admitt
weekli
discharg
patient
week
cg
colonis
retrospect
includ
studi
patient
isol
genotyp
use
microsatellitebas
mlva
method
suscept
cg
isol
azol
determin
nccl
refer
method
first
last
isol
per
strain
per
patient
suscept
flc
itraconazol
voriconazol
vrc
posaconazol
patient
data
includ
azol
exposur
sicu
stay
retrospect
collect
acquir
flc
resist
defin
mic
last
isol
flc
mgml
increas
mic
sicu
stay
result
thirti
nine
patient
admit
sicu
includ
characterist
patient
includ
mean
age
year
median
sicu
stay
day
rang
mean
sap
ii
score
main
underli
disord
abdomin
surgeri
polytrauma
patient
harbor
one
cg
strain
except
one
patient
colonis
two
differ
strain
acquir
azol
resist
observ
six
patient
without
azol
exposur
thirti
three
patient
given
azol
antifung
sicu
stay
high
daili
dose
dd
flc
vrc
mean
dd
mgday
nine
present
sicuacquir
resist
cg
strain
cg
strain
flc
acquir
resist
show
crossresist
azol
signific
risk
factor
acquisit
identifi
among
patient
data
characterist
azol
regimen
use
durat
total
dose
cg
genotyp
conclus
acquisit
crossazol
resist
follow
azol
exposur
occur
frequent
sicu
patient
antifung
agent
other
azol
ie
candin
polyen
consid
initi
therapi
sicu
patient
suspect
invas
candidiasi
set
prior
azol
exposur
background
lifethreaten
candida
infect
becom
import
clinic
problem
fluconazol
one
azol
wide
use
prophylaxi
therapi
candida
infect
widespread
repeat
use
fluconazol
result
resist
candida
isol
object
aim
studi
investig
mutat
gene
determin
possibl
contribut
efflux
pump
confer
fluconazol
resist
c
albican
isol
method
seven
fluconazoleresist
suscept
dosedepend
rsdd
ten
fluconazolesuscept
c
albican
isol
cultur
variou
clinic
specimen
includ
studi
suscept
strain
amphotericin
b
fluconazol
itraconazol
ketokonazol
clotrimazol
flucytosin
determin
broth
microdilt
method
accord
clsi
standard
restrict
enzym
analysi
perform
use
pagi
enzym
pcr
isol
mutat
sequenc
analysi
done
mutat
gene
overexpress
efflux
pump
also
investig
microdilut
method
use
substrat
inhibitor
result
seven
fluconazol
rsdd
isol
found
resist
flucytosin
except
one
suscept
amphotericin
b
isol
except
one
resist
itraconazol
ketoconazol
except
one
suscept
clotrimazol
mutat
detect
strain
mutat
determin
three
rsdd
isol
mutat
determin
group
strain
sequenc
analysi
thought
play
role
resist
evalu
advanc
studi
possibl
overexpress
efflux
pump
determin
especi
three
fluconazoleresist
c
albican
isol
conclus
mutat
gene
overexpress
efflux
pump
determin
effect
mechan
rsdd
c
albican
isol
howev
mechan
resist
overexpress
mutat
gene
also
investig
object
resist
triazol
recent
report
aspergillu
fumigatu
af
isol
cultur
patient
invas
aspergillosi
investig
genet
related
clinic
isol
method
collect
triazol
resist
af
isol
phenotyp
genotyp
characteris
use
isol
resist
vitro
itraconazol
exhibit
elev
mic
voriconazol
posaconazol
combin
tandem
repeat
promot
amino
acid
substitutiton
gene
predomin
genet
chang
isol
cultur
patient
admit
univers
medic
centr
twentysix
azol
suscept
isol
randomli
select
control
genet
related
investig
phylogenet
tree
made
result
genet
analysi
indic
presenc
clade
within
collect
af
isol
azoleresist
isol
genet
distinct
azoleresist
isol
cluster
togeth
singl
clade
indic
genet
related
branch
azoleresist
isol
shorter
genet
distanc
match
azol
suscept
control
isol
cluster
azoleresist
af
isol
distinct
clade
short
genet
distanc
suggest
close
genet
related
resist
isol
sinc
azol
resist
appear
emerg
recent
evolut
resist
mechan
need
investig
object
recent
emerg
triazoleresist
report
clinic
aspergillu
fumigatu
af
isol
unclear
azol
resist
aris
therapi
due
caus
azol
exposur
investig
possibl
azoleresist
present
environment
af
isol
method
soil
leav
seed
compost
sampl
obtain
local
plant
nurseri
local
garden
centr
soil
also
sampl
surround
radboud
univers
nijmegen
medic
center
nijmegen
netherland
addit
af
isol
hospit
indoor
environ
present
fungu
cultur
collect
test
resist
sampl
cultur
sabouraud
agar
plate
without
itraconazol
azoleresist
af
isol
match
repres
azolesensit
control
isol
phenotyp
suscept
profil
clsi
refer
method
molecular
resist
mechan
gene
determin
well
molecular
strain
identif
genotyp
analysi
perform
determin
environment
isol
cluster
clinic
isol
result
af
cultur
environment
sampl
exhibit
azol
resist
phenotyp
resist
isol
also
cultur
soil
flower
bed
isol
seed
compost
plant
nurseri
compost
garden
centr
five
isol
hospit
indoor
environ
azoleresist
patient
room
hospit
water
tandem
repeat
substitut
present
resist
isol
resist
mechan
previous
describ
domin
chang
triazoleresist
clinic
isol
genotyp
analysi
show
isol
uniqu
genet
cluster
environment
resist
isol
cluster
togeth
one
clade
environment
isol
also
show
cluster
azol
resist
clinic
isol
conclus
azoleresist
af
present
environ
sinc
azoleresist
af
cultur
environ
manipul
human
link
exposur
azol
fungicid
seem
plausibl
molecular
analysi
azol
resist
environment
isol
may
suggest
patient
acquir
azol
resist
aspergillu
diseas
inhal
resist
conidia
environ
aspergillu
speci
use
eucast
methodolog
extend
dilut
seri
c
leitner
p
warn
den
innsbruck
manchest
uk
object
test
amphotericin
b
aspergilli
problemat
amphotericin
b
minimum
inhibitori
concentr
mic
aspergillu
speci
cluster
mgml
mic
help
distinguish
suscept
resist
aspergillu
spp
except
isol
aspergillu
terreu
complex
perform
continu
step
dilut
seri
amphotericin
b
mgml
mgml
step
evalu
mic
isol
aspergillu
spp
isol
aspergillu
fumigatu
complex
n
terreu
complex
n
aspergillu
flavu
complex
n
aspergillu
niger
complex
n
obtain
patient
suffer
invas
aspergillosi
store
water
room
temperatur
suscept
test
perform
accord
eucast
methodolog
conidia
form
mould
inoculum
size
cfuml
rpmi
supplement
glucos
rpmi
g
cultur
medium
use
mic
read
done
incub
mic
valu
defin
nogrowth
visual
endpoint
addit
studi
vivo
respons
sever
isol
amphotericin
b
outcom
data
obtain
earlier
temporarili
neutropen
dissemin
mous
model
invas
aspergillosi
result
mic
distribut
follow
fumigatu
complex
rang
mgml
modal
mic
mgml
flavu
complex
mgml
modal
mic
mgml
terreu
complex
mgml
biphas
distribut
one
modal
mic
mgml
anoth
mgml
niger
complex
mgml
modal
mic
mgml
flavu
niger
complex
distribut
approxim
gaussian
suggest
epidemiolog
cutoff
therefor
mgml
fumigatu
niger
terreu
complex
mgml
flavu
complex
abl
correl
vivo
vitro
data
mice
infect
aspergillu
spp
show
mic
mgml
n
success
outcom
mic
mgml
n
fail
amphotericin
b
therapi
p
extend
serial
amphotericin
b
dilut
allow
clear
differ
suscept
pattern
within
variou
aspergilli
test
clinic
studi
need
evalu
use
suggest
epidemiolog
cutoff
valu
defin
clinic
breakpoint
amphotericin
b
r
baxter
b
fireman
n
lewi
oakland
us
syndrom
gb
acut
neurolog
syndrom
may
lead
paralysi
known
associ
infect
campylobact
mycoplasma
etc
swine
flu
vaccin
programm
increas
gb
case
tie
vaccin
sinc
time
concern
vaccin
eg
menactra
td
kaiser
permanent
kp
medic
care
organis
mco
million
member
northern
california
complet
electron
medic
record
member
vsd
vaccin
safeti
datalink
collabor
project
cdc
immun
safeti
offic
iso
compos
medic
care
organis
collect
medic
vaccin
data
million
member
annual
data
organis
compil
conduct
studi
vaccin
advers
advent
method
preliminari
analysi
look
gb
occur
within
week
vaccin
kp
ncal
member
age
analysi
use
novel
case
seri
like
approach
instead
look
vaccin
potenti
gb
time
window
relat
usual
case
seri
approach
look
vaccin
person
gb
examin
proport
vaccin
case
vaccin
window
vs
remaind
year
use
logist
regress
compar
proport
vaccin
case
whose
vaccin
occur
window
versu
expect
assum
associ
vaccin
season
vaccin
like
influenza
estim
expect
odd
proport
vaccin
given
insid
vs
outsid
window
new
method
control
season
confound
exploratori
analysi
multipl
vaccin
risk
window
use
novel
analyt
method
found
possibl
increas
risk
gb
period
vaccin
td
verif
chart
review
plan
extend
analysi
entir
vsd
studi
popul
analyt
method
control
well
confound
includ
season
model
may
applic
vaccin
safeti
studi
object
brucellosi
import
common
bacteri
zoonos
variou
vaccin
subunit
vaccin
propos
prevent
diseas
immunogen
brucella
abortu
ribosom
protein
promis
candid
antigen
develop
subunit
vaccin
brucellosi
research
protect
recombin
fusion
protein
balbc
mous
evalu
method
amplifi
gene
clone
vector
construct
transform
saccharomyc
cerevisia
express
protein
supernat
purifi
affin
chromatographi
column
balbc
mous
immunis
four
group
fusion
protein
group
brucella
abortu
group
hsa
group
pb
group
elisa
ltt
test
challeng
one
week
last
inject
carri
bacteri
count
spleen
immunis
balbc
mous
done
one
month
challeng
virul
strain
b
abortu
elisa
test
antibodi
titer
fusion
protein
group
high
ltt
test
differnc
si
compar
hsa
pb
signific
p
bacteri
count
spleen
goup
decreas
differ
bacteri
count
spleen
goup
group
signific
p
result
indic
recombin
protein
abil
prolifer
lymphocyt
stimul
humor
immun
protect
object
extraintestin
pathogen
escherichia
coli
expec
caus
wide
varieti
patholog
sepsi
neonat
mening
urinari
tract
infect
respons
signific
mortal
morbid
human
anim
result
tremend
cost
healthcar
system
expec
strain
becom
increasingli
resist
antibiot
prevent
measur
vaccin
pathogen
e
coli
strain
achiev
goal
method
base
previou
find
genom
analysi
select
target
virul
factor
uropathogen
associ
protein
identifi
relev
immunogen
region
unknown
three
dimension
structur
protein
simul
furthermor
mhci
mhcii
epitop
well
proteasom
cleveag
site
predict
consid
data
two
recombin
modular
protein
design
contain
sever
epitop
bear
subfrag
separ
linker
sequenc
unlik
present
mhci
mhcii
receptor
express
recombin
vaccin
protein
two
fulli
synthet
gene
synthesis
use
optimis
codon
bia
enhanc
protein
express
enterobacteriacea
evalu
two
differ
applic
rout
mous
model
new
multiepitop
vaccin
protein
obtain
high
humor
cellular
immun
respons
first
use
purifi
vaccin
protein
administ
nasal
second
use
novel
bacteri
antigen
deliveri
system
effici
administ
oral
target
vaccin
directli
cytoplasm
mammalian
cell
vivo
enhanc
cellular
tcell
mediat
immun
respons
elicit
cellular
humor
immun
respons
evalu
use
ifng
elispot
subclass
specif
antibodi
elisa
immunis
mice
show
titr
increas
specif
igg
serum
well
iga
antibodi
vagin
wash
increas
ifng
secret
tcell
specif
recombin
vaccin
protein
challeng
model
periton
signific
reduct
bacteri
load
could
achiev
immunis
mice
conclus
subfrag
vaccin
contain
multipl
epitop
effect
expec
mous
model
research
done
evalu
potenti
approach
human
dini
g
trigo
tavar
e
andrad
veigamalta
fonseca
ribeiro
cabrita
p
ferreira
porto
coimbra
pt
virulenceassoci
immunomodulatori
protein
produc
streptococcu
sobrinu
use
therapeut
vaccin
dental
cari
rat
enolas
identifi
one
sobrinu
immunomodulatori
protein
studi
use
recombin
sobrinu
enolas
renolas
target
antigen
assess
therapeut
effect
dental
cari
rat
model
method
group
wistar
rat
oral
infect
approxim
sobrinu
five
consecut
day
fed
cariogen
solid
diet
five
day
later
oral
immunis
renolas
pb
shamimmunis
plu
alum
adjuv
reimmunis
week
later
throughout
studi
sobrinu
colonis
assess
cari
lesion
evalu
rat
complet
level
salivari
iga
igg
serum
igg
antibodi
recombin
enolas
determin
antibodi
produc
renolaseimmunis
anim
test
human
enolas
moreov
sever
organ
collect
histolog
observ
result
higher
level
salivari
iga
igg
specif
recombin
protein
detect
immunis
rat
control
signific
decreas
sulcal
proxim
enamel
dentin
cari
score
observ
renolaseimmunis
anim
histopatholog
analysi
variou
organ
show
oral
immunis
renolas
induc
detect
tissu
modif
moreov
antibodi
produc
immunis
renolas
show
crossreact
recombin
human
enolas
therapeut
vaccin
recombin
sobrinu
enolas
confer
protect
rat
dental
cari
seem
harm
physiolog
effect
anim
rat
result
indic
sobrinu
renolas
could
promis
safe
candid
test
vaccin
trial
dental
cari
human
portugues
patent
usa
patent
pend
work
support
para
e
tecnologia
fct
feder
grant
although
menb
predomin
strain
mani
region
world
today
truli
global
vaccin
avail
prevent
particular
meningococc
infect
twoyear
nationwid
vaccin
campaign
new
zealand
omv
menb
vaccin
develop
specif
clonal
outbreak
one
specif
serosub
type
respons
epidem
countri
success
conclud
howev
date
broadcoverag
menb
vaccin
elus
unlik
serogroup
menb
polysaccharid
produc
poor
respons
immun
system
vaccin
develop
appli
technic
expertis
develop
safe
effect
meningococc
vaccin
overcom
obstacl
pioneer
new
recombin
vaccin
menb
rmenb
techniqu
known
revers
vaccinolog
potenti
vaccin
candid
creat
analys
entir
genom
sequenc
highli
power
menb
strain
genet
engin
investig
potenti
antigen
scientist
identifi
strain
surfac
protein
best
induc
antibodi
respons
build
genom
approach
novarti
develop
broadcoverag
vaccin
offer
protect
multipl
strain
menb
phase
ii
trial
demonstr
satisfactori
safeti
toler
immunogen
addit
rmenb
first
recombin
menb
protein
vaccin
induc
immun
respons
infant
european
countri
number
notifi
case
legionnair
diseas
ld
increas
last
decad
easier
diagnost
reliabl
report
data
collect
countri
ewgli
european
work
group
legionella
infect
show
fold
increas
case
ld
case
compar
analysi
nosocomi
n
vs
nonnosocomi
n
case
perform
nosocomi
case
suffer
significantli
frequent
neoplast
diseas
vs
frequent
immunosuppress
vs
median
age
year
interquartil
rang
nosocomi
case
vs
year
interquartil
rang
differ
sex
distribut
nosocomi
nonnosocomi
ld
observ
mortal
significantli
higher
among
nosocomi
case
vs
p
thirtyseven
patient
among
nosocomi
case
patient
among
nonnosocomi
case
diagnos
cultur
organ
isol
speci
serogroup
monoclon
subgroup
determin
nosocomi
ld
often
caus
less
virul
legionella
strain
l
nonpneumophila
l
pneumophila
nonserogroup
sg
l
pneumophila
sg
belong
mab
subgroup
invas
mould
infect
present
problem
term
diagnosi
therapi
increasingli
common
nosocomi
set
predomin
fungal
pathogen
hospit
water
case
detect
spore
mould
aspergillu
spp
mucoral
fusarium
spp
immunocompromis
patient
risk
mould
infect
caus
high
morbid
mortal
despit
antifung
therapi
incid
nosocomi
mould
infect
continu
increas
despit
widespread
use
air
filtrat
system
suggest
hospit
sourc
mould
exist
water
system
worldwid
shown
colonis
pathogen
mould
mould
present
hospit
water
system
genera
recov
municip
water
number
speci
isol
surfacedsourc
water
higher
number
isol
groundwat
water
mould
probabl
part
biofilm
water
system
mould
spore
hyphal
fragment
may
releas
water
aerosolis
showerhead
tap
toilet
cistern
aspir
drink
contamin
water
may
lead
patient
exposur
literatur
report
connect
recov
mould
hospit
water
patient
isol
anaissi
ej
cid
anaissi
ej
blood
warri
j
hosp
incect
warri
j
clin
microbiol
molecular
epidemiolog
investig
strain
hamper
genet
divers
mould
amplifi
fragment
length
polymorph
short
tandem
repeat
analysi
seem
discrimin
type
method
earli
initi
antifung
therapi
revers
underli
host
defect
remain
cornerston
treatment
nosocomi
fungal
infect
mortal
nosocomi
fungal
infect
remain
high
new
therapeut
prevent
strategi
need
current
water
treatment
insuffici
remov
mould
hospit
water
prevent
waterborn
nosocomi
mould
infect
high
risk
patient
includ
pointofus
filtrat
steril
water
drink
bath
shower
avoid
aerosolis
investig
water
tube
system
done
properli
identifi
water
qualiti
hospit
surfacesourc
water
like
contain
pathogen
mould
underground
water
mould
like
present
cold
water
shower
hot
water
stage
data
need
assess
exact
role
water
nosocomi
fungal
infect
pseudomona
stenotrophomona
burkholderia
hospit
water
matter
debilit
patient
intens
care
unit
individu
render
profoundli
neutropen
follow
chemotherapi
haematolog
malign
risk
develop
infect
includ
associ
gramneg
bacteria
environment
origin
infect
caus
bacteria
difficult
manag
partli
inher
acquir
antimicrobi
resist
manifest
microorgan
partli
deficit
patient
host
defenc
result
neutropenia
underli
condit
thu
press
need
develop
effect
intervent
prevent
exogen
acquisit
infect
environment
sourc
respect
wide
rang
aquat
sourc
includ
icemak
machin
aqueou
solut
disinfect
nebul
apparatu
consid
import
outbreak
infect
associ
gramneg
bacteria
pseudomona
stenotrophomona
spp
applic
discrimin
molecular
type
techniqu
pulsedfield
electrophoresi
characteris
related
environment
patient
isol
highlight
increas
import
hospit
water
suppli
system
includ
potabl
water
water
faucet
epidemiolog
infect
caus
environment
gramneg
recent
prospect
studi
conduct
nonoutbreak
situat
suggest
hospit
water
system
may
also
signific
endem
sporad
infect
associ
bacteria
howev
isol
environment
bacteria
potabl
water
suppli
indistinguish
patient
clinic
isol
answer
question
whether
patient
acquir
bacteria
water
faucet
whether
faucet
directli
indirectli
contamin
patient
nevertheless
accumul
evid
suggest
intervent
pointofus
water
filtrat
minimis
elimin
gramneg
bacteria
aquat
sourc
patient
environ
may
effect
infect
control
intervent
find
provid
impetu
systemat
prospect
studi
establish
whether
intervent
adopt
integr
compon
infect
control
programm
facil
provid
care
patient
risk
gramneg
infect
treat
hbv
monoinfect
patient
recent
year
consider
progress
treatment
chronic
hepat
b
interferon
convent
peg
first
drug
use
although
advantag
finit
durat
therapi
persist
respons
loss
dnahbv
aghb
obtain
end
therapi
one
third
case
propos
patient
factor
known
influenc
posit
outcom
larg
number
nucleosidenucleotid
analogu
present
avail
treat
hepat
b
efficaci
lamivudin
alon
first
nucleosid
analogu
use
limit
high
rate
resist
adefovir
efficaci
compar
lamivudin
low
resist
rate
entecavir
tenofovir
particularli
activ
control
hepat
b
viru
replic
associ
minim
resist
develop
even
long
treatment
durat
drug
telbivudin
emtricitabin
clevudin
becom
new
treatment
option
near
futur
firstlin
therapeut
regimen
usual
includ
either
monotherapi
potent
agent
low
rate
resist
could
futur
includ
combin
nucleo
ide
analogu
agent
shown
effect
improv
virolog
biochem
histolog
featur
high
proport
patient
chronic
hepat
b
howev
elimin
hepat
b
viru
suppress
hbv
replic
furthermor
emerg
drug
resist
hbv
becom
problemat
longterm
therefor
physician
care
select
treat
start
treatment
monitor
patient
treatment
multidrug
mdr
efflux
protein
widespread
amongst
microorgan
includ
pathogen
membran
protein
contribut
emerg
antibiot
resist
twocompon
system
tc
receptor
membran
protein
play
key
role
metabol
sensit
antibiot
mani
microorgan
design
novel
antibacteri
drug
would
greatli
facilit
knowledg
structur
membran
protein
poorli
understood
difficulti
obtain
purifi
protein
crystal
qualiti
describ
structur
genom
strategi
amplifi
express
purif
characteris
protein
success
strategi
import
step
toward
reproduc
product
transport
receptor
protein
screen
drug
bind
optimis
crystallis
condit
enabl
subsequ
structur
determin
drug
design
multidrug
resist
gramneg
bacteria
known
result
overexpress
efflux
pump
extrud
varieti
unrel
antibiot
prior
reach
target
although
number
method
develop
assess
overexpress
efflux
use
univers
efflux
pump
substrat
ethidium
bromid
eb
use
radiolabel
antibiot
presenc
absenc
inhibitor
efflux
pump
method
labour
intens
rel
imprecis
lend
interlaboratori
use
develop
number
method
identifi
overexpress
efflux
activ
mdr
pathogen
bacteria
without
use
specialis
instrument
b
assess
specif
activ
gene
regul
code
transport
compon
rnd
efflux
pump
c
assess
evalu
overal
efflux
pump
activ
via
semiautom
system
distinguish
accumul
eb
efflux
also
identifi
agent
inhibit
efflux
activ
well
defin
condit
control
accumul
efflux
method
c
fulli
describ
assess
evalu
intrins
overexpress
efflux
activ
mdr
e
coli
enterobact
aerogen
salmonella
enterobacteriacea
membran
permeabl
play
key
role
level
susceptibilityresist
antimicrobi
recent
year
modif
bacteri
envelop
decreas
product
porin
increas
express
efflux
pump
system
report
modif
frequent
associ
resist
mechan
alter
antibiot
molecul
modif
drug
target
variou
clinic
isol
show
multidrugresist
mdr
phenotyp
enterobact
aerogen
klebsiella
pneumonia
salmonella
enterica
sever
gene
variou
chemic
factor
involv
emergenceselect
mdr
isol
bacteri
isol
exhibit
notic
reduct
number
function
porin
per
cell
strong
decreas
synthesi
express
function
alter
porin
highlevel
express
efflux
system
eg
overexpress
acrabtolc
pump
simultan
presenc
mechan
confer
effici
resist
strain
ensur
dissemin
colonis
patient
favour
acquisit
addit
mechan
resist
mara
rama
ompx
involv
complex
regul
cascad
control
membran
permeabl
activ
particip
trigger
mdr
phenotyp
certain
mutat
regul
gene
induc
overexpress
efflux
system
downregul
porin
synthesi
addit
specif
molecul
salicyl
imipenem
chloramphenicol
abl
activ
mdr
respons
phenomenon
observ
vitro
cultur
bacteria
presenc
drug
antibiot
treatment
colonisedinfect
patient
effector
trigger
express
specif
gene
mara
rama
target
gene
locat
downstream
regul
cascad
redund
regul
overlap
control
pathway
effect
extern
induc
activ
contribut
select
dissemin
preserv
enterobact
aerogen
mdr
strain
salmonella
enteritidi
common
aetiolog
agent
foodborn
salmonellosi
worldwid
fluoroquinolon
wide
use
famili
antibiot
treatment
life
threaten
salmonellosi
signific
public
health
concern
emerg
salmonella
isol
reduc
fluoroquinolon
suscept
resist
fluoroquinolon
larg
attribut
mutat
quinolon
resistancedetermin
region
qrdr
target
gene
overproduct
efflux
pump
paper
present
data
describ
role
local
eg
acrr
global
regul
includ
mara
sox
rob
ram
effluxmedi
resist
nalidix
acid
ciprofloxacin
field
isol
invitro
select
ciprofloxacin
resist
salmonella
enteritidi
isol
gene
express
assess
realtim
pcr
invas
determin
cocultur
bacteri
cell
fit
cost
antibiot
resist
examin
highthroughput
phenotyp
microarray
use
assess
pleiotrop
effect
insert
mutant
construct
phage
transduct
use
number
global
regul
genoand
phenotyp
mutant
reexamin
determin
effect
insert
base
analysi
find
support
adopt
unifi
function
model
describ
regul
rather
data
suggest
evolutonalri
histori
strain
may
consider
determin
influenc
regul
control
gene
express
rnd
efflux
pump
enteritidi
along
pleiotrop
phenotyp
neisseria
meningitidi
humanspecif
pathogen
caus
sepsi
mening
high
mortal
use
transgen
mous
model
bioluminesc
label
meningococci
monitor
bacteri
spread
infect
bacteria
accumul
nasal
mucosa
colonis
depend
meningococc
pili
outer
membran
protein
lethal
diseas
accompani
bacteri
enrich
thyroid
gland
decreas
thyroid
hormon
level
bacteri
visualis
demonstr
wave
bacteri
clearanc
growth
select
bacteria
express
phase
variabl
outer
membran
protein
opa
indic
import
bacteri
factor
meningococc
lipooligosaccharid
lo
long
identifi
major
inflammatori
mediat
fulmin
meningococc
sepsi
mening
howev
wildtyp
meningococci
lo
mutant
induc
equival
diseas
sever
similar
proinflammatori
respons
mice
fail
caus
fatal
sepsi
mice
taken
togeth
data
reveal
novel
diseas
dynam
organ
target
meningococc
diseas
fatal
associ
meningococc
sepsi
mice
induc
proinflammatori
host
respons
recognit
one
unidentifi
nonlo
compon
across
europ
incid
meningococc
diseas
vari
per
per
popul
per
annum
case
fatal
rate
overal
approxim
amongst
survivor
rel
high
frequenc
sever
sequela
includ
hear
impair
neurocognit
abnorm
sever
skin
soft
tissu
abnorm
includ
loss
limb
renal
failur
physician
paediatrician
treat
meningococc
diseas
observ
rang
sever
rel
benign
diseas
sever
physiolog
disrupt
lead
death
gener
term
present
mening
tend
better
prognosi
whilst
present
sever
sepsi
syndrom
worst
prognosi
studi
factor
associ
sever
meningococc
diseas
difficult
confound
factor
sporad
natur
diseas
mark
differ
access
health
system
individu
mani
studi
shown
outcom
meningococc
diseas
associ
phenotyp
infect
organ
odd
death
diseas
highest
certain
sequenc
type
exampl
complex
complex
precis
phenotyp
respons
enhanc
virul
sequenc
type
precis
defin
major
virul
determin
neisseria
meningitidi
includ
polysial
capsul
lp
immunotyp
sialyl
outer
membran
protein
includ
opa
opc
whilst
consist
segreg
virul
determin
clonal
group
associ
sever
diseas
organ
express
serogroup
c
associ
fatal
outcom
number
host
factor
identifi
import
determin
sever
diseas
chief
amongst
age
present
worst
prognosi
associ
adult
may
explain
increas
sophist
paediatr
intens
care
twin
studi
indic
death
sever
infecti
diseas
famili
compon
case
meningococc
diseas
larg
number
studi
conduct
investig
role
gene
encod
compon
immun
system
inflammatori
respons
coagul
pathway
difficulti
face
geneticist
death
easili
verifi
end
point
purpos
studi
genet
modifi
sever
diseas
death
rate
mean
small
cohort
avail
studi
howev
associ
studi
reveal
relationship
number
gene
likelihood
death
meningococc
diseas
includ
fc
receptor
polymorph
plasminogen
activ
inhibitor
type
properdin
defici
polymorph
within
interleukin
interleukin
receptor
antagonist
sever
countri
increas
report
isol
neisseria
meningitidi
reduc
sensit
penicillin
treatment
failur
report
extrem
rare
studi
fail
demonstr
associ
reduc
penicillin
suscept
fatal
outcom
doctor
consid
emerg
treatment
newlypres
case
penicillin
commun
mandatori
controversi
recent
studi
suggest
treatment
home
inject
penicillin
may
associ
increas
sever
diseas
discuss
meningococc
infect
continu
caus
signific
morbid
mortal
especi
young
children
adolesc
europ
neisseria
meningitidi
serogroup
b
c
caus
major
diseas
effect
licens
vaccin
exist
group
b
vaccin
consist
purifi
capsul
serogroup
c
w
exist
mani
year
use
limit
outbreak
control
travel
due
limit
durat
protect
afford
singl
dose
ii
poor
immunogen
young
infant
conjug
meningococc
c
vaccin
overcom
limit
first
meningococc
conjug
vaccin
licens
enter
use
first
unit
kingdom
subsequ
introduc
mani
european
countri
impress
impact
reduc
incid
infect
ongo
surveil
meningococc
infect
follow
introduct
vaccin
togeth
immunolog
studi
provid
insight
mechan
immun
protect
role
immunolog
memori
discuss
area
remain
poorli
understood
highlight
neisseria
meningitidi
commonli
caus
meningococc
mening
young
adult
major
caus
endem
mening
identif
patient
meningococc
mening
difficult
typic
sing
symptom
bacteri
mening
may
present
petechi
skin
rash
tradit
consid
hallmark
meningococc
diseas
absent
one
third
patient
present
meningococc
mening
also
occur
viral
mening
physic
examin
alon
may
perform
well
enough
accur
diagnos
rule
mening
examin
cerebrospin
fluid
import
requir
confirm
diagnosi
identifi
caus
organ
allow
test
antibiot
sensit
help
rationalis
treatment
view
urgent
natur
test
one
issu
physician
face
emerg
depart
set
whether
cranial
comput
tomographi
requir
lumbar
punctur
time
critic
manag
patient
suspect
meningococc
mening
first
step
manag
meningococc
mening
obtain
blood
cultur
start
antimicrobi
therapi
adjunct
dexamethason
indic
prehospit
parenter
antibiot
therapi
recommend
mani
countri
use
remain
controversi
first
difficulti
set
identifi
patient
meningococc
mening
second
dilemma
whether
patient
benefit
prehospit
treatment
gener
practition
decid
treat
patient
suspect
bacteri
mening
parenter
antibiot
dexamethason
given
first
dose
manag
critic
ill
neurolog
patient
meningococc
mening
difficult
pose
import
dilemma
sign
system
diseas
occur
frequent
patient
meningococc
mening
associ
mortal
unfavour
outcom
system
diseas
frequent
necessit
cardiopulmonari
support
admiss
intens
care
unit
meningococc
sepsi
frequent
associ
coagul
disord
dissemin
intravascular
coagul
intracrani
complic
rais
intracrani
pressur
hydrocephalu
brain
infarct
occur
arthriti
occur
patient
bacteri
arthriti
requir
prolong
antibiot
joint
drainag
adjunct
treatment
strategi
dexamethason
antiendotoxin
antibodi
recombin
bactericid
permeabl
increas
protein
activ
protein
c
describ
import
controversi
area
review
relev
literatur
discuss
framework
current
treatment
guidelin
object
accur
assess
risk
factor
colonis
antibiot
resist
bacteria
arb
often
confound
scanti
data
antibiot
use
aim
studi
prospect
defin
incid
new
colonis
due
arb
per
day
antibiot
determin
mean
time
acquisit
measur
patientsrisk
factor
acquir
arb
compar
genotyp
pattern
strain
method
prospect
multicentr
cohort
studi
includ
inpati
pt
start
antibiot
plan
sampl
nose
rectum
taken
start
antibiot
day
arb
includ
meticillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococci
vre
ciprofloxacinresist
pseudomona
aeruginosa
crpa
pulsedfield
gel
electrophoresi
done
defin
genet
related
strain
result
total
swab
pt
process
overal
carriag
rate
newli
acquir
arb
mean
durat
deviat
antibiot
therapi
prior
detect
new
colonis
mrsa
rang
vre
rang
crpa
rang
incid
arb
per
day
therapi
carbapenem
glycopeptid
cephalosporin
gen
quinolon
highest
rate
observ
carbapenem
dialys
diabet
pt
gen
cephalosporin
pt
cronic
renal
impair
use
carbapenem
ci
age
ci
signific
predictor
new
arb
acquisit
p
strain
genet
unrel
except
serial
isol
singl
patient
risk
arb
colonis
deepli
vari
exposur
differ
antibiot
mainli
relat
pt
underli
condit
length
hospitalis
period
screen
high
risk
pt
undergo
antibiot
particular
carbapenem
might
suggest
result
total
antibiot
use
averag
analys
show
tempor
relat
mrsa
incid
associ
detect
c
difficil
except
usag
broadspectrum
cephalosporin
model
indic
signific
impact
consumpt
abhr
mrsa
c
difficil
intervent
model
integr
transfer
model
show
effici
second
hand
hygien
campaign
addit
tempor
effect
use
five
broadspectrum
antimicrobi
explain
incid
mrsa
time
increas
antibiot
use
increas
incid
mrsa
isol
per
pd
current
level
ie
fluoroquinolon
signific
impact
month
later
macrolid
gener
cephalosporin
cefepim
piperacillintazobactam
convers
hand
hygien
campaign
reduc
mrsa
incid
decreas
mrsa
observ
aggreg
level
relat
trend
mrsa
incid
use
abhr
differ
antibiot
class
associ
abhr
use
detect
c
difficil
model
druguseversussuscept
relat
use
timeseri
analys
use
tool
complement
tradit
epidemiolog
approach
background
antibiot
consumpt
human
popul
factor
emerg
resist
organ
import
track
populationbas
consumpt
data
ongo
basi
explor
determin
region
variat
antibiot
consumpt
provinc
british
columbia
bc
method
obtain
data
bc
pharmanet
databas
outpati
oral
antibiot
prescript
prescript
express
defin
daili
dose
ddd
per
inhabit
accord
world
health
organ
anatom
therapeut
chemic
system
geograph
inform
system
gi
map
use
display
spatial
variat
antibiot
consumpt
bc
explor
relationship
antimicrobi
consumpt
socioeconom
climat
factor
use
pearson
correl
overal
classspecif
rate
consumpt
describ
health
servic
deliveri
area
geographi
result
overal
antibiot
consumpt
highest
northern
health
region
lowest
interior
health
region
correl
found
antibiot
consumpt
socioeconom
climat
factor
higher
rate
antibiot
consumpt
associ
aborigin
popul
higher
famili
incom
juli
total
precipit
invers
relationship
found
consumpt
juli
averag
temperatur
analysi
classspecif
antibiot
consumpt
identifi
differ
geograph
pattern
consumpt
socioeconom
associ
higher
rate
penicillin
blactam
macrolid
consumpt
seen
aborigin
popul
younger
popul
age
year
higher
ratio
physician
popul
higher
famili
incom
greater
juli
total
precipit
invers
correl
found
antibiot
consumpt
older
age
age
year
mortal
rate
warmer
juli
temperatur
conclus
differ
rate
antibiot
consumpt
exist
within
provinc
appropri
polici
affect
antibiot
consumpt
commun
design
look
relationship
antibiot
consumpt
socioeconom
determin
relat
impact
collect
data
hospit
antibiot
use
standardis
method
differ
european
countri
data
use
answer
two
research
question
trend
hospit
antibiot
use
time
effect
adjust
bed
day
admiss
trend
hospit
antibiot
use
method
total
hospit
particip
studi
one
hospit
countri
collect
monthli
data
total
antibiot
use
year
start
januari
crude
data
antibiot
use
convert
atc
drug
classif
defin
daili
dose
ddd
result
antibiot
use
measur
ddd
increas
hospit
decreas
hospit
underli
trend
reduc
length
stay
hospit
consequ
annual
chang
ddd
per
occupi
bed
day
dbd
also
greater
annual
chang
ddd
per
admiss
dad
hospit
overal
five
distinct
pattern
antibiot
use
time
increas
antibiot
use
fulli
explain
increas
clinic
activ
hospit
increas
ddd
time
remain
adjust
either
bed
day
admiss
increas
antibiot
use
entir
explain
increas
clinic
activ
hospit
increas
ddd
time
revers
decreas
dbd
dad
henc
appar
increas
antibiot
use
entir
due
larg
increas
clinic
activ
diverg
dbd
dad
hospit
increas
ddd
revers
adjust
admiss
persist
adjust
bed
day
diverg
result
consequ
increas
number
admiss
combin
reduc
length
stay
appar
increas
antibiot
use
like
explain
increas
clinic
activ
decreas
antibiot
use
fulli
explain
decreas
clinic
activ
hospit
decreas
antibiot
use
entir
explain
decreas
clinic
activ
hospit
conclus
interpret
longitudin
surveil
data
antibiot
use
facilit
present
chang
ddd
without
adjust
clinic
activ
addit
adjust
data
antibiot
use
influenc
number
admiss
length
stay
consequ
adjust
clinic
activ
done
admiss
occupi
bed
day
version
extract
rout
administr
countri
primari
outcom
measur
total
parenter
use
express
percentag
total
outpati
antibiot
use
averag
proport
outpati
parenter
antibiot
treatment
total
use
data
greec
bulgaria
iceland
european
countri
rang
russia
czech
republ
see
figur
total
outpati
use
rang
franc
greec
total
use
russia
three
commonli
use
antibiot
group
parenter
treatment
cephalosporin
finland
norway
penicillin
hungari
norway
aminoglycosid
norway
estonia
three
commonli
use
antibiot
substanc
parenter
treatment
cefazolin
russia
one
countri
ceftriaxon
franc
one
countri
cefuroxim
poland
one
countri
conclus
outpati
parenter
antibiot
treatment
repres
total
outpati
antibiot
use
european
countri
studi
howev
total
outpati
antibiot
use
use
differ
antibiot
group
substanc
strike
variat
proport
parenter
antibiot
use
europ
well
indepth
data
outpati
antibiot
use
need
explain
variat
e
meyer
lapatschek
bechthold
g
schwarzkopf
monnet
p
gastmeier
f
schwab
freiburg
munich
de
stockholm
se
berlin
de
object
test
whether
reduct
thirdgener
cephalosporin
use
sustain
posit
impact
high
endem
preval
k
pneumonia
e
coli
surgic
intens
care
unit
icu
intervent
switch
piperacillin
combin
blactamaseinhibitor
standard
therapi
periton
intraabomin
infect
method
segment
regress
analysi
interrupt
time
seri
use
analys
antibiot
consumpt
resist
data
month
intervent
antimicrobi
usag
densiti
ad
express
daili
defin
dose
ddd
normalis
per
patientday
proport
resist
isol
rp
calcul
divid
number
resist
isol
total
number
isol
speci
test
antibiot
multipli
resist
densiti
rd
express
number
resist
isol
pd
intervent
associ
signific
sustain
decreas
use
use
decreas
pd
intervent
result
mean
estim
reduct
total
antibiot
use
pd
equival
reduct
total
antibiot
use
show
signific
month
month
chang
intervent
piperacillin
piperacillintazobactam
show
signific
increas
level
pd
continu
increas
pd
per
month
intervent
intervent
associ
signific
quarterli
chang
rd
k
pneumonia
e
coli
resist
contrast
reduc
use
switch
piperacillin
follow
continu
increas
rd
e
coli
resist
piperacillin
per
pd
per
quarter
continu
decreas
p
aeruginosa
resist
piperacillin
per
quarter
conclud
concentrati
reduct
gener
cephalosporin
necessarili
follow
posit
impact
resist
situat
icu
set
replac
piperacillin
blactamas
inhibitor
might
likewis
provid
select
pressur
e
coli
k
pneumonia
improv
resist
might
suffici
restrict
intervent
risk
area
rather
may
essenti
includ
whole
hospit
even
commun
mj
struelen
f
buyl
r
mechtler
metzgercek
w
kern
lechner
h
mittermay
f
allerberg
object
develop
valid
qualiti
indic
qi
assess
clinic
perform
antibiot
use
part
antibiot
strategi
intern
euproject
aim
improv
antibiot
therapi
hospit
care
method
intern
team
expert
four
disciplin
develop
select
qi
structur
hospit
organis
resourc
process
care
diagnost
treatment
prophylact
practic
outcom
drug
use
develop
qi
achiev
step
identif
qi
literatur
b
multicriteria
score
rank
base
scientif
valu
applic
c
gener
discuss
final
consensu
qi
select
result
base
potenti
qi
structur
process
outcom
qi
select
develop
structur
qi
describ
organis
resourc
well
commun
evalu
tool
avail
hospit
level
implement
multimod
multidisciplinari
antibiot
stewardship
programm
process
qi
focuss
four
care
process
surgic
prophylaxi
indic
drug
choic
time
durat
administr
manag
communityacquir
pneumonia
blood
cultur
legionella
antigen
test
drug
choic
empir
treatment
manag
staphylococcu
aureu
bacteraemia
echocardiographi
iv
cathet
remov
durat
effect
therapi
ivpo
switch
treatment
equival
bioavail
antibiot
outcom
indic
focuss
antibiot
use
conclus
intern
consensu
develop
structur
process
qi
provid
tool
evalu
intens
hospit
antibiot
stewardship
programm
audit
key
treatment
prophylact
practic
process
qi
test
feasibl
reliabl
sensit
improv
pilot
hospit
erntel
g
skoog
car
elowson
h
hanberg
c
jorup
odenholt
prag
k
j
struw
e
torel
p
ulleryd
stockholm
se
object
object
studi
perform
descript
point
preval
studi
pp
antimicrobi
use
relat
diagnos
swedish
hospit
protocol
design
present
demograph
data
well
amount
indic
antimicrobi
agent
treatment
record
relat
diagnos
prophylact
use
commun
acquir
cai
hospit
acquir
infect
hai
three
nationwid
pp
perform
novemb
novemb
novemb
three
area
identifi
intervent
last
pp
durat
periop
prophylaxi
treatment
communityacquir
pneumonia
use
fluoroquinolon
communityacquir
cystiti
women
direct
inform
hospit
physician
feedback
earlier
result
use
intervent
strategi
result
patient
treat
antimicrobi
agent
hospit
includ
three
pp
number
admit
patient
correspond
admit
patient
sweden
one
day
admit
patient
treat
antimicrobi
indic
treatment
cai
hai
prophylaxi
adult
cultur
taken
oral
treatment
parenter
treatment
minor
chang
pattern
overal
use
antimicrobi
observ
howev
lower
urinari
tract
infect
women
rel
use
mecillinam
trimethoprim
increas
respect
use
fluoroquinolon
decreas
commun
acquir
pneumonia
signific
chang
observ
pp
result
show
decreas
periop
treatment
longer
one
day
onedos
periop
prophylaxi
lower
gastrointestin
tract
increas
total
amount
antimicrobi
use
adult
calderaro
g
piccolo
c
gorrini
peruzzi
g
dettori
c
chezzi
g
snounou
parma
pari
fr
object
malaria
frequent
import
infect
itali
relat
increas
number
travel
migratori
flow
endem
countri
microscop
examin
poor
sensit
may
give
problem
differenti
plasmodium
falciparum
pf
p
malaria
pm
p
oval
po
p
vivax
pv
especi
case
low
parasitaemia
mix
infect
circumv
limit
molecular
assay
base
develop
sever
research
group
includ
us
studi
aim
accur
promptli
diagnos
case
malaria
describ
occurr
area
compar
result
microscopi
molecular
assay
order
assess
use
assay
diagnost
practic
conclus
despit
microscopi
remain
refer
diagnost
method
rapid
inexpens
case
molecular
assay
one
allow
correct
diagnosi
malaria
particularli
detect
infect
speci
pf
mix
infect
howev
studi
one
pcr
assay
develop
us
show
higher
accuraci
po
detect
due
specif
primer
design
done
recognis
variant
po
gene
pcr
prove
sensit
specif
microscopi
chang
pictur
malaria
epidemiolog
area
detect
singl
mix
infect
miss
microscopi
reveal
singl
mix
infect
incorrectli
diagnos
microscopi
give
speciat
case
microscopi
limit
result
genu
identif
preval
malaria
case
area
well
itali
import
africa
due
pf
follow
po
pv
experi
rapid
accur
diagnosi
malaria
allow
administ
prompt
target
therapi
posit
impact
clinic
manag
patient
spanish
patient
children
age
year
old
remain
patient
adult
women
women
fit
endem
area
obtain
nation
spain
detect
igm
antibodi
children
also
one
child
found
posit
result
pcr
water
filtrat
method
use
river
sand
activ
carbon
remov
intestin
protozoan
parasit
contamin
drink
water
pointofus
treatment
zinyowera
c
muchanetakubara
n
midzi
moyo
saungwem
p
nziramasanga
mduluza
harar
zw
baltmor
us
introduct
drink
water
contamin
microorgan
caus
estim
million
case
gastrointestin
ill
annual
worldwid
unicef
estim
approxim
million
die
waterborn
diseas
year
clean
safe
water
mendatori
everi
household
chlorin
use
water
disinfect
kill
protozoan
parasit
object
analys
sand
filter
differ
type
activ
carbon
experiment
capabl
remov
protozoan
parasit
drink
water
materi
method
known
human
intestin
protozoan
parasit
put
water
pour
either
metal
plastic
bucket
mesh
screen
bottom
bucket
contain
either
coars
fine
sand
water
collect
filtrat
spun
analys
protozoan
parasit
activ
carbon
name
baobab
shell
macadamia
nut
shell
amarula
stone
local
wood
carbon
commerci
activ
carbon
activ
carbon
use
zimbabw
nation
water
author
zinwa
water
treatment
plant
analys
separ
activ
carbon
place
distil
water
known
amount
protozoan
parasit
incub
hour
constant
shake
room
temperatur
water
siev
use
test
cotton
cloth
allow
parasit
pass
spun
analys
protozoan
parasit
result
conclus
fine
sand
effici
captur
protozoan
parasit
coars
sand
activ
local
wood
charcoal
reduc
number
parasit
water
whilst
commerci
activ
carbon
adsorb
intestin
protozoan
parasit
except
entamoeba
coli
reduc
amarula
stone
reduc
parasit
activ
carbon
zinwa
reduc
parasit
whilst
activ
carbon
baobab
shell
macadamia
nut
shell
complet
adsorb
parasit
activ
carbon
capabl
adsorb
giardia
lamblia
except
zinwa
activ
carbon
fine
sand
combin
either
commerci
carbon
activ
wood
carbon
activ
carbon
baobab
shell
macadamia
nutshel
potenti
use
media
use
household
point
use
treatment
water
remov
parasit
applic
anoth
method
chlorin
order
kill
bacteri
cell
introduct
molecular
assay
detect
entamoeba
histolytica
giardia
lamblia
cryptosporidium
hominisparvum
respect
dientamoeba
fragili
alreadi
describ
sensit
andor
specif
microscopi
date
routin
appli
replac
timeconsum
microscop
analysi
protozo
gastrointestin
gi
pathogen
intern
control
molecular
assay
simultan
detect
four
protozoa
singl
faec
sampl
valid
compar
tripl
fece
test
tft
microscop
analysi
also
algorithm
complet
parasitolog
diagnosi
implement
realtim
pcr
assay
laboratori
routin
creat
method
tft
set
fix
perezayala
j
perezmolina
p
zamarron
f
norman
c
jimenez
navarro
r
lopezvelez
madrid
es
object
studi
main
diagnos
among
return
travel
respect
geograph
area
visit
length
type
travel
method
tropic
medicin
unit
ramon
cajal
hospit
referr
unit
immigr
ill
return
travel
attend
sinc
year
comprehens
microbiolog
studi
perform
case
length
travel
divid
three
group
short
medium
day
longterm
wherea
type
travel
classifi
four
group
profession
high
low
risk
phr
plr
tourism
high
low
risk
thr
tlr
discret
variabl
compar
mean
chi
squar
fisher
exact
test
quantit
data
independ
sampl
ttest
use
result
travel
consult
depart
progress
increas
number
patient
year
mean
age
travel
year
interquartil
rang
women
main
diagnos
suspect
bacteri
gastrointestin
infect
bacteri
growth
confirm
sonnei
salmonella
sp
campylobact
sp
c
difficil
observ
mainli
travel
north
africa
southwest
asia
second
frequent
diagnosi
parasit
intestin
infect
g
lamblia
e
histolytica
saginata
lumbricoid
stercorali
case
one
parasit
found
third
diagnosi
order
frequenc
malaria
produc
p
falciparum
follow
p
vivax
acquir
mainli
subsaharan
africa
conclus
type
length
travel
associ
bacteri
gi
infect
tlr
day
travel
length
determin
parasit
gi
infect
increas
risk
travel
day
malaria
associ
type
travel
less
risk
tlr
glycopeptid
vancomycin
teicoplanin
bind
ctermin
dalanyldalanin
daladala
lipid
ii
peptidoglycan
precursor
block
transglycosyl
transpeptid
reaction
acquir
vanaand
vanbtyp
resist
enterococci
result
product
modifi
precursor
end
daladlact
dlac
glycopeptid
exhibit
low
bind
affin
elimin
daladala
end
precursor
synthesis
host
ddl
ligas
direct
interact
drug
lipid
ii
lead
disrupt
barrier
function
bacteri
membran
exposur
aureu
telavancin
result
timeand
concentrationdepend
loss
membran
potenti
increas
membran
permeabl
quantit
flow
cytometri
assay
indic
major
aureu
fulli
depolaris
within
hour
follow
exposur
clinic
relev
telavancin
concentr
data
provid
mechanist
basi
potent
activ
drug
gisahgisa
clinic
isol
observ
vitro
vivo
microorgan
acquir
vantyp
glycopeptid
resist
telavancin
like
teicoplanin
induc
vanb
gene
cluster
thu
vanatyp
isol
reduc
suscept
telavancin
wherea
vanbtyp
strain
remain
fulli
suscept
meticillinresist
staphylococcu
aureu
mrsa
common
pathogen
isol
complic
skin
soft
tissu
infect
cssti
telavancin
investig
rapidli
bactericid
lipoglycopeptid
antibiot
multifunct
mechan
action
gramposit
bacteria
includ
mrsa
two
larg
intern
phase
studi
atla
compar
efficaci
safeti
telavancin
mgkg
iv
everi
hour
vancomycin
telavancin
may
provid
use
altern
vancomycin
treatment
patient
cssti
includ
caus
mrsa
independ
express
toxin
gene
pvl
hospitalacquir
pneumonia
hap
common
healthcareacquir
infect
contribut
death
increas
bodi
evid
demonstr
delay
hap
treatment
use
inappropri
antibiot
dramat
increas
mortal
hap
defin
respiratori
infect
develop
hour
hospit
admiss
proport
patient
hap
associ
mechan
ventil
case
term
ventilatorassoci
pneumonia
vap
patient
vap
mortal
rate
increas
infect
caus
multidrugresist
pathogen
past
year
incid
nosocomi
pneumonia
due
gramposit
rel
gramneg
organ
increas
staphylococcu
aureu
especi
meticillinresist
staphylococcu
aureu
mrsa
penicillinresist
pneumococci
replac
gramneg
bacteria
predomin
caus
nosocomi
pneumonia
telavancin
novel
investig
rapidli
bactericid
lipoglycopeptid
multifunct
mechan
action
gramposit
bacteria
includ
inhibit
cell
wall
peptidoglycan
synthesi
disrupt
function
integr
bacteri
membran
telavancin
rapidli
bactericid
broad
rang
clinic
relev
gramposit
bacteria
includ
mrsa
telavancin
recent
evalu
two
larg
phase
studi
involv
patient
hap
includ
patient
vap
caus
gramposit
bacteria
mrsa
ident
multin
multicentr
randomis
doubleblind
studi
compar
efficaci
safeti
telavancin
mgkg
iv
everi
hour
vancomycin
g
iv
everi
hour
dose
optimis
allow
per
individu
site
guidelin
day
elig
patient
includ
men
women
age
year
older
hap
caus
suspect
confirm
gramposit
pathogen
primari
efficaci
analysi
studi
noninferior
telavancin
compar
vancomycin
clinic
cure
rate
clinic
evalu
ce
patient
testofcur
visit
day
end
studi
treatment
sever
communityacquir
pneumonia
updat
mortal
mechan
medic
intervent
symposium
organis
novarti
pharma
epidemiolog
guidelin
process
care
clinic
experi
sever
communityacquir
pneumonia
mortal
cap
patient
outpati
inpati
intub
patient
recent
studi
estim
mortal
near
icu
patient
requir
inotrop
site
care
assess
base
sever
ill
key
affect
diagnost
workup
empir
antibiot
pneumonia
sever
index
psi
predict
patient
discharg
home
safe
occasion
underestim
sever
particularli
young
patient
without
comorbid
sever
respiratori
failur
psi
use
document
outcom
equival
empir
antibiot
wherea
delay
appropri
antibiot
worsen
surviv
class
ivv
pneumococc
bacterem
pneumonia
easi
use
identifi
patient
high
risk
mortal
might
benefit
earli
icu
admiss
recent
updat
idsaat
guidelin
cap
includ
major
minor
criteria
indic
need
icu
admiss
score
gener
account
comorbid
potenti
problem
older
patient
biomark
may
complement
score
predict
outcom
sever
assess
base
piro
concept
includ
comorbid
copd
immunocompromis
age
multilobar
opac
shock
sever
hypoxaemia
acut
renal
failur
bacteraemia
ard
piro
score
obtain
icu
h
admiss
point
given
present
featur
rang
point
mean
piro
score
significantli
higher
nonsurvivor
survivor
vs
higher
score
significantli
associ
higher
mortal
prolong
length
icu
stay
day
mechan
ventil
p
roc
curv
show
piro
score
outperform
apach
ii
p
atsidsa
criteria
p
predict
mortal
achiev
auc
predictor
admiss
hospit
hdu
icu
care
achiev
auc
respect
believ
highlight
limit
track
trigger
tool
postpon
oxygen
assess
associ
signific
delay
initi
antibiot
delay
oxygen
assess
associ
increas
mortal
hr
therefor
suggest
implement
simpl
care
bundl
improv
manag
cap
ed
use
evidencebas
variabl
immedi
puls
oxymetri
assess
cornerston
initi
step
patient
sever
infect
almost
invari
show
evid
activ
coagul
system
lung
amongst
frequent
affect
organ
sever
infect
sepsi
abund
presenc
intravascular
extravascular
fibrin
appear
specif
hallmark
acut
lung
injuri
follow
sepsi
much
obviou
fibrin
deposit
organ
tissu
factor
tf
regard
primari
initi
coagul
sever
infect
effect
block
tissu
factor
pathway
either
recombin
tissu
factor
pathway
inhibitor
rtfpi
antitissu
factor
antibodi
experiment
sepsi
attenu
lung
injuri
partial
prevent
pulmonari
dysfunct
addit
inhibit
tissu
factor
activ
prevent
local
activ
coagul
model
pneumonia
anoth
mechan
contribut
fibrin
deposit
lung
local
depress
fibrinolysi
due
increas
plasminogen
activ
inhibitor
type
effect
pulmonari
coagul
fibrinolysi
regul
variou
proinflammatori
cytokin
lectur
discuss
regul
impact
pulmonari
coagul
sever
infect
p
f
laterr
brussel
tissu
factor
pathway
inhibitor
tfpi
endogen
molecul
antiinflammatori
anticoagul
activ
howev
tfpi
overwhelm
increas
express
tissu
factor
tf
scap
tifacogin
recombin
tfpi
replenish
endogen
tfpi
restor
haemostasi
retrospect
analysi
larg
randomis
clinic
trial
tifacogin
patient
sever
sepsi
optimist
reveal
patient
cap
document
microbi
sourc
infect
receiv
concurr
heparin
combin
lower
mortal
compar
patient
receiv
placebo
even
though
signific
effect
seen
overal
sever
sepsi
popul
laterr
et
al
critic
care
submit
result
suggest
tifacogin
may
reduc
mortal
patient
scap
requir
heparin
potenti
benefit
tifacogin
current
test
phase
iii
captiv
studi
approxim
patient
captiv
compar
current
scap
standard
care
combin
scap
standard
care
plu
adjunct
tifacogin
either
mgkghr
mgkghr
hour
continu
infus
studi
object
determin
whether
treatment
tifacogin
earli
diseas
process
reduc
incid
mortal
prevent
develop
dissemin
intravascular
coagul
multipl
organ
system
failur
studi
entri
criteria
base
idsa
at
guidelin
plu
clinic
diagnosi
communityacquir
pneumonia
specif
requir
presenc
either
major
criterion
requir
mechan
ventil
need
therapeut
vasopressor
minor
criteria
hypotens
despit
adequ
fluid
resuscit
pao
fio
ratio
respiratori
rate
noninvas
ventilatori
support
bun
new
onset
confus
multilobar
pneumonia
platelet
count
cellsmm
fall
previou
hour
leukopenia
hypothermia
primari
endpoint
studi
day
caus
mortal
secondari
endpoint
includ
treatment
failur
need
mechan
ventil
incid
dissemin
intravascular
coagul
durat
icu
admiss
length
hospitalis
overal
treatment
benefit
observ
tifacogin
pharmacoeconom
analysi
also
perform
surviv
data
also
collect
day
month
year
assess
longterm
safeti
patient
sever
sepsi
show
substanti
abnorm
sever
biomark
inflamm
coagul
abnorm
inconsist
correl
syndrom
sever
major
heterogen
sourc
infect
lung
abdomen
urin
variabl
caus
microorgan
communityacquir
pneumonia
cap
common
caus
communityacquir
sever
sepsi
icu
repres
well
characteris
diseas
protocolis
treatment
henc
analysi
biomark
homogen
popul
may
import
defin
diseas
sever
candid
new
therapeut
approach
subgroup
analysi
result
optimist
studi
tifacogin
sever
sepsi
patient
reveal
decreas
mortal
scap
patient
treat
tifacogin
document
microbiolog
infect
concurr
treat
heparin
trend
toward
reduc
mortal
also
seen
scap
patient
procalcitonin
ngml
laterr
et
al
critic
care
submit
overal
sever
sepsi
popul
evid
activ
coagul
pf
baselin
opal
et
al
idsa
treat
tifacogin
result
warrant
investig
led
initi
captiv
studi
tifacogin
patient
scap
moreov
resolut
human
genom
led
discoveri
new
genom
biomark
associ
scap
mortal
hope
investig
genom
marker
classic
biomark
level
chang
clinic
cours
diseas
possibl
futur
predict
patient
potenti
risk
decompens
patient
like
benefit
earli
treatment
tifacogin
candida
albican
main
speci
associ
opc
nonalbican
increas
mutiresist
candida
albican
nonalbican
strain
emerg
chang
consequ
long
term
prescript
narrow
spectrum
antifung
agent
repeat
prescript
oral
system
antifung
agent
moreov
heavili
treat
immunocompromis
popul
import
limit
potenti
drugdrug
interact
therefor
nation
intern
guidelin
issu
recommend
use
local
antifung
therapi
spectrum
extend
candida
speci
first
line
treatment
opc
clinic
practic
treatment
complianc
immunocompromis
patient
repres
challeng
favour
local
antifung
agent
easi
use
occurr
oropharyng
candidiasi
immunocompromis
patient
carri
high
burden
term
patient
discomfort
sinc
mucos
colonis
risk
factor
system
dissemin
oropharyng
candidiasi
impli
earli
treatment
initi
system
activ
antifung
carri
challeng
drugdrug
interact
well
potenti
varieti
organ
toxic
although
topic
treatment
clearli
prefer
localis
superfici
infect
system
activ
antifung
use
frequent
like
azol
differ
patient
group
benefit
addit
topic
treatment
option
oropharyng
candidiasi
particular
patient
hivaid
patient
neoplast
diseas
hiv
infect
subject
receiv
multipl
concomit
medic
suffer
oropharyng
candidiasi
risk
interact
system
antifung
treatment
haart
need
minimis
thu
guidelin
recommend
first
line
local
antifung
therapi
incid
rate
oropharyng
candidiasi
vari
within
highli
complex
cancer
patient
popul
depend
type
tumour
treatment
modal
cytostat
use
consequ
oropharyng
candidiasi
may
decreas
food
sometim
even
liquid
intak
loss
weight
reduc
gener
state
qualiti
life
potenti
subsequ
decreas
chemotherapi
dose
increas
interv
cycl
may
neg
impact
therapeut
success
group
immunocompromis
patient
import
detect
treat
oropharyng
candidiasi
start
avail
new
local
antifung
agent
limit
system
exposur
daili
dose
favour
patient
complianc
optimis
manag
oropharyng
candidiasi
immunocompromis
patient
establish
new
type
biolog
sensor
base
microfabr
silicon
cantilev
array
cantilev
micron
long
micron
wide
less
micron
thick
miniaturis
ultrasensit
fastrespond
sensor
applic
chemistri
physic
biochemistri
medicin
respond
bend
due
absorpt
molecul
shift
reson
frequenc
oper
differ
environ
gaseou
environ
liquid
oper
liquid
microcantilev
sensor
abl
detect
biochem
reaction
cantilev
functionalis
specif
biochem
probe
receptor
sensit
detect
correspond
target
molecul
applic
lie
field
labeland
amplificationfre
detect
dna
hybridis
detect
protein
well
antigenantibodi
reaction
detect
larger
entiti
bacteria
fungi
present
detect
fungal
growth
within
two
hour
use
reson
microcantilev
coat
nutrit
media
past
year
concept
lab
chip
loc
develop
great
level
matur
microfluid
system
nowaday
employ
varieti
applic
physic
analyt
chemistri
medic
applic
recent
biolog
one
show
increas
interest
experi
singl
cell
shown
great
opportun
present
first
exampl
given
loc
analysi
lithium
drug
frequent
use
manicdepress
patient
whole
blood
subsequ
present
sensor
system
monitor
cultiv
paramet
temperatur
oxygen
content
ph
cell
growth
system
intend
use
monitor
microcel
cultur
compat
standard
wellplat
format
anoth
exampl
millionchamb
petridish
shown
cultiv
bacteri
cultur
follow
exampl
microfluid
cell
trap
enabl
timelaps
experi
cell
undergo
apoptosi
studi
confoc
microscopi
use
chemic
modifi
qdot
shown
photost
cellimag
apoptot
process
particularli
import
long
timelaps
experi
carri
would
normal
suffer
bleach
convent
fluoresc
probe
final
celltrap
chip
shown
gene
transfect
individu
cell
use
electropor
specif
transfect
construct
subsequ
transloc
cytosol
nucleu
human
mesenchym
stem
cell
influenc
extern
bfgf
signal
demonstr
last
exampl
demonstr
import
futur
role
experiment
singl
cell
chip
use
cell
experiment
space
new
paradigm
labinacel
passeng
ship
isol
commun
high
popul
densiti
crowd
public
room
live
accommod
share
sanitari
facil
common
water
food
suppli
henc
infecti
diseas
easili
transmit
aboard
outbreak
measl
rubella
varicella
meningococc
mening
hepat
legionnair
diseas
influenza
gastroenter
among
passeng
crew
report
fear
health
public
reason
howev
consequ
usual
less
seriou
ferri
carri
peopl
two
close
port
cruis
ship
vessel
cruis
last
week
month
often
visit
remot
area
vari
sanit
standard
evacu
may
possibl
day
ferri
often
carri
medic
personnel
cruis
ship
rule
physician
nurs
cruis
compani
emphas
ill
prevent
preemploy
medic
screen
vaccin
programm
crew
well
detail
rigid
ship
sanit
procedur
one
hundr
outbreak
infecti
diseas
particularli
gastrointestin
diseas
report
associ
ship
despit
good
perform
health
inspect
outbreak
gastroenter
per
cruis
increas
almost
tenfold
increas
mostli
attribut
noroviru
highlight
inabl
environment
programm
fulli
predict
prevent
risk
factor
common
persontoperson
fomit
spread
diseas
much
publicis
outbreak
global
threat
led
cruis
compani
cooper
close
local
nation
intern
public
health
author
effort
result
detail
protocol
deal
everi
aspect
shipboard
sanit
normal
circumst
threat
outbreak
outbreak
includ
mandatori
hand
disinfect
person
enter
ship
strict
isol
demand
case
gastroenter
minimum
hour
last
symptom
isol
aboard
difficult
riski
bedsid
test
quickli
diagnos
rule
noroviru
therefor
high
cruis
industri
wish
list
almost
imposs
ship
compli
differ
requir
port
press
intern
challeng
port
countri
agre
uniform
vessel
sanit
programm
passeng
ship
holiday
provid
ideal
opportun
increas
sexual
contact
whether
taken
home
abroad
travel
releas
form
normal
social
restraint
commun
like
drink
alcohol
take
illeg
drug
whilst
away
travel
advic
usual
includ
inform
prevent
prophylaxi
tradit
infecti
diseas
rare
address
risk
plan
unplan
sexual
activ
whilst
abroad
well
risk
chlamydia
trachomati
neisseria
gonorrhoea
infect
travel
also
risk
hiv
hepat
b
syphili
tropic
sexual
transmit
diseas
std
chancroid
granuloma
inguinal
lymphogranuloma
venereum
need
advic
prior
travel
prophylaxi
access
care
return
accord
risk
symptom
part
routin
consult
travel
clinic
particularli
relev
may
sex
tourist
may
also
requir
addit
inform
potenti
legal
issu
select
diagnosi
individu
nation
surveil
system
apart
quantiti
qualiti
import
infecti
diseas
europ
larg
unknown
experi
last
decad
shown
impact
increas
european
health
system
inde
societi
due
huge
increas
travel
activ
immigr
current
estim
assum
germani
alon
patient
fall
sick
everi
year
journey
outsid
europ
addit
health
system
cope
unknown
number
migrant
need
treatment
varieti
condit
overal
inform
relev
infecti
diseas
endem
area
compar
easi
get
inform
diseas
return
travel
much
difficult
acquir
intern
studi
done
regard
question
result
limit
data
avail
import
infecti
diseas
europ
especi
notifi
countri
tropneteurop
network
surveil
import
infecti
diseas
europ
found
network
tri
foster
collabor
clinician
throughout
contin
order
increas
inform
exchang
knowledg
import
infect
select
diagnosi
report
regularli
anonymis
form
sever
outbreak
among
travel
immigr
detect
sinc
foundat
network
wwwtropnetnet
fever
import
clinic
sign
import
infecti
diseas
post
travel
common
caus
includ
life
threaten
diseas
like
malaria
less
danger
quit
common
diagnos
dengu
fever
present
give
overview
epidemiolog
clinic
data
frequent
caus
fever
post
travel
disucuss
three
fundament
option
exist
prevent
travel
diarrhoea
td
reduct
exposur
chemoprophylaxi
immunis
accord
recent
review
evid
miss
avoid
danger
food
beverag
reduc
risk
td
among
mani
drug
sugget
chemoprophylaxi
probiot
show
best
low
protect
efficaci
rate
bismuth
subsalicyl
modestli
effect
among
antibacteri
agent
trimethoprimsulfamethoxazol
doxycyclin
other
consid
obsolet
antimicrobi
resist
preval
enter
bacteri
pathogen
antimicrobi
resist
also
becom
increas
problem
widespread
use
fluoroquinolon
fear
system
reaction
limit
prescript
medic
poorli
absorb
antibiot
mainli
rifaximin
far
attract
agent
avail
european
countri
whole
cellbsubunit
wcb
cholera
vaccin
repeatedli
shown
prevent
td
ltetec
strain
possibl
even
pathogen
similarli
new
heat
labil
ltetec
transcutan
patch
vaccin
effect
beyond
ltetec
vaccin
recommend
paramount
underlin
protect
efficaci
far
complet
td
may
still
occur
en
rout
current
prophylact
measur
truli
satisfactori
self
therapi
td
remain
import
strateg
option
td
quinolon
seem
still
effect
part
world
lack
recent
data
frequenc
resist
analysi
td
stool
sampl
contin
indic
azithromycin
drug
choic
seasia
often
singl
antimicrobi
dose
suffici
cure
td
increas
concern
postinfecti
irrit
bowel
syndrom
consid
liber
approach
respect
inclus
antimicrobi
travel
kit
vancomycin
imperfect
agent
like
everi
antibiot
nevertheless
day
use
success
hospit
nurs
facil
home
first
line
agent
treatment
infect
due
meticillinresist
staphylococcu
aureu
infect
caus
broad
array
gramposit
bacteria
individu
allerg
otherwis
intoler
blactam
antibiot
enorm
success
clinic
experi
come
spite
widespread
use
nonapprov
indic
base
breakpoint
anted
discoveri
isol
reduc
suscept
without
detail
appreci
tissu
penetr
sometim
circumst
suboptim
ancillari
intervent
drainag
debrid
remov
foreign
materi
patient
toler
vancomycin
well
surprisingli
advers
effect
appear
frequent
higher
usual
dose
utilis
infect
due
organ
high
end
mic
distribut
randomis
doubleblind
prospect
clinic
trial
larg
fail
identifi
newer
agent
superior
clinic
efficaci
vancomycin
despit
tantalis
signal
possibl
advantag
agent
mrsa
potenti
advantag
would
support
anticip
differenti
cost
newer
agent
remain
determin
time
better
antibiot
vancomycin
introduc
assum
right
place
therapi
howev
long
expect
vancomycin
achiev
imposs
treat
infect
due
nonsuscept
organ
site
penetr
antibiot
remain
attract
therapeut
option
tabl
statist
signific
differ
rate
mortal
among
two
group
conclus
c
albican
still
common
candida
speci
major
differ
distribut
candidaemia
isol
among
patient
last
three
year
renal
failur
found
risk
factor
associ
c
albican
candidaemia
prior
antifung
therapi
either
prohylact
empir
found
associ
nonalbican
candidaemia
well
known
appropri
empir
antifung
therapi
import
factor
contribut
low
morbid
mortal
rate
centr
surveil
data
object
echinocandin
increasingli
use
initi
manag
invas
candidiasi
ic
howev
agent
costli
altern
ivpo
convers
programm
reduc
cost
use
antimicrobi
high
oral
bioavail
convers
agent
differ
class
new
concept
object
present
studi
determin
effect
ivpo
convers
programm
echinocandin
oral
azol
clinic
outcom
resourc
utilis
method
consecut
patient
receiv
echinocandin
evalu
studi
period
post
implement
ivpo
intervent
antifung
therapi
complet
discontinu
patient
upon
recommend
ivpo
switch
durat
total
intraven
antifung
therapi
reduc
phase
figur
fluconazol
common
agent
use
po
switch
follow
voriconazol
recurr
clostridium
difficil
associ
diarrhoea
cdad
emerg
problem
hospitalis
patient
nurs
home
pathogenesi
cdad
involv
disturb
homeostasi
normal
bacteri
colonis
larg
bowel
enabl
outgrowth
pathogen
c
difficil
strain
recurr
cdad
may
explain
failur
antibiot
erad
c
difficil
spore
germin
grow
bowel
lack
normal
colon
flora
hostdef
mechan
absenc
normal
colonis
defenc
mechan
illustr
find
clinic
recurr
cdad
may
caus
differ
strain
initi
infect
strain
wilcox
furthermor
coinfect
multipl
strain
describ
patient
factor
associ
recurr
older
age
comorbid
hospitalis
patient
cdad
requir
isol
precaut
prevent
epidem
spread
cdad
often
prolong
hospit
stay
initi
treatment
metronidazol
vancomycin
day
effect
patient
maroo
treatment
relaps
consist
second
cours
antibiot
day
success
rate
mcfarland
subsequ
relaps
treat
week
vancomycin
follow
taperedpuls
vancomycin
regimen
last
sever
week
consequ
recurr
cdad
requir
longterm
often
ineffect
antibiot
treatment
costli
isol
precaut
hospitalis
patient
effect
treatment
strategi
recurr
cdad
need
urgent
eiseman
et
al
describ
success
treatment
patient
sever
antibiot
induc
diarrhoea
enema
contain
donor
stool
sinc
initi
report
patient
treat
donor
faec
recurr
cdad
report
literatur
borodi
clinic
improv
mostli
seen
day
respons
patient
without
report
recurr
side
effect
relat
faecal
therapi
report
efficaci
faecal
therapi
cdad
may
explain
unknown
inhibitori
substanc
bacteriocin
produc
infus
donor
bacteria
restor
faecal
physiolog
implant
miss
flora
compon
importantli
randomis
control
trial
lack
may
reason
faecal
therapi
becom
gener
accept
treatment
strategi
recurr
cdad
appar
lack
interest
faecal
therapi
may
also
relat
reluct
physician
distast
natur
therapi
success
treat
patient
recurr
cdad
suspens
donor
faec
protocol
outlin
tabl
prior
intervent
cdad
recur
median
durat
day
antibiot
metronidazol
vancomycin
isol
precaut
taken
week
hospitalis
patient
faec
deliv
bowel
colonoscopi
nasoduoden
tube
note
three
patient
infect
pcr
ribotyp
strain
often
respond
convent
antibiot
therapi
conclus
healthi
donor
faecal
enema
administr
seem
promis
tool
fight
recurr
cdad
respond
convent
antibiot
therapi
also
pcr
ribotyp
strain
infect
patient
recent
randomis
control
trial
compar
efficaci
donor
stool
suspens
vancomycin
recurr
cdad
initi
introduct
clostridium
difficileassoci
diarrhoea
cdad
becom
common
problem
quebec
hospit
well
mani
european
countri
examin
associ
crowd
patient
emerg
depart
room
condit
hospit
ward
acquisit
nosocomi
clostridium
difficil
infect
set
universityaffili
commun
hospit
montreal
quebec
nest
casecontrol
studi
design
condit
logist
regress
analysi
perform
use
administr
data
patient
age
admit
emerg
depart
ed
medic
unit
recent
antibiot
prescript
relationship
three
group
variabl
ed
exposur
measur
length
stay
level
crowd
inpati
variabl
unit
room
type
number
room
chang
antibiot
type
occurr
nosocomi
cdad
examin
control
sever
factor
previous
identifi
associ
cdad
transmiss
associ
occurr
cdad
group
administ
antibiot
sampl
conclus
studi
fail
identifi
signific
associ
nosocomi
cdad
measur
ed
crowd
increas
patient
contact
due
room
chang
use
multib
ward
room
howev
valid
methodolog
support
associ
antibiot
prescript
nosocomi
cdad
occurr
alreadi
quot
literatur
note
tempor
decreas
report
rate
clostridium
difficil
infect
institut
sinc
studi
period
april
march
suggest
like
reason
improv
housekeep
practic
period
thermal
condit
kill
c
difficil
spore
pb
ie
organ
challeng
also
evalu
use
spore
suspens
test
two
differ
make
wbpw
evalu
result
data
suspens
test
show
c
difficil
spore
count
reduc
minut
simulatedus
test
demonstr
wardbpw
use
without
deterg
effect
elimin
c
difficil
spore
inocul
plastic
stainless
steel
bedpan
wherea
cpdbpw
thermal
disinfect
default
cycl
two
make
wbpw
cpdbpw
minut
guidanc
document
recommend
thermal
condit
adequ
reprocess
bedpan
exposur
condit
result
reduct
spore
howev
min
thermal
cycl
combin
dri
cycl
min
use
cpdbpw
kill
c
difficil
spore
test
show
use
alkalin
deterg
along
wbpw
reliabl
elimin
c
difficil
spore
conclus
despit
wide
use
minut
data
show
thermal
condit
alon
effect
kill
c
difficil
spore
alkalin
deterg
use
wbpw
abl
elimin
c
difficil
spore
bedpan
recommend
alkalkin
deterg
alway
use
wbpw
reduc
risk
c
difficil
spore
remain
reprocess
bedpan
could
pose
risk
nosocomi
transmiss
harbour
haplotyp
describ
ancestr
allel
gave
rise
variant
trend
although
larg
regionalis
must
taken
account
target
skin
infect
well
infect
includ
communityacquir
pneumonia
summari
emerg
tendenc
toward
increas
incid
camrsa
decreas
suscept
antimicrobi
agent
must
consid
choos
empir
treatment
option
us
citi
camrsa
common
pathogen
cultur
patient
skin
soft
tissu
infect
emerg
depart
epidem
communityassoci
mrsa
diseas
also
report
rural
area
canada
similar
pattern
emerg
occur
west
coast
affect
concern
risk
greater
incid
communityacquir
pneumonia
caus
mrsa
futur
although
sever
pneumonia
caus
camrsa
report
children
soon
pathogen
emerg
us
report
adult
rare
typic
associ
influenza
viru
infect
howev
center
diseas
control
prevent
report
case
sever
mrsa
cap
six
patient
die
although
small
sampl
patient
case
nonetheless
underscor
need
healthcar
provid
extrem
vigil
case
sever
cap
caus
mrsa
emerg
mrsa
strain
sinc
complic
treatment
aureu
infect
glycopeptid
vancomycin
teicoplanin
mani
case
therapeut
altern
glycopeptid
remain
firstlin
option
infect
due
mrsa
suspect
diagnos
howev
vancomycin
treatment
failur
uncommon
even
mrsa
strain
fulli
suscept
vancomycin
mic
mgml
reduct
efficaci
vancomycin
mrsa
strain
high
vancomycin
mic
mgml
describ
observ
studi
low
number
patient
suggest
subtl
chang
mic
may
explain
clinic
failur
find
requir
healthcar
practition
consid
altern
treatment
look
futur
newer
activ
compound
develop
improv
treatment
armamentarium
communityacquir
infect
drug
resist
aureu
searchanddestroy
consid
one
effect
mean
curtail
increas
preval
nosocomi
resist
organ
includ
meticillinresist
staphylococcu
aureu
mrsa
implement
strategi
certain
european
countri
decreas
preval
mrsa
infect
nosocomi
set
first
time
nevertheless
parallel
increas
mrsa
isol
commun
set
includ
nurs
home
healthcareassoci
facil
observ
past
decad
consequ
communityacquir
mrsa
infect
increasingli
recognis
nosocomi
set
make
difficult
integr
prevent
strategi
standard
hospit
procedur
moreov
influx
welldispers
commun
clone
carri
type
iv
staphylococc
cassett
chromosom
sccmec
type
iv
nosocomi
set
demonstr
countri
high
preval
mrsa
commun
potenti
associ
isol
product
panton
valentin
leucocidin
pvl
clinic
concern
initi
empir
coverag
pathogen
organ
restrict
standard
antimicrobi
treatment
protocol
communityand
hospitalacquir
mrsa
infect
includ
nonblactam
antimicrobi
among
glycopeptid
consid
gold
standard
date
isol
case
complet
glycopeptid
resist
aureu
vrsa
report
howev
lowlevel
resist
vancomycinintermedi
aureu
visa
document
worldwid
isol
display
thicken
cell
wall
affect
activ
glycopeptid
recent
data
also
demonstr
isol
mrsa
isol
heterogen
subpopul
decreas
suscept
glycopeptid
heterogen
visa
possibl
slight
rise
modal
vancomycin
mic
valu
within
suscept
categori
mic
rang
mgml
may
affect
clinic
success
glycopeptid
treatment
possibl
observ
differ
infect
includ
bacteraemia
true
incid
mrsa
popul
decreas
suscept
glycopeptid
unclear
might
depend
popul
structur
distribut
maintain
vigil
surveil
resist
trend
critic
ensur
appropri
coverag
treatment
option
invas
mrsa
infect
current
includ
vancomycin
linezolid
daptomycin
tigecyclin
quinupristindalfopristin
addit
number
compound
combat
grow
resist
problem
develop
includ
novel
glycopeptid
dalbavancin
telavancin
oritavancin
nextgener
cephalosporin
ceftobiprol
ceftarolin
demonstr
excel
vitro
activ
mrsa
visa
vrsa
addit
new
agent
armamentarium
critic
manag
patient
infect
due
mrsa
encount
hospit
commun
set
epidemiolog
respiratori
viru
infect
use
xtag
rvp
test
j
b
mahoni
chong
smieja
petrich
buracond
j
babwah
hamilton
ca
background
discoveri
five
new
respiratori
virus
sinc
year
advanc
molecular
technolog
allow
detect
respiratori
virus
singl
test
studi
epidemiolog
respiratori
viru
infect
method
total
np
specimen
collect
symptomat
patient
yr
yr
use
studi
approxim
specimen
age
group
sect
blindli
dfa
cultur
result
unknown
specimen
submit
region
virolog
laboratori
month
novemb
octob
nucleic
acid
extract
use
minimag
extractor
biomerieux
test
idtag
rvp
test
tmbioscienc
respiratori
virus
bocaviru
use
separ
pcr
clinic
inform
collect
chart
review
result
analys
month
age
twenti
five
bocaviru
infect
dual
infect
rhinoentero
rsv
bocaviru
preval
age
group
p
influenza
metapneumoviru
coronaviru
present
winterspr
month
parainfluenza
type
present
summer
month
other
distribut
across
month
discuss
studi
indic
follow
rhinoenteroviru
preval
viru
infect
symptomat
children
adult
rsv
rhinoenteroviur
bocaviru
show
higher
infect
rate
children
compar
adult
dual
infect
mostli
boca
rhinoenteroviru
occur
children
summer
influenza
metapneumoviru
coronaviru
display
winter
season
averag
rate
posit
diagnos
per
month
yr
group
compar
adult
jemiel
barbani
staub
grandgirard
gorgievskihrisoho
bern
ch
respiratori
virus
among
frequent
human
pathogen
worldwid
lead
signific
number
hospitalis
especi
children
immunecompromis
patient
sever
new
diagnost
tool
respiratori
virus
recent
appear
market
includ
xtag
respiratori
viral
panel
rvp
luminex
molecular
diagnost
goal
present
studi
compar
new
multiplex
pcr
method
convent
direct
immunofluoresc
dif
children
nasopharyng
aspir
follow
virus
respiratori
sincyti
viru
rsv
adenoviru
adv
parainfluenza
virus
pif
influenza
virus
b
well
human
metapneumoviru
hmpv
rvp
kit
permit
addit
detect
enterorhinovirus
coronavirus
parainfluenza
viru
total
nasopharyng
aspir
dif
neg
dif
posit
sampl
analys
rsv
piva
hmpv
dif
posit
sampl
respect
confirm
posit
viru
rvp
adv
howev
dif
posit
sampl
also
adv
posit
rvp
sampl
discrep
result
current
reanalys
dif
second
independ
pcr
note
find
dif
neg
sampl
posit
analys
rvp
great
part
due
addit
enterorhinovirus
detect
rvp
also
addit
rsv
pif
adv
hmpv
posit
sampl
miss
dif
assay
final
use
rvp
detect
mani
doubl
tripl
infect
versu
singl
doubl
infect
detect
dif
implic
find
diagnost
well
clinic
practic
discuss
one
hundr
thirti
seven
sampl
swab
specimen
nasopharyng
aspir
bronchoalveolar
lavag
sampl
collect
octob
decemb
hospitalis
patient
investig
presenc
respiratori
virus
sixti
three
percent
posit
one
viru
coinfect
detect
among
test
detect
rsv
parinfluenza
virus
virus
detect
cultur
direct
test
addit
detect
metapneumovirus
enterorhino
virus
varicella
zoster
infect
luminex
rvp
adapt
routin
work
laboratori
give
result
within
hour
clinician
sensit
specif
detect
broad
rang
respiratori
virus
use
luminex
rvp
assay
applic
routin
viral
diagnost
j
fox
k
pabbaraju
k
tokaryk
wong
wong
k
ho
calgari
ca
background
object
detect
broad
rang
respiratori
virus
use
sensit
nucleic
acid
amplif
test
nat
invalu
individu
patient
diagnosi
manag
outbreak
wide
rang
potenti
pathogen
make
test
expens
labori
use
individu
realtim
nat
object
studi
compar
multiplex
detect
respiratori
viral
target
use
luminex
xtagtm
respiratori
viral
panel
rvp
individu
realtim
nat
use
provlab
alberta
method
nasopharyng
sampl
prescreen
dfa
influenza
ifv
b
parainfluenza
piv
respiratori
syncyti
viru
rsv
direct
fluoresc
antigen
dfa
posit
sampl
exclud
compar
studi
respiratori
specimen
collect
decemb
may
nucleic
acid
extract
undertaken
use
easymag
extractor
reagent
individu
realtim
nat
comparison
rvp
direct
ifva
ifvb
rsv
human
metapneumoviru
hmpv
respiratori
adenovirus
total
specimen
part
analysi
specimen
analys
prospect
retrospect
rvp
posit
result
coronavirus
picornavirus
obtain
rvp
assay
sampl
subsequ
screen
addit
realtim
nat
target
test
part
current
diagnost
routin
result
total
specimen
posit
one
respiratori
virus
individu
nat
one
posit
result
rvp
assay
rate
detect
hmpv
ifva
compar
method
posit
result
respect
detect
rate
ifvb
rsv
realtim
assay
correspondingli
rvp
assay
detect
adenoviru
superior
inhous
nat
posit
compar
rvp
assay
howev
rvp
assay
identifi
sampl
picornaviru
posit
confirm
sequenc
half
identifi
individu
nat
undertaken
enterovirus
rhinovirus
ifva
posit
specimen
subtyp
rvp
assay
total
sampl
posit
coronavirus
detect
luminex
rvp
confirm
realtim
rtpcr
assay
conclus
luminex
rvp
assay
meet
current
standard
sensit
specif
also
allow
multiplex
detect
respiratori
viral
target
consider
time
cost
save
compar
altern
nat
method
becom
front
line
respiratori
viru
test
laboratori
pregnant
women
increas
risk
malaria
infect
although
import
advanc
made
last
year
mechan
explain
increas
suscept
parasit
diseas
yet
fulli
understood
malaria
infect
pregnanc
may
associ
matern
fetal
morbid
mortal
sever
burden
depend
level
prepregn
acquir
immun
malaria
thu
consequ
infect
sever
nonimmun
women
acquir
certain
level
antimalari
immun
highli
endem
area
frequenc
sever
infect
higher
primigravida
decreas
increas
pariti
nonimmun
women
risk
similar
across
pariti
malaria
may
import
direct
caus
matern
mortal
malaria
infect
pregnanc
may
import
neg
effect
infant
health
intrauterin
growth
retard
prematur
directli
congenit
infect
control
malaria
pregnanc
adequ
case
manag
implement
prevent
tool
public
health
prioriti
malaria
endem
area
emerg
infect
driven
climat
chang
emerg
infect
driven
climat
chang
past
present
probabl
also
futur
emerg
infecti
diseas
caus
pathogen
transmit
arthropod
vector
sensit
climat
commonli
assum
driven
climat
chang
howev
priori
reason
expect
rate
system
biolog
demograph
process
respond
chang
pattern
temperatur
moistur
stress
way
inevit
increas
risk
human
livestock
infect
prerequisit
reliabl
earli
warn
futur
systemspecif
explan
past
tickborn
enceph
tbe
one
two
widespread
preval
medic
signific
vectorborn
diseas
europ
present
case
studi
epidemiolog
data
fine
tempor
spatial
resolut
record
major
upsurg
incid
recent
decad
time
degre
abrupt
upsurg
differ
markedli
countri
even
district
within
countri
signific
discontinu
temperatur
condit
across
europ
could
creat
gener
permiss
environ
tbe
viru
transmiss
improv
circumst
necessari
larval
nymphal
stage
tick
cofe
rodent
pattern
climat
chang
howev
uniform
within
countri
provid
sole
even
import
explan
extrem
spatiotempor
heterogen
tbe
epidemiolog
instead
nexu
interact
factor
affect
risk
infect
exposur
human
risk
differ
forc
space
time
power
model
analysi
situat
central
eastern
europ
establish
mani
factor
driven
socioeconom
chang
associ
end
soviet
rule
includ
climat
land
cover
land
use
wildlif
agricultur
practic
industri
activ
un
employ
incom
western
nordic
europ
must
incorpor
achiev
coher
paneuropean
explan
principl
may
appli
period
epidem
crimeacongo
haemorrhag
fever
varicellazost
vzv
caus
chickenpox
viru
establish
latenc
cranial
nerv
dorsal
root
ganglia
vzv
dna
detect
neuron
human
trigemin
ganglia
autopsi
median
viral
genom
per
posit
neuron
latent
vzv
dna
rare
ever
detect
nonneuron
cell
viru
reactiv
latent
infect
ganglia
caus
shingl
varicella
vaccin
viru
may
also
reactiv
caus
shingl
especi
immunocompromis
patient
use
pcr
detect
vzv
dna
blood
immunocompromis
patient
present
abdomin
pain
absenc
rash
allow
earli
therapi
prior
develop
rash
shingl
least
six
vzv
gene
gene
express
latent
infect
ganglia
human
construct
vzv
mutant
lack
five
gene
found
three
gene
essenti
replic
cell
cultur
one
import
effici
replic
one
dispens
replic
mutat
code
region
one
latenc
gene
gene
result
impair
replic
vitro
mark
reduct
latenc
rodent
replac
nativ
promot
one
latenc
gene
gene
major
immediateearli
cytomegaloviru
promot
result
viru
replic
level
compar
wildtyp
viru
viru
impair
latenc
rodent
studi
suggest
chang
code
promot
region
latenc
gene
vzv
might
serv
use
vaccin
candid
vaccin
might
less
like
establish
latenc
reactiv
human
may
especi
use
immunocompromis
patient
role
rna
regul
virul
antibiot
resist
gene
express
small
noncod
rna
control
pathogenesi
mani
bacteria
use
form
cellcel
signal
term
quorum
sens
coordin
gene
express
function
popul
densiti
quorum
sens
enabl
bacteria
coordin
populationwid
respons
play
crucial
role
virul
complex
quorum
sens
network
enabl
bacteria
detect
signal
provid
inform
regard
number
individu
popul
differ
speci
bacteria
present
commun
addit
input
environment
metabol
signal
recent
becom
clear
small
noncod
rna
srna
often
central
regul
modul
gene
express
central
step
quorum
sens
cascad
therefor
coordin
complex
network
control
virul
bacteria
importantli
multipl
function
redund
srna
act
togeth
key
step
regulatori
cascad
differ
srna
differenti
express
respond
differ
signal
thu
provid
mechan
integr
differ
environment
stimuli
translat
combin
inform
appropri
output
studi
quorum
sens
signal
name
autoinduc
unlik
quorum
sens
signal
speciesspecif
produc
detect
wide
varieti
bacteria
allow
interspeci
commun
studi
interspeci
signal
consortia
found
escherichia
coli
manipul
signal
organ
human
pathogen
vibrio
cholera
interfer
speci
abil
regul
virul
show
enter
bacterium
synthas
lux
regul
srna
object
iclaprim
icl
belong
diaminopyrimidin
class
antimicrobi
dihydrofol
reductas
dfhr
inhibitor
trimethoprim
tmp
well
known
repres
icl
exhibit
expand
spectrum
activ
notabl
potent
import
gramposit
pathogen
includ
meticillinresist
aureu
mrsa
purpos
studi
substanti
previou
studi
mode
action
icl
aureu
method
one
tmpsuscept
wtdhfr
atcc
two
tmpresist
dhfr
one
carri
specif
point
mutat
one
multidrug
resist
strain
use
studi
dhfr
overexpress
purifi
use
determin
ki
bind
isotherm
titrat
calorimetri
itc
cocrystallis
icl
tmp
result
icl
tmp
exhibit
competit
bind
three
enzym
icl
ki
lower
tmp
wt
respect
itc
icl
tmp
produc
exotherm
bind
neg
chang
enthalpi
associ
constant
ka
enzym
icl
stronger
tmp
calcul
deltag
kcalmol
cocrystallis
data
show
diaminopyrimidin
moieti
icl
tmp
bind
similarli
wtand
enzym
lipophil
part
molecul
situat
hydrophob
channel
enzym
form
sidechain
residu
larger
size
icl
lipophil
residu
result
enlarg
hydrophob
contact
surfac
area
protein
conclus
icl
tmp
bind
inhibit
aureu
enzym
similar
manner
increas
potenc
icl
toward
tmpr
dhfr
enzym
due
larger
bind
contact
area
agreement
enhanc
activ
icl
tmp
tmpr
aureu
isol
conclus
broadspectrum
carbapenem
exquisit
potent
activ
gramposit
pathogen
respiratori
pathogen
h
influenza
catarrhali
potenti
use
new
agent
treatment
seriou
communityand
hospitalacquir
respiratori
tract
infect
object
aim
studi
examin
vivo
efficaci
new
prolinerich
antibacteri
peptid
previous
prove
vitro
bactericid
enter
bacteri
strain
method
femal
mice
g
pretreat
mgkg
cisplatin
day
impair
kidney
clearanc
similar
human
challeng
intraperiton
ip
cfu
per
g
mous
extendedspectrum
blactamas
produc
e
coli
strain
four
hour
challeng
mgkg
imipenem
mgkg
administ
mice
concentr
antimicrobi
prior
drug
administr
blood
taken
tail
vein
mice
either
infect
untreat
infect
treat
group
determin
blood
bacteri
count
result
blood
bacteri
count
amount
cfuml
hour
challeng
exceed
cfuml
hour
untreat
mice
contrast
concentr
decreas
blood
bacteri
level
two
unit
four
hour
administr
eg
cfuml
similar
imipenem
treatment
continu
dose
either
peptid
imipenem
retain
blood
bacteri
count
lowest
detect
level
conclus
knowledg
first
antibacteri
peptid
effect
mortal
model
gramneg
system
infect
exert
bactericid
activ
vivo
dose
compar
tradit
antibiot
without
notabl
toxic
side
effect
support
sbarro
health
research
organ
hungarian
otka
object
osteomyel
infect
bone
primarili
caus
staphylococci
treatment
often
requir
combin
surgic
intervent
prolong
antibiot
therapi
gener
reli
outpati
parenter
antibacteri
therapi
week
report
develop
new
class
prodrug
rifamycin
tether
bisphosphon
moieti
possess
high
affin
osseou
tissu
compound
deliv
antibiot
directli
infect
site
concentr
releas
time
exert
therapeut
activ
method
compound
synthesis
tether
rifabutin
rifalazil
adequ
design
rifamycin
bisphosphon
moieti
via
cleavabl
coval
linker
affin
compound
toward
bone
powder
determin
individu
measur
amount
unbound
prodrug
supernat
bioassay
total
amount
materi
follow
exposur
bovin
bone
powder
phosphatebuff
salin
pb
centrifug
rate
cleavag
determin
resuspend
obtain
bone
pellet
either
pb
serum
pb
overnight
measur
bioassay
drug
content
supernat
centrifug
result
total
prodrug
synthesis
use
differ
chemic
andor
enzymat
cleavabl
linker
rifamycin
deriv
prodrug
display
near
quantit
bone
bind
valid
select
bisphosphon
boneseek
moieti
follow
incub
bonebound
prodrug
level
regener
parent
antibiot
rang
mol
pb
mol
rat
serum
abil
bisphosphon
rifamycin
class
prodrug
bind
effici
bone
powder
releas
parent
antibacteri
agent
time
establish
vitro
suggest
could
use
deliv
antibacteri
rifamycin
bone
system
administr
augur
well
potenti
approach
toward
prevent
treatment
osteomyel
rak
e
goncharova
vinogradov
e
ryabchikova
chinarev
tuzikov
n
bovin
ryzhikov
koltsovo
moscow
ru
background
human
infect
influenza
b
virus
initi
specif
interact
viral
glycoprotein
hemagglutinin
carbohydr
chain
cell
surfac
receptor
termin
predominantli
disaccharid
synthet
analog
cellular
receptor
abl
compet
natur
cellular
receptor
potenti
develop
antiinfluenza
therapeut
synthesi
lowmolecular
inhibitor
influenza
viru
prefer
develop
therapeut
reason
possibl
toxic
immunogen
incomplet
biodegrad
polymer
compound
object
studi
compar
antiinfluenza
activ
clarifi
mechan
action
lowmolecular
highmolecular
polymer
compound
contain
disaccharid
conduct
compar
studi
antivir
effect
lowand
highmolecular
hemagglutinin
inhibitor
influenza
b
virus
inhibit
assay
infecti
focu
form
mdck
cell
characteris
efficaci
inhibitor
vivo
investig
mous
model
base
measur
valu
fifti
percent
respiratori
infecti
dose
mice
elucid
mechan
action
hemagglutinin
inhibitor
examin
influenza
virion
morpholog
neg
contrast
techniqu
valu
fifti
percent
inhibit
concentr
obtain
mdck
microm
lowmolecular
hemagglutinin
inhibitor
microm
highmolecular
hemagglutinin
inhibitor
intranas
administr
mgkg
lowmolecular
inhibitor
mgkg
polymer
inhibitor
complet
protect
mice
influenza
viru
infect
electron
microscop
studi
virion
morpholog
show
direct
damag
influenza
viru
particl
lowand
highmolecular
compound
allow
us
propos
mechan
virucid
action
hemagglutinin
inhibitor
conclus
data
show
signific
antivir
effect
lowand
highmolecular
hemagglutinin
inhibitor
influenza
virus
low
micromolar
concentr
although
consid
highmolecular
hemagglutinin
inhibitor
candid
antiinfluenza
drug
due
probabl
toxic
limit
biocompat
polym
lowmolecular
hemagglutinin
inhibitor
potenti
prevent
influenza
viru
infect
specif
virucid
therapeut
tick
lyme
borrelliosi
detect
borrelia
bissettii
south
bohemia
region
czech
republ
case
singl
multipl
infect
human
n
rudenko
golovchenko
n
piskunova
ruzek
l
grubhoff
cesk
budejovic
cz
twelv
serum
sampl
patient
symptomat
borreliosi
sampl
cardiac
valv
tissu
patient
endocard
cardial
stenosi
associ
chronic
borreli
infect
collect
hospit
cesk
budejovic
cz
serolog
test
gave
neg
result
case
goal
project
analys
sampl
human
origin
molecular
techniqu
serum
cardiac
valv
tissu
use
direct
dna
purif
flagellin
gene
chosen
target
analysi
pcr
primer
set
amplif
fla
gene
borrelia
burgdorferi
sensu
lato
bb
sl
complex
use
direct
sequenc
amplicon
indic
presenc
differ
sequenc
clone
step
allow
separ
nineti
six
recombin
sampl
sequenc
silico
rflp
analysi
restrict
endonucleas
conduct
virtual
hybridis
probe
design
detect
bb
sl
speciespecif
probe
use
maximum
parsimoni
heurist
search
perform
paup
implement
treebisectionreconnect
algorithm
align
charact
long
parsimoni
inform
recognis
speci
bb
sl
complex
use
control
result
case
confirm
carri
b
burgdorferi
ss
b
bissettii
b
garinii
multipl
spirochet
speci
coinfect
sampl
defin
doubl
infect
b
burgdorferi
ss
b
bissettii
tripl
infect
b
bissettii
b
burgdorferi
ss
b
garinii
ident
speci
confirm
similar
search
use
genbank
rflp
pattern
virtual
hybridis
paup
recent
thought
genospeci
firmli
establish
well
accept
might
caus
lyme
diseas
ld
ie
b
burgdorferi
sensu
stricto
b
afzelii
b
garinii
howev
genospeci
also
connect
ld
isol
human
ld
symptom
b
bissettii
b
spielmanii
first
isol
b
bissettii
sampl
human
origin
slovenia
result
second
evid
involv
b
bissettii
ld
europ
presenc
b
bissettii
singl
strain
human
symptomat
borreliosi
chronic
borreli
infect
strong
support
fact
b
bissettii
member
ld
complex
caus
agent
diseas
north
sea
island
ameland
g
noordhoek
jjwn
jacob
jmm
brouwer
jpam
jacob
ah
brandenburg
leeuwarden
ballum
groningen
nl
object
dutch
island
ameland
describ
previous
hot
spot
borrelia
burgdorferi
tick
investig
percentag
infect
tick
risk
subsequ
develop
clinic
symptom
lyme
diseas
person
one
tick
bite
consult
famili
practic
island
method
januari
decemb
tick
collect
patient
test
presenc
borrelia
dna
pcr
six
month
remov
patient
question
erythema
migran
symptom
possibl
relat
b
burgdorferi
infect
blood
sampl
taken
subset
patient
investig
b
burgdorferi
antibodi
result
tick
b
burgdorferi
dna
detect
forti
patient
bitten
least
one
posit
tick
follow
inform
avail
person
posit
tick
neg
tick
person
tick
remov
within
hour
includ
person
posit
tick
none
patient
report
erythema
migran
twelv
person
report
nonspecif
red
discolor
skin
fulfil
critera
em
site
tick
bite
first
week
tick
bite
four
bitten
posit
tick
eight
neg
tick
surprisingli
four
patient
posit
tick
consult
famili
doctor
treat
doxycyclin
wherea
none
eight
neg
tick
one
patient
bitten
posit
tick
skin
hour
report
system
symptom
compat
lyme
diseas
report
red
site
tick
bite
lyme
serolog
perform
person
posit
tick
two
posit
includ
patient
system
symptom
serolog
perform
seven
person
neg
tick
one
posit
igg
conclus
cohort
patient
tick
bite
chanc
develop
lyme
diseas
low
even
tick
posit
b
burgdorferi
probabl
relat
fact
major
tick
remov
within
hour
find
support
polici
describ
dutch
cboguidelin
lyme
borreliosi
preserv
antibiot
therapi
patient
develop
symptom
lyme
diseas
j
oliv
jr
n
rudenko
golovchenko
l
grubhoff
statesboro
us
cesk
budejovic
cz
recent
studi
borrelia
isol
cultur
sampl
collect
varieti
rodent
bird
tick
differ
local
southern
region
unit
state
addit
larg
group
highli
divers
strain
relat
borrelia
bissettii
anoth
rather
homogen
group
strain
repres
borrelia
burgdorferi
sensu
stricto
group
isol
unusu
characterist
found
isol
cultur
ear
biopsi
rodent
peromyscu
gossypinu
neotoma
floridana
main
reservoir
host
borrelia
southern
us
rodent
trap
differ
local
south
carolina
septemb
till
august
new
methodolog
multilocu
sequenc
analysi
mlsa
involv
studi
rrfrrl
intergen
spacer
region
rr
rrna
gene
flagellin
gene
ospa
gene
gene
use
clarifi
taxonom
statu
new
highli
homogen
group
south
carolina
isol
recognis
speci
b
burgdorferi
sl
complex
use
control
associ
speci
lyme
diseas
group
confirm
multipl
result
mlsa
virtual
hybridis
rrfrrl
spacer
region
flagellin
gene
ospa
gene
probe
previous
describ
experiment
use
among
loci
identif
b
burgdorferi
sl
speci
show
ident
uniqu
rflp
pattern
discov
rrfrrl
intergen
spacer
region
flagellin
gene
south
carolina
isol
uniqu
signatur
nucleotid
alloc
rrna
gene
maximum
parsimoni
heurist
search
perform
paup
implement
treebisectionreconnect
algorithm
loci
phylogenet
analysi
show
main
speci
b
burgdorferi
sl
complex
form
coher
cluster
sequenc
south
carolina
isol
cluster
togeth
separ
speci
b
burgdorferi
sl
complex
contrari
dogma
b
burgdorferi
sl
present
wide
distribut
southern
us
occur
mani
part
previous
thought
occur
substanti
amount
addit
result
highli
support
design
new
b
burgdorferi
sl
speci
southern
unit
state
analysi
cultur
borrelia
strain
south
carolina
still
progress
new
speci
describ
formal
anoth
articl
cerar
e
sabljic
k
ogrinc
f
strle
ljubljana
si
object
common
microbiolog
approach
confirm
borreli
infect
detect
antibodi
borrelia
burgdorferi
sensu
lato
bodi
fluid
serolog
method
method
differ
relat
sever
characterist
includ
sensit
specif
ideal
serolog
test
avail
aim
studi
analys
compar
detect
immun
respons
three
differ
serolog
test
present
studi
test
sera
patient
suspect
lyme
borreliosi
collect
routin
work
three
serolog
method
target
differ
borreli
antigen
immunofluoresc
assay
ifa
local
isol
b
afzelii
strain
frequent
isol
borrelia
speci
slovenia
use
antigen
ii
lyme
borreliosi
elisa
kit
dakocytom
denmark
antigen
purifi
nativ
b
burgdorferi
flagellum
iii
chemiluminisc
immunoassay
liaison
diasorin
saluggia
itali
antigen
igm
antibodi
detect
ospc
igg
antibodi
vl
e
antigen
use
presenc
borreli
igm
antibodi
patient
sera
ascertain
ifa
elisa
liaison
respect
presenc
igg
antibodi
establish
ifa
elisa
liaison
respect
communityacquir
lower
respiratori
tract
infect
three
test
gave
concord
result
igm
igg
antibodi
respect
conclus
detect
borreli
igm
antibodi
elisa
found
sensit
two
test
liaison
found
sensit
test
detect
igg
antibodi
differ
sensit
three
test
could
result
differ
antigen
andor
distinct
method
utilis
antibodi
detect
discrep
find
obtain
ident
sera
strongli
indic
need
standardis
serolog
method
detect
borrelia
burgdorferi
sensu
lato
infect
j
v
fingerl
hurm
mk
viljanen
j
oksi
turku
fi
munich
de
object
previous
report
result
antibiot
treatment
studi
dissemin
lyme
borreliosi
mainli
neuroborreliosi
lnb
arthriti
la
analys
whether
treatment
iv
ceftriaxon
follow
cours
oral
amoxicillin
oksi
et
al
eur
j
clin
microbiol
infect
di
differ
clinic
outcom
evalu
visual
analogu
scale
observ
two
group
addit
borrelia
serolog
use
inhous
whole
bacterium
elisa
commerci
assay
base
borreli
flagella
antigen
ideia
dako
carri
patient
sampl
statist
signific
differ
antibodi
respons
found
patient
receiv
amoxicillin
placebo
importantli
chang
antibodi
level
associ
clinic
outcom
indic
test
use
predict
outcom
object
present
studi
examin
develop
borrelia
specif
antibodi
patient
use
array
borreli
antigen
specif
want
look
serolog
marker
good
respons
antibiot
treatment
method
sampl
drawn
patient
initi
antibiot
treatment
month
treatment
analys
use
hous
recombin
igg
igm
line
immunoblot
igg
antigen
igm
antigen
goettner
et
al
j
clin
microbiol
recomblot
borrelia
igg
immunoblot
antigen
mikrogen
patient
independ
treatment
includ
analysi
pair
sampl
avail
patient
associ
outcom
chang
antibodi
direct
individu
antigen
statist
test
use
pearson
chisquar
test
pvalu
less
consid
statist
signific
declin
igg
antibodi
vlse
observ
often
patient
good
outcom
patient
poor
outcom
declin
observ
often
patient
lnb
patient
la
ii
declin
igg
antibodi
ospc
observ
often
patient
good
outcom
compar
patient
poor
outcom
vlse
declin
ospc
igg
antibodi
observ
often
patient
lnb
la
result
suggest
declin
antibodi
direct
vlse
ospc
protein
may
use
indic
good
outcom
antibiot
treatment
lyme
borreliosi
last
decad
influenza
pneumonia
rank
lead
caus
death
unit
state
develop
world
problem
even
acut
respiratori
tract
infect
lead
caus
death
children
outsid
neonat
period
streptococcu
pneumonia
lead
bacteri
caus
pneumonia
sepsi
otiti
media
mening
account
signific
portion
mortal
influenza
also
major
contributor
primari
infect
interact
bacteri
pathogen
increas
incid
sever
pneumonia
pneumococcu
common
secondari
pathogen
follow
influenza
typic
interpandem
year
affect
mainli
young
frail
elderli
staphylococcu
aureu
seen
commonli
highli
virul
viral
strain
circul
emerg
recent
year
caus
necrotis
pneumonia
copathogen
influenza
healthi
children
young
adult
laboratori
studi
mechan
underli
interact
respiratori
virus
influenza
viru
bacteri
pathogen
pneumonia
aureu
approach
taken
isol
specif
virul
factor
viru
bacterium
use
genet
approach
modifi
delet
allow
assess
impact
relev
anim
model
certain
theme
cooper
pathogen
emerg
analysi
give
us
insight
specif
pathogen
mechan
reveal
differ
differ
viralbacteri
pair
differ
strain
one
pathogen
find
laboratori
relat
back
epidemiolog
coinfect
human
help
defin
challeng
face
moder
morbid
mortal
pathogen
ultim
goal
work
appli
knowledg
facilit
treatment
prevent
common
diseas
target
cooper
interact
make
coinfect
deadli
recognis
socal
spanish
influenza
pandem
major
death
due
flu
occur
day
onset
symptom
overwhelm
major
case
pandem
influenza
sign
symptom
resolv
day
subgroup
signific
mortal
ill
worsen
second
week
ill
abund
evid
mortal
pandem
due
combin
influenza
plu
bacteri
superinfect
common
bacteri
caus
death
pneumococcu
nosocomi
spread
group
streptococci
often
lethal
staphylcoccc
infect
young
soldier
death
due
influenza
complic
bacteraemia
antibiot
avail
naiv
believ
antibiot
reliabl
save
individu
suffer
cytokin
storm
pandem
influenza
simultan
bacteraemia
prophylact
antibiot
consid
progress
pneumonia
may
imposs
predict
amount
antibiot
need
given
consider
infect
influenza
addit
approach
reduc
mortal
vaccinationvaccin
pandem
influenza
strain
first
prioriti
vaccin
avail
vaccin
current
howev
avail
prevent
pneumococc
infect
data
randomis
trial
pneumococc
conjug
vaccin
pcv
show
children
immunis
pcv
less
hospitalis
pneumonia
due
endem
influenza
valent
pneumococc
vaccin
highli
protect
bacteraemia
given
healthi
young
adult
widespread
pcv
administr
children
includ
booster
dose
second
year
life
essenti
ensur
protect
plu
best
chanc
herd
immun
pcv
type
older
popul
healthcar
worker
militari
personel
first
respond
receiv
vaccin
pandem
threat
level
reach
level
attempt
made
time
also
strengthen
exist
recommend
immunis
risk
elderli
person
vaccin
pandem
influenza
plan
present
fail
recognis
potenti
essenti
role
pneumococc
vaccin
prevent
mortal
pandem
influenza
strain
camrsa
addit
hospit
screen
extend
high
risk
surgic
unit
admiss
object
superantigen
exotoxin
toxic
shock
toxin
appear
major
virul
factor
hospit
meticillinresist
staphylococcu
aureu
clone
hamrsa
japan
staphylococc
enterotoxin
may
involv
septic
shock
mrsa
enterocol
control
enterotox
mrsa
infect
examin
homeostasi
intestin
bacteria
mrsa
prolifer
accord
control
intestin
bacteria
four
gam
broth
tube
prepar
tube
inocul
cfuml
viabl
escherichia
coli
enterococcu
faecali
bacteroid
fragili
cultiv
hour
independ
cultiv
next
gam
broth
tube
prepar
inocul
mix
strain
mix
cultiv
b
manag
eight
day
total
parent
nutrit
tpn
continu
administr
antacid
viabl
bacteri
count
larg
bowel
male
wistar
rat
bodi
weight
count
inocul
cfurat
solut
gastric
tube
day
four
viabl
mrsa
count
compar
among
mix
cultiv
tube
ad
moxalactam
mox
metronidazol
mtn
moxmtn
b
chemoprophylaxi
cp
group
rat
inocul
mrsa
solut
three
day
oral
antibiot
kanamycin
mtn
mox
group
rat
administ
mox
three
day
inocul
mrsa
solut
probiot
group
probiot
biothre
r
oral
administ
everi
day
inocul
mrsa
solut
result
independ
cultiv
mix
cultiv
logcfuml
b
viabl
bacteri
count
aureu
tpn
mrsa
tpnmrsa
signific
abl
consid
mrsa
multipl
control
intestin
bacteria
count
mrsa
respect
mrsa
prolifer
suppress
two
major
intestin
bacteria
b
count
mrsa
elev
cpmrsamox
diarrhoea
observ
count
decreas
treatment
probiot
frequenc
diarrhoea
decreas
conclus
disturb
intestin
flora
suggest
major
caus
enterotox
mrsa
infect
control
intestin
flora
import
prevent
enterotox
mrsa
infect
genet
techniqu
puls
field
gel
electrophoresi
pfge
provid
high
discrimin
power
time
consum
costli
recent
year
transform
raman
spectroscopi
rapid
identif
type
tool
clinic
microbiolog
techniqu
provid
inform
overal
molecular
composit
intact
bacteri
cell
highli
specif
isol
use
valid
raman
spectroscopi
type
method
mrsa
accord
recent
publish
guidelin
method
isol
cultur
hr
trypticas
soy
agar
plate
biomass
suspend
microlit
steril
distil
water
transfer
onto
quartz
slide
allow
dri
spectroscop
fingerprint
obtain
use
dedic
raman
spectromet
requir
second
per
sampl
cluster
analysi
fingerprint
perform
use
pair
wise
correl
distanc
measur
combin
ward
cluster
algorithm
reproduc
raman
procedur
high
multipl
measur
set
isol
result
isolatespecif
cluster
use
wellcharacteris
strain
collect
found
discriminatori
power
compar
gold
standard
pfge
conclus
use
raman
spectroscopi
type
method
signific
decreas
turnaround
time
achiev
allow
intervent
limit
transmiss
taken
earlier
type
inform
gather
techniqu
compar
inform
obtain
genotyp
method
therefor
conclud
raman
spectroscopi
easytous
rapid
altern
battl
mrsa
hbv
infect
prior
initi
art
omit
resourcelimit
set
initi
proteas
inhibitorcontain
antiretrovir
regimen
sever
clinic
event
grade
event
accord
anr
classif
hospitalis
extens
hospitalis
death
review
valid
committe
risk
factor
nanhr
sever
clinic
event
analys
use
multivari
cox
model
plasma
hiv
rna
viral
load
pvl
timedepend
covari
result
median
followup
month
patientyear
nanhr
sever
clinic
event
record
patient
incid
nanhr
sever
clinic
event
higher
aidsrel
event
one
patientyear
patientyear
respect
frequent
nanhr
sever
clinic
event
bacteri
infect
n
cancerrel
event
n
cardiovascular
n
psychiatr
event
n
adjust
multivari
analysi
occurr
first
nanhr
sever
clinic
event
significantli
frequent
patient
older
year
hazard
ratio
hr
confid
interv
ci
coinfect
hcv
hr
ci
time
event
hr
ci
pvl
copiesml
time
event
hr
ci
factor
associ
bacteri
infect
similar
associ
type
nanhr
sever
clinic
event
risk
hr
increas
level
virolog
failur
ci
pvl
copiesml
ci
pvl
copiesml
factor
associ
nonaid
cancer
age
hr
ci
time
event
tend
protect
effect
hr
ci
p
conclus
record
high
incid
nanhr
sever
clinic
event
fold
hivdefin
event
patient
popul
virolog
failur
may
favour
occurr
nanhr
sever
clinic
event
especi
bacteri
infect
result
give
argument
interrupt
antiretrovir
treatment
object
aim
characteris
genet
divers
integras
region
circul
estonia
compar
genet
divers
bsubtyp
virus
arv
treatment
naiv
arvtn
experienc
te
patient
method
total
arvtn
median
age
male
idu
te
none
treat
integras
inhibitor
ini
analys
virus
latter
popul
least
one
primari
rt
drm
averag
number
commonli
seen
mutat
n
n
n
direct
sequenc
plasma
viral
rna
popul
perform
region
aa
subtyp
carri
use
phylogenet
analysi
neighborjoin
function
posit
preval
report
ini
resist
mutat
noguera
c
fortuni
l
duran
l
alsina
g
claret
e
esplugu
barcelona
es
object
haartrel
longterm
toxic
increasingli
report
perinatallyhivinfect
children
includ
hyperlactataemia
dyslipaemia
hepat
bone
marrow
toxic
plan
interrupt
haart
pih
aris
potenti
reduc
drug
exposur
toxic
method
present
case
seri
perinatallyhivinfect
paediatr
patient
girl
median
age
year
pih
optim
longterm
respons
firstlin
haart
regimen
underw
singl
pih
hemoglobin
total
neutrophil
count
lactat
level
triglycerid
total
ldl
hdl
cholesterol
alanin
aminotransferas
amylas
plasmat
level
assess
pih
month
later
therapi
nonparametr
test
use
appropri
result
pih
patient
remain
median
time
year
therapi
proteas
inhibitorbas
regimen
complet
suppress
viral
replic
respect
one
month
treatment
interrupt
blip
hiv
plasmat
viral
load
median
valu
log
copiesml
rang
observ
case
hiv
viral
load
stabilis
thereaft
clinic
progress
occur
despit
progress
decreas
cell
percentagescount
observ
case
none
patient
reiniti
therapi
followup
one
year
pih
decreas
total
cholesterol
median
valu
mgdl
wilcoxon
rank
test
p
ldl
cholesterol
mgdl
p
hdl
cholesterol
mgdl
p
lactat
level
mmoll
p
observ
chang
observ
rest
studi
paramet
variabl
remain
within
normalaccept
valu
timepoint
none
patient
show
symptom
consist
hyperlactataemia
hepat
pancreat
neither
haart
pih
conclus
seri
pih
lead
signific
decreas
total
hdl
cholesterol
lactat
level
howev
paramet
remain
within
normal
valu
baselin
pih
clinic
symptom
observ
longterm
clinic
consequ
haartrel
toxic
perinatallyhivinfect
paediatr
patient
remain
unknown
well
potenti
benefit
haartspar
strategi
